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ABSTRACT  
  
 Spinal muscular atrophy (SMA) results from α-motor neuron loss in the spinal 
cord due to low levels of the survival of motor neuron (SMN) protein, required for 
proper spliceosome assembly. The reduced levels of SMN cause muscle atrophy and 
ultimately death in the most severe cases. Although mouse models of SMA recapitulate 
many features of the human disease, it is still unclear whether their phenotypes are 
primarily due to motor neuron deficits. If so, motor neuron-selective restoration of 
normal SMN levels should have a great positive impact on SMA mice. To test this, we 
first exogenously raised normal human SMN in severe SMA mice that die perinatally, 
by driving its expression selectively in motor neurons with an Hb9 promoter. We found 
no extension of survival. We detected motor neuronal-SMN protein expression in Hb9-
SMN transgenic mice from mid embryogenesis to postnatal day 6. However, mRNA for 
transgenic SMN was undetected by late embryogenesis. These results suggest that 
expression of Hb9-SMN declines before SMN levels are most needed perinatally. 
Second, we increased endogenous motor neuronal-SMN expression following 
embryonic Hb9-dependent Cre recombination of a conditional hybrid mutant allele 
(Smnres) in another severe SMA mouse model (SMA7-like). Cre recombination 
irreversibly transforms the Smnres allele to WT. We confirmed that recombination of 
Smn
res occured exclusively in the spinal cord. Yet, unlike a previous study that used 
choline acetyltransferase (ChAT) as a driver on the same mice, we found no 
improvement in survival, weight, motor behavior or presynaptic neurofilament 
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accumulation. However, like in ChATCre+ SMA mice, we detected rescue of endplate 
size and mitigation of neuromuscular junction (NMJ) denervation status. Real time-PCR 
showed that the expression of spinal cord SMN transcript was sharply reduced in 
Hb9
Cre+ SMA mice relative to ChATCre+ SMA mice. This suggests that our lack of 
overall phenotypic improvement was most likely due to an unexpectedly poor 
recombination efficiency driven by Hb9Cre. Nonetheless, the low levels of SMN were 
sufficient to rescue two NMJ structural parameters indicating that these motor neuron 
cell-autonomous phenotypes are very sensitive to changes in motor neuronal-SMN 
levels. 
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RT-PCR                      Reverse Transcriptase Polymerase Chain Reaction 
SMA Spinal Muscular Atrophy 
Smn                             Survival Of Motoneuron Gene (Mouse) 
SMN                           Survival Of Motoneuron Gene (Human) 
SMN                           Survival of Motoneuron Protein 
TA                              Tibialis Anterior 
U snRNP                    Uridine-Rich Small Nuclear Ribonucleoprotein Particle 
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CHAPTER I 
 INTRODUCTION: 
BACKGROUND AND SIGNIFICANCE  
  
1.1 OVERVIEW 
 Spinal Muscular Atrophy (SMA) is an autosomal recessive neuromuscular 
disorder affecting approximately 1:10,000 [1] to 1:6,400 children [2, 3] with a frequency 
of carriers of 1:35 to 1:50 [2]. Second to cystic fibrosis, SMA is the most common 
genetic infantile disorder and it is included in a group with other neurological disorders 
caused by alterations in genes with important roles in RNA metabolism [4, 5]. Currently, 
there is no cure for this disease. SMA is characterized by lower α-motor neuron loss in 
the ventral horn of the spinal cord [6, 7] giving rise to symmetrical muscle weakness and 
atrophy of voluntary muscles followed by atrophy of trunk muscles and commonly 
concluding in death by respiratory failure in the most severe cases [7-10]. This 
phenotype is caused by the paucity in production of the Survival of Motor Neuron 
protein (SMN) varying from embryonic lethality to impairment of the motor system. 
SMA patients have low levels of this protein, particularly in spinal motor neurons [11]. 
 The phenotype and symptoms of SMA vary widely, i.e. it is a very 
heterogeneous disease [12] that makes precise classification a challenging task; the 
prognosis can range from early infant death to normal adult life with only mild 
weakness. The different forms of SMA have been grouped into three types depending on 
the age of onset and symptoms [4, 13], although many patients do not classify cleanly 
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into a single type. Type I, Werdnig-Hoffmann disease, (Werdnig, 1894; Hoffmann, 
1900) is the most severe form of SMA characterized by muscle atrophy and hypotonia 
with death occurring usually in the first two years of life due to heart and respiratory 
failure. Type II, is the intermediate form of the disease in which children may survive 
beyond four years and can develop some muscular functions, such as sitting up, but are 
unable to walk or stand without assistance. The symptoms usually appear around 18 
months of age; these patients have serious respiratory problems and a short life 
expectancy. Type III SMA (Kugelberg–Welander or juvenile SMA) is a mild form of the 
disease in which patients could potentially survive to late adulthood but with some 
muscle weakness observed by the second year of age [4, 8, 14]. There is also a very mild 
type of SMA that develops in adults over 30 years old often called type IV SMA [8]. 
 
1.2 THE SMN PROTEIN 
 The evolutionarily conserved (294-amino acid long) 38kDa SMN protein is 
expressed ubiquitously, although not in the same levels (high in brain, spine, kidney, 
liver; moderate in cardiac and skeletal muscle; low in fibroblasts and lymphocytes) [1, 8, 
15]. It is unclear, despite the ample knowledge of SMN biochemistry, why the loss of 
this protein gives rise to a neuronal phenotype characterized by a degenerative process 
while other tissues, where it is also expressed, remain unhindered [16, 17]. Spinal cord 
levels of SMN are much lower in SMA than in healthy patients [17].  
 Experiments of SMN depletion in yeast have lead to the conclusion that this 
protein has a conserved essential function in eukaryotes [17, 18]. This is not surprising 
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since it has been widely accepted that SMN is required for proper spliceosome assembly 
having a crucial role in the biogenesis of uridine-rich small nuclear ribonucleoprotein 
particles (U snRNPs) [8, 19]. Small nuclear ribonucleoproteins (snRNPs) are key in the 
processing of pre-mRNA to mRNAs [5, 8]; certain snRNPs are critical for the 
recognition of splice sites and the catalytic removal of introns from pre-mRNA. Each 
snRNP contains a small nuclear RNA (snRNA) and an extremely stable core of seven 
Sm proteins. The snRNP biogenesis pathway for snRNAs involves nuclear export of 
snRNA, Sm-core assembly in the cytoplasm, and re-import of the mature snRNP. The 
assembly of the snRNA:Sm core is carried out by the SMN macromolecular complex, 
which rigorously identifies RNAs as snRNAs and binds the RNA-binding Sm proteins 
(See Fig. 1.1 for detailed pathway) [5, 8, 20]. The cytoplasmic SMN complex contains 
the SMN-interacting protein 1 (SIPI) as well as the Sm proteins. The N-terminal part of 
the SMN protein is involved in SIPI biding and association with RNA, the middle region 
constitutes a Tudor domain, which is necessary and sufficient for the binding of Sm 
proteins, and the C-terminal of SMN is also important for Sm binding and its 
oligomerization [21].  Other functions of SMN include transcription, pre-mRNA splicing 
catalysis, metabolism of snoRNPs, axonal RNA transport, stress responses, and 
suppression of apoptosis [8, 22-24].   
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Fig. 1.1. Schematic model of snRNP assembly by the SMN complex. Small nuclear ribonucleoproteins 
(snRNPs) are active in recognizing and removing introns from pre-mRNA in the nucleus. Each snRNP 
particle is composed of small nuclear RNA (snRNA), several Sm proteins and a number of specific 
proteins unique to each snRNP. A) The SMN complex: SMN functions in the cytoplasm to assemble Sm 
proteins onto the snRNAs to produce an active snRNP particle. The SMN complex is composed of SMN, 
Gemins2-8 and unrip. SMN is an oligomer that self-associates, a critical process for SMN function. B) 
Detailed overview of the ordered cellular pathway of SMN in the formation of snRNPs: in the 
cytoplasm, the chloride conductance regulatory protein (pICln) and the 20S methylosome capture the 7 
Sm proteins. The protein arginine methyltrasferase (PRMT5 complex) and PRMT7 methylate the Sm 
proteins. This process transforms the Sm proteins into high affinity substrates of the SMN complex. Then, 
Sm proteins are released from pICln-PRMT5 complex and bind the SMN complex.  snRNA is transcribed 
in the nucleus and then binds the export proteins to be translocated to the cytoplasm. The SMN complex 
places the Sm proteins onto the snRNA. The stem and loop of the UsnRNA are necessary and sufficient 
for the association with the SMN complex. The snRNA is hypermethylated, allowing the SnRNA/SMN 
complex to bind snurportin and importin, which mediates transport of the SMN complex with an 
assembled snRNP into the nucleus. In the nucleus the SMN complex and snRNPs localize to the Cajal 
body/gem and snRNPs undergo further maturation. Adapted from Burghes and Beattie (2009) [5] and 
Pellizzoni et al. (2002) [25]. 
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 Liu and Dreyfuss first described an interesting localization pattern for SMN. 
They determined that SMN is localized in discrete “dot-like” structures named gems (for 
Gemini coiled bodies) near to coiled  (Cajal) bodies in the nucleus  (Fig. 1.2) [26]. Gems 
and Cajal bodies, although they are two distinct structures, have similar functions and 
achieve a dynamic relationship in which they interact with each other [15, 26, 27].  
 
 
 
Fig. 1.2. The SMN protein is localized in discrete structures called gems. A) DIC image of gems 
(pointed out by arrowheads) in HeLa cells [26]. B) An anti-SMN monoclonal antibody localizes SMN 
within gems in HeLa cells [8]. Adapted from Liu and Dreyfuss (1996) [26] & Coady and Lorson (2011) 
[8]. 
 
 SMN can also be found in the cytoplasm [6, 8, 16, 24, 26] and in axons (in vivo), 
branch points, dendrites and growth cones (in vitro)  (Fig. 1.3) [9, 16, 17, 28]. The C-
terminal of Exon 7 is critical for SMN localization in the cytoplasm [16]. 
 
 
    
 
Fig. 1.3. Neuronal localization of SMN. SMN granules localized to the axonal process (arrows) and its 
growth cone (arrowhead). From Zhang et al. (2003) [16]. 
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 SMN is known to form a complex with Gemins 2–8 and unrip to allow the 
assembly of Sm proteins onto snRNAs [28]; SMN also interacts with itself and Gemins 
2-6 forming an oligomerized complex [26, 27]. When SMN is found in granules inside 
axons it is transported bi-directionally with Gemins 2 and 3 [9]. SMN also interacts with 
arginine and glycine rich-substrate proteins that are high-affinity binders of the SMN 
complex and regulate the ribonucleoprotein assembly processes [27]; it also associates 
with fibrillarin and the RGG box region of hnRNP U [26]. 
 The degree of snRNP assembly activity inversely correlates with severity of 
SMA mice, the decrease in assembly results in decreased levels of UsnRNA (U11 and 
U12), which are important in splicing minor introns found in a subset of genes [28]. 
Also, SMN deficiency impairs U7 snRNP assembly; this SMN-dependent U7 reduction 
affects endonucleolytic cleavage of histone mRNAs and even changes in histone gene 
expression. This was very recently found both in humans and mouse models in a study 
by Tisdale and collaborators (2013) [29]. The lack of normal quantities of SMN causes 
synaptic pathology in the SMA mouse models assayed up to date. One example is that 
synaptic vesicles have been observed to more likely be located in the periphery of the 
presynaptic terminal [30]. This indicates that at least one of the compartments of the 
neuromuscular synapse, the presynaptic compartment, is highly affected during the SMA 
pathology.  
 According to Torres-Benito et al. (2011), there are two hypotheses attempting to 
explain why the reduction in SMN expression causes mainly a motor neuron disease. 
The first hypothesis is based on the assumption that the disruption in RNA processing 
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has a more detrimental effect on motor neurons, while the other hypothesis under 
investigation suggests that SMN plays crucial roles in the axons and synapses of these 
cells, besides the formation of U snRNPs, causing their death upon its depletion [9]. This 
second hypothesis is not without merit considering that numerous studies have reported 
SMN in axonal transport granules, and its interaction with numerous mRNA-binding 
proteins not involved in splicing regulation suggest a role for SMN in axonal RNA 
metabolism [10, 31].  
 SMN can be found within axons that contain non Sm-related proteins (hnRNPs Q 
and R). These proteins are involved in the active transport of some mRNAs, such as β-
actin, to the axon growth cone [16, 28]. Some of these mRNAs have been found 
significantly reduced in the growth cone in SMA mouse models. Thus, axon transport 
seems to be a critical pathway disrupted in SMA. Fallini et al. presented novel findings 
in 2010 on the fast active transport of SMN-containing granules which move along live 
primary motor neuron axons anterogradely and retrogradely indicating that SMN does 
have an axon specific role [31]. Furthermore, the axons of motor neuron cultures from 
severe SMA mice and zebrafish SMN knock out model are shorter [28]. Zhang et al. 
(2003) determined that SMN is actively transported to neuronal processes and that 
because exon-7 is involved in cytoplasmic localization, SMN-associated RNPs may 
show inefficient delivery into axons contributing to the SMA pathology [16]. Although 
unlikely to contribute to the SMA pathology, an isoform of SMN, including only the 
amino terminus, has been found solely in axons [5].    
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 In vivo studies disrupting the function of SMN have provided clues into the role 
of the SMN protein on aiding in cell survival [24].  Vyas et al. (2002) assessed the role 
of SMN in apoptosis by expressing human SMN protein in undifferentiated and 
differentiated PC12 cells or in Rat-l cells, on which apoptosis was induced by 
withdrawal of trophic support or c-Myc. They determined that SMN delays the onset of 
apoptosis by acting on mechanisms that mediate cell death through the mitochondrial 
release of cytochrome c. SMN inhibits the release of cytochrome c and cleavage of 
caspase-3. The C terminal domain of the protein, in particular exons 6 and 7, plays a key 
role in fulfilling this function [24].  
 
 1.3 THE SMN GENE 
 Lefebvre et al. (1995) identified, cloned and characterized a gene which they 
coined SMN and suggested it was involved in the SMA phenotype. This gene was found 
duplicated in the SMA locus (a region with low copy repeat elements) mapping to 
chromosome 5q13 [4]. SMN is ~20kb in length and has nine exons termed 1, 2a, 2b, and 
3-8 [32]. Although there are two, nearly identical, human genes that produce the SMN 
protein, SMN1 (telomeric) and SMN2 (centromeric) [15], only SMN1 is the source for 
full-length SMN (FL-SMN) [11]. SMN2 differs from SMN1 in single nucleotide 
differences in exons 7 and 8 out of the nine exonic regions of the SMN gene. The 
important single nucleotide difference is a cytosine (C) to thymine (T) transition in exon 
7 [1, 11, 19, 33]; this nonpolymorphic nucleotide difference is responsible for exon 7 
inclusion in the transcript from SMN1. The change causes alternate mRNA splicing, due 
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to disruption in overlapping regulatory elements, eliminating exon 7 that leads to an 
approximate 90% reduction in FL-SMN both in healthy and SMA children (Fig. 1.4) [2, 
11, 19, 23, 33]. Exon 7 is comprised by 54 nucleotides, is part of an exon splice 
enhancer (ESE), and contains the translation termination signal for all full-length 
products [11, 34]. Exon 7 inclusion is tightly regulated by positive and negative 
regulatory elements [34].  
 The protein derived from the truncated transcript produced from SMN2, 
designated SMNΔ7, does not associate with other proteins necessary for the formation of 
the spliceosome complex i.e., it cannot fulfill its canonical function, and ultimately 
becomes degraded due to instability [8, 11, 35, 36].  It is important to mention that in 
both SMN1 and SMN2 the first 4.6kb of their promoters are identical, thus possible 
promoter differences do not account for the varying levels of SMN produced by each 
[11, 17]. 
 
 
Fig. 1.4. Representation of the human SMN locus. Telomeric SMN1 and centromeric SMN2, map on 
chromosome 5. They both have nine exons and eight introns but encode varying levels of the SMN 
protein. A C–T transition in exon 7 explains the difference between the two almost identical genes. In 
SMN2 this alters a critical exonic splice enhancer preventing exon 7 inclusion during splicing causing over 
85% reduction in full-length SMN. SMN2 produces mostly a minimally functional truncated product 
(SMNΔ7). Bands for the full-length and truncated products are seen in the lower middle panel. From 
Lorson et al. (2010) [34]. 
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 Mutations in SMN1 cause the SMA phenotype [2, 8, 37, 38].  Approximately 
96% of SMA patients have a deletion in SMN1 (Fig. 1.5). In the cases where the gene is 
retained, patients can suffer the disease due to intragenic mutations [7]. According to 
Coovert et al. (1997), some of the SMN1 mutations observed in patients are deletions 
that disrupt exon 7 splicing, deletion of 4-5 base pairs in exon 3, a duplication of 11 base 
pairs in exon 6 or other possible missense mutations in exons 6 and 7. Most of the small 
mutations are compound heterozygotes and about 75% are non-deletion/conversion 
mutations. Because mutations in the telomeric SMN1 gene were consistently found in 
patients with the SMA phenotype, it was coined as the gene responsible for this 
neurodegenerative disorder.. The coding region between exons 6 and 7 became the focus 
of many studies because its transcript appeared to be essential for the normal functioning 
of both motor neurons and their targets [15].  
 
 
 
Fig. 1.5. Genomic organization of the SMN locus in type I and III SMA patients. A) SMA occurs due 
to a deletion of the SMN1 gene causing significant decrease in full-length SMN. SMN2 gene remains 
present and compensates for the loss when present in several copies. B) SMA type III occurs because 
SMN1 is converted into SMN2. Despite the absence of SMN1, type III SMA is less severe because there 
are an increased number of SMN2 genes on each chromosome; this would lead to a higher amount of SMN 
protein. Modified from Frugier et al. (2002) [39].  
 
 
 
	
A B 
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 Homozygous absence of Smn in mice and all the other SMA animal models is 
embryonic lethal [5, 40, 41]. In mice, there is massive cell death before embryo 
implantation [10]. In other animals, the timing of lethality is dependent upon the levels 
of SMN provided by the mother’s SMN gene [5].The absolute lack of SMN in humans is 
unknown. Thus, it can be assumed that it is also embryonic lethal [8, 23]. Only one copy 
of SMN1 or Smn (in animal models) is enough to be asymptomatic. Carriers show no 
obvious signs of pathology. This is evident in animal models heterozygous for a 
mutation in Smn as well as humans with just one copy of SMN1 and no copies of SMN2 
to compensate [42]. Only humans possess the two genes SMN1 and SMN2. According to 
Rochette et al. (2001), their genetic analysis of allelic variants in chimpanzee’s prove 
that even though the SMN gene duplication occurred more than 5 million years ago, 
before humans and chimpanzee diverged evolutionarily, SMN2 appears only in the 
lineage of Homo sapiens [43]; thus compensatory mechanisms provided by the existence 
of more than one allele expressing the SMN protein are unique to humans. This 
functional advantage in humans may be due to quantitative differences between humans 
and other animals in terms of their motoneuron-muscle physiology [17]. 
 In spite this gene duplication providing a counterbalance, the centromeric gene 
SMN2 can only compensate for the lack of SMN1, lessening the severity of the disease, 
when it is present in multiple copies producing larger quantities of FL-SMN and the 
truncated SMNΔ7 protein [40, 44-46]. Swoboda et al. (2005) have demonstrated that 
when SMN2 is found in a low copy number (< 3) the phenotype of the disease is more 
severe in terms of motor unit number estimation [14]. A study that performed a 
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quantitative analysis on the copy number of SMN2 in 375 SMA patients found that about 
80% of the type I SMA patients assayed carry one or two copies of SMN2, 82% of 
patients with type II SMA carry three copies of SMN2, and 96% of patients with type III 
SMA carry three or four copies of SMN2 [47]. 
 Even though SMN1 is the gene widely accepted as the responsible for causing the 
SMA pathology, a study by Srivastava and co-authors (2001) stated that homozygous 
absence of SMN2 could cause childhood onset of the disease without any disruption of 
the SMN1 gene. Their data came from one 5 year-old patient with childhood SMA 
presenting symptoms such as distal muscle weakness and wasting, delayed motor 
development and hypotonia. They concluded that SMN2 might add more susceptibility 
in some populations of SMA patients [12]. Additionally, it is worthy to note that there 
seems to be a correlation between homozygous deletions of SMN2 and patients with 
sporadic adult-onset lower motor neuron disease (LMND) since 36% of patients assayed 
by Moulard et al. (1998) presented this genetic alteration [48]. 
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1.4 SMA PATHOLOGICAL HALLMARKS 
 
  
 
Fig. 1.6. Schematic representation of some neuropathological hallmarks of SMA patients and SMA 
animal models. Cell death characterizes spinal motor neurons; there are signs of denervation, reduction in 
the number of afferent synapses with proprioceptive neurons, neurofilament (NF) aggregates at the 
endplates, reduced neurotransmitter (NT) release, and immature acetylcholine receptor (AChR) subunits. 
In the case of humans, heterotopic (mispositioning) motor neurons located around the gray matter of the 
anterior horn can be seen. From Fallini et al. (2012) [10]. 
 
 
 
 When SMN is reduced below normal levels an aberrant neuromuscular 
phenotype is observed in SMA patients and animal models. The pathological hallmark is 
the loss of -motor neurons of the ventral spinal cord (Fig. 1.6 and 1.7B) and lower 
brainstem with some heterotopy of these cells in the ventral white matter (Fig. 1.6) [10, 
49]. Remaining motor neurons may appear swollen or chromatolytic, and intramuscular 
nerves show abnormal beading and Wallerian degeneration [49]. There is a reduction in 
the number of afferent synapses with proprioceptive neurons (Fig. 1.6) [10, 50] with 
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sensory axons degenerating in type I patients [51]. Additionally, osteoporosis and 
scoliosis may accompany neuromuscular symptoms [52]. 
 Muscles are affected in both anatomy and function. Moderate to severe 
weakness, neurogenic atrophy, and acute or chronic denervation of specific muscle 
groups characterizes SMA. Mainly, patients experience profound hypotonia (floppy 
infant syndrome) [49]. Severe SMA skeletal muscles consist of numerous rounded, 
atrophic fibers interspersed with one or more hypertrophic myofibers (Fig 1.7C); fibers 
also appear immature, resembling myotubes with central nuclei and persistence of the 
checkerboard pattern of type I and type II fibers, while muscle from patients with milder 
forms of SMA show signs of numerous cycles of denervation and re-innervation and 
may sometimes exhibit myopathic features such as fiber splitting, central nuclei, 
basophilia and an increase in endomysial connective tissue [53].  
 
 
Fig. 1.7. Main neuronal and muscular pathological phenotype in Spinal Muscular Atrophy. Cresyl 
echt violet staining from a control hypoglossal nucleus section reveals clear presence of -motor neurons 
(arrowheads) in A) while the post-mortem tissue from an SMA patient B) lacks this staining indicating 
motor neuron loss. C) Hematoxylin-eosin (H&E) staining of skeletal muscle fibers shows atrophic muscle 
fibers interspersed with hypertrophic fibers (asterisks). Scale bar: A) and B): 30 µM; C): 20µM. Adapted 
from Monani and De Vivo (2013) [49]. 
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 The Smn defect can destabilize the sarcolemma as determined by a clear 
reduction of dystrophin expression and upregulation of utrophin, which are components 
of skeletal muscle fibers linking the F-actin cytoskeleton to the extracellular matrix, at 
least from observations in mice [54].  
 Mice show signs of denervation in a subset of muscles [51], indicating that there 
are differing levels of vulnerability between distinct pools of motor neurons; meanwhile, 
generalized muscle denervation is not as widely observed in humans [10], even though 
this would be the assumption considering that weakness and paralysis of skeletal 
muscles are hallmarks of SMA. Motor neuronal synaptic defects could better explain this 
phenomenon. 
 Spinal circuitry dysfunction, both in humans and mouse models, is an important 
characteristic in the disease that appears very early. In mouse models, primary afferent 
boutons onto motor neuron somata and proximal dendrites are lost, thus greatly and 
progressively weakening the synapses between these two cell types. This phenomenon 
precedes motor neuron death and follows a pattern that emulates the pattern of 
progressive muscle weakness that occurs initially in projections towards proximal 
muscle targets [55].  
 Pathology also includes defects of the pre- and post-neuromuscular synapse. 
These are probably the earliest pathological hallmarks of the disease and there is 
evidence that abnormalities of the distal end of the motor unit likely precede those of the 
motor neuron cell body [30]. These defects were initially observed in model mice but 
have been confirmed in patient tissue as well [49]. 
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 Normal postsynaptic clusters of acetylcholine receptors (AChRs) at the 
neuromuscular junction (NMJ) appear at first shaped as simple plaques and then become 
successively more complex as perforated plaques, “C”-shaped, branched configurations, 
and eventually the mature “pretzels” [40]. AChR clusters in mutant mice do not 
differentiate at the same rate and when compared to control mice have a higher 
percentage of plaque-shaped receptors [40], which should have developed into more 
complex forms at that stage; thus a hallmark of the SMA-NMJ is immature AChR 
clusters (Fig. 1.5) [10].  
 An important early sign of pathology at the NMJ is the accumulation of 
phosphorylated neuronal intermediate filaments, neurofilament (NF), at perykarions and 
axon terminals [10, 56-58]. This may be seen in conjunction with a reduction of the 
postsynaptic region and defect of axonal sprouting [10, 58]. This abnormal accumulation 
seems to be the result of changes in cellular NF distribution and not expression [58]. In 
Cifuente-Diaz’s (2002) experiments using an SMA mouse model, accumulation of 
phosphorylated NF is neither associated with hyperphosphorylated tau nor caused by 
deregulation of Cdk5/p35 activity or distribution even though NF is a substrate of 
protein kinases [58]. Atypical neurofilament accumulation has been linked to several 
other neurodegenerative diseases, such as amyotrophic lateral sclerosis, Parkinson’s 
disease, and Alzheimer’s disease [59]. Mutant motor neurons may also have 
eccentrically positioned nuclei associated with indentations of the nuclear membrane 
[58]. 
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 Pathology in non-neuronal tissue can also greatly contribute to the overall decline 
in SMA patients and animal models. For example, patients (usually the ones with only 
one copy of SMN2) can present severe symptomatic bradycardia, heart defects such as 
atrial and ventricular septal defects, arrhythmias, dilated right ventricle, hypoplastic left 
heart syndrome, respiratory failure and sudden death [52, 60]. Even patients with milder 
types of SMA present cardiac problems such as heart block progressing to complete 
atrioventricular block. Some other cardiac symptoms in severe to intermediate mild 
patients include arrhythmias co-occuring with cardiomyopathies, hyperhidrosis, poor 
circulation, tachyarrhythmia, altered RR interval variation, decreased sympathetic skin 
response, and affected vasodilation [61]. SMA mice also suffer from cardiac problems 
such as cardiomyopathy and autonomic nervous system (ANS) defects leading to 
congenital bradyarrhythmia and heart block. If these symptoms progress the mice will 
eventually die from heart failure. SMA mouse hearts are smaller in size and flaccid [61-
63]. Liver alterations such as the reduction of circulating insulin-like growth factor 
(IGF1) seen in severe SMA mice indicate the importance of other tissues in the diseased 
states [64].  
 Also, additional to the main cellular pathology observed, other cellular 
impairments are present and contribute to the overall deterioration. For example, some 
cytoskeletal elements are altered with SMN-deficient cells having impairments in 
microtubules [10]. 
 
 
  18 
1.5 THERAPEUTIC STRATEGIES 
 Outside of supportive care there is no cure for SMA at present. Several drugs 
have been tested in clinical trials but so far none have proven both efficacious and safe. 
Nonetheless, therapeutic efforts aiming at increasing availability of the SMN protein, 
either by direct viral delivery or by enhancing full-length SMN protein expression from 
SMN2 [37], are approaching the translational stage of development. Past and present 
efforts have focused on using small RNA molecules to modulate the endogenous SMN2 
gene by activating the SMN2 promoter or to reprogram the splicing of SMN2 pre-mRNA 
to restore expression of the normal SMN protein (antisense oligonucleotides), gene 
therapy for SMN replacement, stem cells that can differentiate into motor neurons, 
neuroprotective molecules and pathways, and targets downstream of SMN deficiency 
[36, 65]. A summary of therapeutic approaches can be found in Table 1.1.  
 1.5.1 Antisense Oligonucleotides 
 All humans have at least one functional copy of SMN2, even in SMA, thus 
correcting SMN2 exon 7 splicing is a compelling potential treatment. Postnatal increase 
of SMN levels using small compounds and antisense oligonucleotides (ASOs) has 
yielded benefits in animal models of SMA.  ASO based therapy is a great approach since 
there can be a limitless number of compounds that could be tested for the same target 
[66]. Several antisense approaches exist including blocking exonic splicing silencers 
(EESs), intronic splicing silencers (ISSs) or the intron 7–exon 8 junction. 
 To restore SMN2 exon 7 inclusion in SMA, it is essential that splice-switching 
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ASOs target an inhibitory cis-element located within an intronic sequence. The intronic 
splicing silencer (N1 ISS-N1, discovered by Singh et al. 2006) is the main checkpoint of 
SMN2 exon 7 splicing regulation. Once ISS-N1 is deleted exon 7 is included. Anti-N1 
treatment was capable of elevating SMN levels in type I SMA patient cells [67]. 
 ISIS Pharmaceuticals has a proprietary product called MOE (ASOs with 
phosphorothioate backbone and 2′-O-methoxyethyl modification) that confers increased 
nuclease resistance and decrease non-specific protein interactions. MOE gives reduced 
efficacy with a single cerebrospinal fluid delivery but an enhanced efficacy when 
delivered at multiple time points and at high doses peripherally, with an increase in 
survival in mice [68]. Dr. Adrian Krainer’s group and ISIS performed independent 
studies and found that ISS-N1-targeting ASOs stimulate exon 7 inclusion by displacing 
inhibitory factors in SMN2, thus reconstructing a version of the SMN gene capable of 
expressing functional FL-SMN protein [66, 69]. The first in vivo study of an ISS-N1 
targeting ASO was done in severe SMA mice, the SMA7 model (described in detail, 
along with others in the section to follow on SMA animal models).   With SMA ASO 
which increased SMN levels in brain and spinal cord, improved body weight and motor 
behavior [70]. Later on, Krainer et al. along with ISIS performed other in vivo 
experiments on a mild SMA model with ISS-N1 targeting MOE ASOs. They used an 18-
mer MOE ASO (ASO-10-27) that base pairs with ISS-N1; this frees up exon 7 so that it 
can be incorporated into SMN2 mRNA upon splicing. Single intracerebroventricular 
embryonic or neonatal ICV injection completely rescued the phenotype [65].  
 The efficacy of the ASO-10-27 was tested in 2011 (Passini group) when 
  20 
introduced into the cerebral lateral ventricles of SMA7 mice. They found an increase in 
both the number of motor neurons and SMN, improvements in muscle physiology, 
motor behavior and most importantly survival (from two to three/four weeks). They 
performed preliminary testing of this treatment in cynomolgus monkeys. They 
administered intrathecal infusions of ASO-10-27 to all regions of the spinal cord and 
observed that nervous system–directed ASO therapy is tolerable in non-human primates 
and efficacious achieving therapeutically relevant levels of ASO 10-27 [71]. However, 
there is toxicity with this MOE at doses >1.16 mM [72]. Porensky et al. (2012), from the 
Dr. Arthur Burghes group, also demonstrated the efficacy of using small compounds 
against ISS-N1.  Using an ICV-delivered phosphorodiamidate morpholino oligomer 
(MO) they found a significant increase in the lifespan of SMA mice (from 15 to >100 
days), specifically when treatment was administered early on (P0). MOs have a low 
toxicity and a wide distribution of uptake. This MO [HSMN2Ex7D(-10,-29)] is similar 
in sequence to the ASO 10-27 of the Krainer group but with slightly different chemistry 
[72]. More recently, the same group has optimized a type of ASO, the 
phosphorodiamidate morpholino oligonucleotides (PMO). PMOs also promote exon 7 
retention to levels that were high enough to rescue the phenotype in a severe mouse 
model of SMA after a single intracerebroventricular injection. Fourteen PMOs of 
varying lengths were designed to anneal downstream of SMN2 exon 7. Efficiency was 
first studied in vitro in cultured fibroblasts from a type I SMA patient and later on it was 
confirmed in vivo after the lead compound rescued a severely affected mouse model 
actually with a single dose. Out of the fourteen assayed, PMO(-10-34) was identified as 
  21 
the most effective compound for induction of SMN protein after two different in vitro 
delivery systems and this oligonucleotide was the one used for in vivo evaluation. They 
found that PMO(-10-34)  gives the longest survival reported to date for this SMA mouse 
model [73]. 
 Even though CNS treatment has been efficacious, a study by Hua et al. (2011) 
indicates that peripheral targets are also required to rescue the SMA phenotype using 
MOEs [64].  
 ISIS Pharmaceuticals has lead the first clinical trial for an ASO-mediated 
restoration of exon inclusion in a human disease (ISIS-SMNRx). Phase I has concluded. 
Intrathecal infusion of ISIS-SMNRx was well tolerated in SMA patients and 
experiments for future stages of the trial are ongoing [66].  
 Using ASOs can be advantageous for SMA therapy since their efficacy has been 
proven, they are very specific, cost-efficient, and minimally toxic. However, a down side 
of ASO-mediated approaches is that they require sequestration of a splicing cis-element. 
Because the majority of the human genome is transcribed, there is always a risk that an 
ASO could have off-target effects as well as unwanted interactions with proteins, both of 
which contribute to reduced antisense efficacy. Furthermore, there is a lack of clear 
knowledge with the optimal chemistry and the difficulty of repeat dosing [66, 68]. 
 Another approach to using ASOs has been to redirect splicing by blocking the 3′ 
splice site of exon 8 and to inhibit the function of a negative splicing regulator within 
intron 6. The ASO targeting the 3′ splice site of exon 8 incorporated into U7 snRNA for 
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stable expression and increased exon 7 inclusion and SMN protein levels following 
delivery into SMA type-I patient fibroblasts using adeno-associated virus (AAV-5) [34]. 
1.5.2 Transplicing RNAs  
 The Lorson lab from the University of Missouri has proposed an alternative RNA 
therapy encompassing SMN trans-splicing. Trans-splicing requires a synthetic RNA 
(tsRNA) having three domains. The trans-spliced product is a chimeric mRNA that 
expresses functional FL-SMN. The first SMN tsRNA targeted intron 6 and replaced 
SMN2 exon 7 with SMN1 exon 7. SMN protein was augmented after AAV-2 delivery of 
this construct into a cell line. Next, the tsRNA vector was co-expressed with a short 
ASO designed to block the downstream splicing at exon 8 to promote a trans-splicing 
event. This was very effective in vivo with higher levels of the SMN protein in the brain 
and spinal cord of injected mice extending the lifespan about 70% [74-76]. 
 There is a unique therapeutic candidate, Tetracycline-like compound, (PTK-
SMA1), which is a synthetic small molecule compound that directly stimulates exon 7 
splicing and increases SMN protein levels in vitro and in vivo in mice. PTK-SMA1 
offers an alternative to antisense oligonucleotide therapies [77]. 
 1.5.3 Gene Therapy 
 Gene therapy vectors are used to provide a continuous source of exogenous FL-
SMN. Several groups have more recently used gene therapy to replace SMN with an 
adeno-associated virus (AAV)-based vector (scAAV9) delivered systemically 
intravenously, intrathecally or intracerebroventricular. This has already been tested in 
larger animals such as pigs and primates with results showing that delivery through the 
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vasculature, crossing the blood brain barrier, is able to transduce motor neurons at 
several levels of the spinal cord [31, 68]. Passini et al. (2010) treated SMA7 mice with 
a single administration of a recombinant adeno-associated virus (AAV8) vector 
encoding hSMN into the CNS (cerebral lateral ventricles and upper lumbar spinal cord) 
and observed an elevation in expression of SMN in the spinal cord, which induced an 
improvement of pathology along with an increase in lifespan to 50 days in comparison to 
the average 14 days for non-treated mice. They also treated the mice with injections of a 
self-complementary AAV (scAAV) vector (recombinant virus having a double-stranded 
DNA genome) that results in earlier onset of gene expression leading to an increase 
survival of 157 days. They concluded that increasing SMN by AAV injections in the 
CNS is very efficient at improving both neuronal and muscular pathologies in a severe 
mouse model of SMA [78]. Gene therapy currently shows promising preclinical efficacy 
without vast toxic effects, it is a one-time treatment and problems with autoimmunity are 
not predicted. However, large amounts of viral doses are required thus it is not the safest 
approach [68]; also the delivery issue has long been an obstacle, because the blood brain 
barrier restricts delivery of therapeutics to the central nervous system (CNS), where an 
insufficiency of functional SMN has the most severe consequences [73].  
 1.5.4 Stem Cells 
 Numerous SMA studies have used fibroblasts from patients or immortalized non-
motor neuron cell lines, but the possibility of using human SMA motor neurons 
generated from induced pluripotent stem cells (iPSCs) open new windows to further 
understand the pathology as well as to serve for accurate drug screening and therapeutic 
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efforts [79]. Stem cell therapy for many diseases including SMA is a compelling 
strategy of cutting edge research. However, more than functioning to replace motor 
neurons, stem cell research for SMA is promising in aiding the amelioration of the 
symptoms by providing trophic support to motor neurons [34]. iPSCs from skin 
fibroblasts of a young SMA patient were successfully differentiated into motor neurons 
expressing specific transcription factors and markers such as choline acetyltransferase 
(ChAT). This work by Ebert et al. (2009) opens the possibility that the underlying 
genetic defect can be repaired in vitro and then non-diseased cells in a state of pre-
differentiation can then be transplanted into the SMA patient [79].  A leading group in 
stem cell research for SMA is that of Dr. S. Corti from the University of Milan (Italy).  
Corti and collaborators have rescued some of the pathological hallmarks and increased 
survival of SMA7 mice after spinal cords were engrafted with primary neural stem 
cells from the spinal cord and embryonic stem (ES) cell-derived neural cell precursors. 
These cells exhibited mostly astrocytic but modest motor neuron characteristics. 
Mitigation of cell loss in the ventral horn suggests that the transplanted cells provided a 
neuroprotective effect. Furthermore, the stem cells secreted neurotrophic factors in 
culture and transplanted spinal cords had increased levels as well, thus the engrafted 
stem cells may be important to provide trophic support to motor neurons [38].   
 In a joint effort, a group led by H.S. Keirstead at the University of California 
(Irvin, CA) and the California Stem Cell Inc. (Irvine, CA), have also made use of stem 
cells as a therapeutic approach to treat SMA type I. They found that transplantation of 
human motor neuron progenitors (hMNP) from human ES cells into SMA7 mice 
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improves muscle atrophy and significantly enhances the number of spared endogenous 
neurons following transplantation by counteracting the disease process through secretion 
of neurotrophic factors to delay the loss of motor neurons; thus corroborating the 
findings by the Corti lab. This group had previously determined an efficient method to 
differentiate human ES cells into high purity populations of human embryonic stem cell-
derived hMNPs reported in Rossi et al. (2010) [80]. In vitro studies were initially 
performed to fully characterize the histopathology of the cell line. The hMNP line 
expressed high levels of Isl1, Hb9, NeuN and Tuj1, all of which are young motor neuron 
markers, as well as secrete and express the growth factors: NGF, VEGF, and NT-3 and 
4. Their in vivo studies served to assess the efficacy of the hMNP therapy. The cells did 
survive and differentiate as expected. A third party GLP facility tested the safety of the 
hMNPs and delivery methods; the toxicology studies validated the safety of this 
approach [81, 82]. An option for improved in vitro modeling is the use of human ES 
cells, which permit genetic manipulation and expand indefinitely in vitro. ES cells can 
differentiate into any cell type, are amenable to genetic manipulation, and readily self-
renew in vitro. Directed differentiation of ES cells into high purity populations of a 
defined cell type can be used to design effective treatments that are both cell and site 
specific; also they mimic early human development and processes leading to embryonic 
death. However, they can usually only model single gene diseases and are accompanied 
by serious social and political ethical debates for their use, thus limiting their potential 
for therapy, drug screening and disease modeling [81, 83].   
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 More recently, Corti’s group has genetically engineered iPSCs from SMA tissues 
to generate healthy motor neurons free from exogenous vectors and transgenic 
sequences. They achieved this by using nonviral, nonintegrating episomal vectors and 
then they used oligonucleotides to genetically correct SMN2 to produce a functional 
SMN1-like protein. Motor neurons derived from genetically corrected SMA-iPSCs 
showed rescue of the disease phenotype. After transplantation into a severe SMA mouse 
model, corrected SMA-iPSC- derived motor neurons improved the disease phenotype. 
These results are very important for potential therapy by generating patient-specific 
iPSCs avoiding problems with immunity, toxicity and ethical issues that come with 
using embryonic stem cells [84]. 
 1.5.5 SMA Drugs  
 Quinazolines have been proven to increase SMN2 promoter activity, and its 
derivatives that cross the blood brain barrier, can increase SMN in vitro as well as 
extend lifespan and improve the phenotype of several SMA mouse models including 
SMN7. Quinazolines are currently moving to phase I clinical trials. Oral bioavailability 
and positive safety results make quinazolines candidates for clinical trials [34, 68]. There 
are currently several C5-substituted 2,4-diaminoquinazoline derivatives under study. 
These compounds can increase SMN mRNA and protein levels and elevate gem number 
in treated SMA patient-derived fibroblast cell lines, and modestly increased survival in 
severe SMA mice. The molecular target of these compounds is DcpS, a scavenger RNA 
decapping enzyme. C5-substituted quinazolines robustly inhibit DcpS decapping 
activity. When C5-substituted quinazolines bind to DcpS, they force the enzyme into an 
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open conformation rendering it non-functional. The potency of SMN2 promoter 
activation strongly correlates with DcpS enzyme inhibition [85]. One quinazoline 
assayed by several groups is RG3039 [86, 87]. Meerbeke et al. (2013) have investigated 
the effects of RG3039 in SMA7 mice. Animals treated with RG3039 at 10 mg/kg/day 
showed increased weights, motor function, motor unit function and survival. This group 
found that RG3039 has an excellent CNS bioavailability in vivo and inhibits DcpS 
enzyme activity both in vitro and in vivo. However, the phenotypic benefit of RG3039 in 
SMA7 mice does not appear to correlate with proportional increases of SMN protein 
expression or snRNP assembly despite some modest changes detected in FL-SMN 
transcript. Treatment with RG3039 produced even better results when given to ChATCre 
Smn
Res conditional SMA mice (described in more detail below in the section on SMA 
animal models), in which SMN expression had already been restored to motor neurons, 
thus this compound can have beneficial effects to improve motor neuron function. 
Recently, a phase I clinical trial was completed with preliminary data indicating good 
safety results in healthy volunteers [86].  
 Another group, led by Dr. Christine DiDonato, has pharmacologically 
characterized the effects of RG3039 on SMA neuromuscular pathologies using the 
Taiwanese and 2B/- SMA mouse models (described in more detail below in the section 
on SMA animal models). They determined that RG3039 increased lifespan and 
improved function in both mouse models, especially upon early treatment. To note, the 
increase in survival in the 2B/- mice was a very impressive ~600% over vehicle treated 
littermates. RG3039 treatment doubled the number of motor neurons containing gems 
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and increased the average number of gems/motor neurons. With their experiments, this 
group concluded that even though RG3039 modestly increased SMN levels in many 
tissues, it did nonetheless in motor neurons and redistributed the protein to the nuclear 
compartment [87]. 
 Another group of compounds, histone deacetylase (HDAC) inhibitors, has shown 
promise in several models of neurodegeneration. Several different HDAC inhibitors are 
Food and Drug Administration (FDA) approved and they have been tested in SMA 
mouse models and in patients [32]. HDAC inhibitors can increase expression of genes 
by modifying chromatin structure. After cell-based drug screens several of these 
compounds were found to increase SMN in lymphoblastoid cell lines from SMA 
patients. HDAC inhibitors can activate the SMN2 promoter and stimulate the inclusion 
of exon 7 thus increasing FL-SMN messenger RNA [41]. Trichostatin A (TSA) is an 
HDAC inhibitor that can augment both SMN2-derived transcript and SMN levels in 
neural tissues and muscle resulting in an increase in lifespan and improvement of 
symptoms in SMA7 mice, especially when combined with nutritional support. Positive 
results were also obtained with sodium butyrate and valproic acid [34, 41]. Another 
HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA), elevated SMN levels in two 
severe SMA mouse models resulting in an increase in their lifespan and amelioration of 
pathological symptoms [88]. 
 TSA, sodium valproate and aclarubin are activators of the STAT5 (signal 
transducers and activator of transcription proteins) pathway, at least in SMA-like mice 
embryonic fibroblasts. The STAT5 pathway can increase SMN. Prolactin, a protein that 
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enables the production of milk and crosses the blood brain barrier, is also a potent 
activator of this pathway and serves as a potential treatment strategy [1]. Farooq et al. 
(2011) have shown that treatment with prolactin increases SMN levels, both in vitro and 
in vivo (wild-type (WT) and SMA7 mice), via the transcriptional activation of SMN 
through the STAT5 pathway [1]. 
 Sodium vanadate is capable of producing improvements in SMA. The problem is 
that vanadate can be toxic. One group has studied how combining sodium vanadate with 
L-ascorbic acid, which detoxifies vanadium, can circumvent the issues with toxicity and 
still yield positive results treating SMA mice. The combined treatment protected cells 
against vanadate-induced cell death and after a month of treatment, mice with late-onset 
SMA had a delayed disease progression, improved motor performance in adulthood, 
enhanced SMN levels and motor neuron numbers, and reduced muscle atrophy while 
achieving substantially decreased vanadium accumulation in these organs [89]. 
 A downside to the SMA drugs out there is that in most cases these compounds 
were found by induction of SMN in patient fibroblast lines. Given that these are not 
motor neurons, it is plausible that these compounds do not induce SMN in vivo in the 
required cell types. This has been true for a number of molecules when tested in mice.  
Of the compounds reported to induce SMN in cultured cells, including some mentioned 
above, phenylbutyrate, hydroxyurea, valproic acid and Salbutamol have been taken to 
clinical trial without evidence of clinical benefit and produced only a modest effect [68]. 
 In some cases, improvements in lifespan and neuromuscular pathology can also 
be obtained without necessarily incrementing SMN. For example, beneficial results were 
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seen after treating a mild SMA model with an inhibitor for Rho-kinase [34]. This is 
something that could also be considered during drug trials. 
 1.5.6 Others 
 In one study recombinant follistatin, an inhibitor of myostatin, modestly 
increased survival and gross motor function of SMAΔ7 mice. Even though rescue was 
not robust the importance of this is that enhanced muscle conditions may contribute to 
the maintenance or stabilization of an intact motor unit and that the possibility exists that 
motor neurons may require additional support for complete rescue. Thus, muscles could 
also be targets in conjunction to SMN-based approaches [90].  Lastly, the least invasive 
approach to therapy is exercise. A study by Grondard et al. (2005) demonstrated that 
physical exercise (running-based training) was successful at increasing lifespan, 
reducing muscular atrophy, enhancing motor neuron survival via neuroprotective effects, 
improving motor behavior, and increased exon 7-containing SMN transcripts in the 
spinal cord of type II SMA mice (mouse model by Hsieh-Li et al. (2000) [46], described 
further in detail in the section below on SMA animal models). They concluded that 
exercise employs its beneficial effects in some way by interfering with the splicing 
regulation of the SMN2, but whether or not this is a cause or consequence of 
neuroprotection was not eluded [91]. 
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Table 1.1. Summary of some therapeutic approaches for SMA. Adapted from Sumner 
(2007) [41] and Mercuri et al. (2012) [52] 
The 
problem 
Therapeutic 
targets 
Therapeutic 
approaches 
Research and/or clinical 
trials completed or 
ongoing 
SMN1 
mutation 
Replacement of 
SMN 
Gene replacement 
therapy 
- 
Alternative 
splicing of 
SMN2 
Inclusion of exon 
7 
Antisense 
oligonucleotides 
New drugs developed by 
ISIS pharmaceuticals 
Decreased 
FL-SMN 
transcript 
Increased 
amounts of SMN 
transcripts 
HDAC inhibitors, 
quinazolines, RG3039, 
aminoglycerides, 
albuterol and prolactin 
Phenylbutyrate 
(randomized controlled 
trial) 
Valproate (randomized 
controlled trial) 
Hydroxyurea (randomized 
controlled trial) 
Albuterol (open-label and 
ongoing randomized 
controlled trial) 
 
SMN 
protein 
deficiency 
Stabilization of 
SMN 
Indoprofen, proteasome 
inhibitors, polyphenols 
- 
Loss of 
motor 
neurons 
Neuroprotection 
Neurotrophic factors, 
stem cells 
Gabapentin (randomized 
controlled trial), Riluzole 
(open-label), Olesoxime 
(TRO19622) 
 
Clinical 
symptoms 
- Palliative care - 
 
 
 
1.6 INSIGHTS FROM DIFFERENT GENETIC ANIMAL MODELS 
 Many animal models have been generated to study the different aspects of SMA. 
They have all been useful to understand gene function, disease pathology, molecular 
mechanisms, and to test the possible targets for a cure; however, it is important to note 
that animal models available have not been able to fully recapitulate the SMA pathology 
observed in humans.  
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 The complete absence of SMN production in Caenorhabditis elegans (in 
experiments with RNA interference [9]) results in embryonic lethality. When SMN is 
reduced, though not fully depleted, lethality is prevented but length in lifespan is 
hindered; there is also a block in the development of late larval stages, infertility, and 
most importantly a reduction in locomotor function. 
 In 2009, a genetic model for SMA was generated using zebrafish. Three 
mutations in Smn1 were identified, all of which lead the zebrafish to exhibit presynaptic 
neuromuscular junction defects [7].  During embryogenesis, mutant axons in zebrafish 
grow abnormally with a reduction in size and numerous branches [9]. It is worthy to 
mention that SMA zebrafish motor neurons have been rescued from some of their 
defects when non-SMN-related snRNPs where reintroduced [23].  
 Drosophila has been used as a model to provide a basis for a better understanding 
of SMA. One study, by Dr. Brian McCabe’s group, found that Drosophila Smn mutants 
have many of the pathological characteristics observed in the human SMA phenotype 
such as a reduction in muscle size, locomotive impairments, motor rhythm, and 
deficiencies at the neuromuscular junction and motor circuitry in general [92]. A very 
important finding for the field has also come from this group. They have attempted to 
restore SMN in either muscles or motor neurons. The phenotypes were not improved 
until SMN was restored to proprioceptive neurons and interneurons in the motor circuit 
to non-autonomously correct defects in motor neurons and muscles and lessen 
pathology. They have proposed that sensory-motor circuit dysfunction could be the 
origin of motor system deficits in the Drosophila SMA model [50, 92].  
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 To identify additional potential therapeutic approaches, Artavanis-Tsaconas and 
collaborators have aimed at identifying genetic and biochemical interactors/modifiers of 
the Drosophila SMN homolog. This group has identified more than 300 candidate genes 
that alter an Smn-dependent phenotype in vivo. Amongst their important results, they 
have found that many of the genes are associated with RNA metabolism, however the 
majority found are not involved with the role of SMN in snRNP biogenesis but with 
transcription, post-transcriptional modifications, RNA transport, and translation 
regulation. Also, they identified functional links between Smn and the FGF pathway. 
This has been corroborated in a mouse model [93-95]. Using Drosophila as an animal 
model has allowed a genome-wide screen detecting specific genes that have a reduced 
expression in mutants and can be considered novel targets for up-regulation and 
restoration of expression to counteract the pathology, as well as proteomic studies and 
bioinformatic analyses to define a unique SMN interactome.  
 SMA mouse models have been invaluable for understanding the underlying 
mechanisms of this pathology since the basic elements of the NMJ structure and function 
are evolutionarily conserved between humans and mice [96]. SMN mutant mice have 
been widely used to determine the tissue-specific role of the SMN protein by both 
selective SMN rescue and depletion experiments. Several transgenic mice have been 
produced to model SMA with varying levels of severity. One of many reasons that 
mouse models are good subjects for SMA is that in the mouse Smn, which produces only 
the full-length SMN, the sequence at the putative ESE is a perfect match to human 
SMN1 over a 15 bp stretch [11, 97]. In several mouse models it seems that most NMJs 
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develop at a slower rate but quite normally compared to controls, thus this SMN related 
defect would not be the main developmental defect in SMA [8]. Some of the mouse 
models are detailed herein.  
 The mouse model that expresses the most severe form of SMA, surviving to only 
P5 at best, has the endogenous mouse Smn gene completely knocked-out but expresses 
small amounts of SMN due to an insertion of the human SMN2 gene to avoid embryonic 
lethality and test the hypothesis that human SMN2 acts as a disease modifier (Smn−/−; 
hSMN2[89Ahmb]
+/+) [44]. These mice are viable at birth but develop a severe muscle 
paralysis and die within the first postnatal days when they carry one or two copies of the 
transgene [10, 44] or can reach adulthood if they carry eight copies of the transgene [44, 
96]. The motor neurons of these mice develop normally and do not show defects in 
motor axon formation or axonal branching but they do have signs of denervation even at 
embryogenesis [5, 98]. Motor neurons cultured from these animals have decreased 
axonal length and reduced growth cone size, and reduced levels of -actin at the growth 
cone [98]. Reduced levels of SMN in this mouse model yield impaired perinatal brain 
development. For example, the hippocampus presents decreased cell density, reduced 
cell proliferation and impaired neurogenesis [99].   
 Until 2013, no physiological study had been performed on the Tibialis Anterior 
(TA) muscle of these mice. Boyer et al. determined that mutant P2 TA muscle 
preparations produced 67% lower peak tetanic force than control littermates, indicating 
that muscle weakness is an early defect, and mutant P5 TA muscle preparations have 
47% less twitch force and 39% less maximum peak tetanic force than controls; they also 
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have an inability to recover from induced muscle fatigue over time [100]. These severe 
SMA mice have been considered a suitable model since SMA is characterized by a 
reduction in SMN production rather than a complete absence. However, their short 
lifespan limits the breath of their pathological assessment. The idea for this model came 
from a previous study by Monani et al. (1999) [11] that proved the unprecedented 
similarity between SMN1 and SMN2. This is the animal model used for Aim 1 reported 
in Chapter II of this dissertation. A very similar mouse model also emulating severe 
SMA was made by Hsieh-Li et al. (2000) a group in Taiwan, hence the common name 
“Taiwanese mouse model”. This mouse carries the null allele Smn–/– due to targeted 
replacement of Smn exon 7 (Smn1tm1Hung) with the hypoxanthine phosphoribosyl-
transferase (HPRT) cassette. It also carries copies of the human SMN2 allele 
[Tg(SMN2)2Hung]. This was done initially to elucidate the roles of human SMN1 and 
SMN2. Transgenic mice with a 115-kb genomic DNA fragment including the hSMN2 
region, part of centromeric NAIP, and intact centromeric SERF1 were crossed to the Smn 
mutant mice [46]. These mice survive perinatally but exhibit SMA symptoms ranging 
from mild to early death even within the same litter, an observation of familial variance 
not frequently found in SMA patients [46, 96, 101]. Severe SMA pups die within the 
first week post birth, intermediate pups die by 12-17 postnatal (P) days, and mild SMA 
mice (carrying four copies of the SMN2 transgene) have a much longer lifespan but 
present muscle weakness and a short thick tail that becomes necrotic and falls off by 1 
month of age with potential for foot and ear necrosis later on in life [101].  Although 
there are some differences between the studies reported by Monani et al. (2000) and 
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Hsieh-Li et al. (2000), the most important finding through these two similar models is 
that SMN2 serves to compensate the absence of Smn, avoiding embryonic lethality, and 
that copy number is inversely proportional to disease severity [13].  
 Le et al. generated a set of mice in 2005 that model severe SMA termed the 
SMAΔ7 mice (Smn-/-; SMN2+/+; SMNΔ7+/+). These mice are able to survive longer with 
an average lifespan of about 2 weeks. They have the same characteristics of the severe 
ones described above and in addition possess cDNA from the SMN locus lacking exon 7 
(SMNΔ7) to resemble the functional protein contribution that can be obtained from a 
copy of the SMN2 gene.  The SMNΔ7 cDNA was initially introduced to assess its 
potential toxicity since there was evidence stating that over-expression of SMNΔ7 in 
neurons was pro-apoptotic [6]. These mice have a milder phenotype due to the formation 
of heterologous complexes between FL-SMN and SMNΔ7 that stabilize SMN by 
increasing the amount of oligomeric SMN [6, 96]. However, even in SMA mice 
transgenically expressing extremely high levels of SMNΔ7 transcript, the protein is 
measurable at only low levels [35]; therefore the truncated protein does not rescue from 
a severe phenotype.  These SMAΔ7 mice were generated by taking cDNA lacking exon 
7 and placing it under control of a 3.4kb SMN promoter fragment and this was then 
inserted into fertilized oocytes of FVB/NJ mice. These mice were later crossed with 
mice having human SMN2 and a mouse-Smn knockout allele [6]. This engineered mouse 
exhibits a progressive loss of motor function and behavior, resembling severe SMA in 
humans [102], and has been found to recapitulate, to some extent, the SMA pathology at 
the level of neuromuscular junctions as well. These mice present a modest loss of motor 
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neurons, around P13, and proprioceptive neurons but have a significant early impairment 
of motor behavior that precedes motor neuron loss; thus, the first behavioral 
abnormalities are most likely due to impairments in motor neuron function [40, 51, 55, 
103]. They also show defects in synaptic transmission with an approximate 50% 
reduction in quantal content [30] along with a very drastic synapse number reduction in 
the sensory-motor connection between proprioceptive sensory neurons and motor 
neurons [51]. Ling et al. (2011) evaluated neuromuscular junctions in about 20 muscles 
of the SMAΔ7 mice and found that neuromuscular denervation in vulnerable muscles 
was widespread consistent with the expected pathology in SMA [104]. In this mouse 
model, the muscle that is most severely affected, in terms of functionality, is the 
transversus abdominis [9]. Interestingly, almost all the NMJs in the hindlimb muscles 
are innervated and capable of neurotransmitter release though some structural 
abnormalities are present; thus, part of the pathology observed in the SMA phenotype 
could instead be due to a significant reduction in central synapses, especially in 
proprioceptive inputs in L3-L5 innervating distal muscles [51].  Another characteristic of 
SMAΔ7 mice is that there is delay in the loss of polyneuronal innervation of some 
anterior muscles [40].  It is important to note that SMAΔ7 mice may suffer from 
bradycardia by P2 even before the onset of some neuromuscular symptoms [61].  
 A variation to SMAΔ7 is the SMAΔ7-like mouse. This mouse carries a 
conditional inducible mutant allele Smnres floxed by Lox-P sites that can be reverted to a 
WT functional allele upon Cre-recombination. The Smnres differs in that it has an 
inverted. 3’ to 5’, translationally silent, mouse Smn exon 7 in the intron between human 
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SMN2 exon 7 and 8. This mutant allele only produces transcripts coding for the 
truncated SMN7 protein. SMAΔ7-like mice present many of the same pathological 
characteristics as the SMAΔ7 mice. They only survive 2 weeks on average, are unable to 
gain weight and thrive, have impaired motor behavior, structural and functional NMJ 
defects, NF accumulation, immature and small AChRs, progressive loss of motor 
neurons in the L1 segment (60% loss by end-stage of disease), small muscles and 
myofibers, NMJs with reduced evoked endplate current (EPC) amplitudes, reduction in 
the probability of synaptic vesicle release, and disruptions of central motor neuron 
synaptic inputs among others [56, 57]. SMAΔ7-like mice serve as a good model to 
determine cell-specific roles in SMA since the mutant allele can be conditionally 
reverted to WT in an individual subset of cells. This is the mouse model used in Aim 2 
reported in Chapter III of this dissertation and will be explained in detail further along. 
 There is one type of mouse model that can survive much longer, even over a 
year, (average 227 days with one copy of the transgene) generated by Monani et al. in 
2003 (SMN2+/+; Smn-/-; SMN1(A2G)+/-). The authors used a cDNA carrying an A2G 
mutation under a 3.4-kb SMN promoter fragment that was later microinjected into 
fertilized mouse oocytes. The mice produced were crossed to low copy SMN2, Smn-/- 
mice. Double transgenic SMN A2G;SMN2+/+;Smn-/- mice were interbred or crossed to 
SMN2
+/+
;Smn
-/- animals to obtain mice carrying 1 to 2 copies of SMN2 plus the mutant 
transgene while lacking mouse Smn (SMN A2G;SMN2+/+;Smn-/-). The A2G transgene 
delays the onset of motor neuron loss thus rendering a milder phenotype. Their 
experiments demonstrated that mice of this genotype had the same phenotype as SMA 
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type III with muscle atrophy and motor neuron degeneration but with restored SMN in 
motor neurons, evidenced by immunocytochemical staining showing the presence of 
gems in the spinal cord. To note, mice with only one copy of A2G are significantly 
smaller than WT littermates and display a reduction in activity. Homozygosity of the 
A2G transgene renders a milder phenotype and has extended the survival of some mice 
up to at least 15 months. SMN A2G is unable to efficiently self-associate, the A2G 
transgene forms higher order SMN complexes only when it is in the presence of low 
levels of full-length SMN. However, the A2G mutant transgene was not capable of 
avoiding embryonic lethality in the absence of SMN2 indicating that mutated SMN 
needs to be expressed in the presence of small amounts of FL-SMN to achieve 
phenotypic modification [37].  
 With one approach to reduce Smn levels, a mouse model was created by 
knocking-in the Smn2B/− allele, akin to SMN2, that disturbs endogenous Smn splicing 
resulting in the production of Δ7Smn mRNA. When the Smn2B/− allele is present with the 
null allele it gives rise to a mouse with a more moderate severity of SMA (mean lifespan 
of 28 days). The Smn2B/− allele has mutations (3 nucleotide substitutions) within the 
exonic splicing enhancer exon 7 of the endogenous Smn gene. Even though they are 
indistinguishable from controls at birth, by two weeks of age Smn2B/− mice start 
exhibiting symptoms of pathology and by the third week are significantly smaller than 
WT littermates. Smn2B/− mice present the characteristic pathological hallmarks of SMA 
observed in patients and mild mouse models such as muscle weakness (one study found 
that P9 TA muscle preparations produced 61% lower peak tetanic force than control 
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littermates, placing the weakness in evidence [100]), gait abnormalities, weight 
reduction, loss of lower motor neurons from the brain stem and spinal cord (around 
P21), pre-synaptic neurofilament accumulation, and denervation alongside post-synaptic 
shrinkage and abnormal endplate morphology. These mice have a significantly lower 
ratio of full-length Smn/Δ7Smn transcript while protein expression is reduced 
ubiquitously [96, 97, 105, 106]. There is a modification to this Smn2B/− allele, the Smn2B-
Neo, that when found homozygous causes embryonic lethality because of a loxP- flanked 
neomycin (neo) gene resistance cassette that impedes normal Smn expression. Smn2B-
Neo/2B-Neo embryos die by E9 due to very low levels of SMN [107, 108]. In the presence 
of Cre recombinase, the embryonic lethality can be rescued by excision of the floxed 
neomycin cassette allowing for postnatal survival. Using a tamoxifen-inducible Cre line 
embryonic lethality can be rescued but only if it is early in gestation [108]. By breeding 
one copy of SMN2 to an Smn2B-Neo/2B-Neo background protein levels were increased and 
embryonic lethality was prevented. However, these pups present a similar 
symptomatology as other severe SMA mouse models such as reduced survival and 
weight gain, diminished motor function with paralysis by P5, bradycardia, loss of 
sensory-motor synapses, motor neuron hyperexcitability and excess synaptic activity, 
and autonomic defects [107].  
 Frugier et al. (2000) from the Judith Melki Lab (France) generated mice carrying 
a deletion of Smn exon 7. The deletion was directed to neurons using the Cre–loxP 
system (Smnf7/SmnΔ7; NSE-Cre+). These mutant mice exhibit a rapid motor deterioration 
and neurogenic atrophy of skeletal muscle leading to complete paralysis and death at ~ 4 
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weeks. They do, nonetheless, have a normal neuronal density in the spinal cord [109]. 
Cifuentes-Diaz et al. (2002) later used this neuronal mutant mouse model and observed a 
dramatic and progressive loss of proximal motor axons (up to 78% reduction) with only 
a mild loss of motor neuron cell bodies [58]. The Melki group also generated a muscle-
specific Smn mutant (Smnf7/SmnΔ7; HSA-Cre+). These are Smnf7/Δ7 mice with Cre-loxP-
mediated deletion of Smn exon 7 in myoblasts and post-mitotic fused myotubes of 
skeletal muscle. HSA-Cre+ mice survive approximately one month [54]. These two 
models from the Melki lab with tissue-specific complete ablation are not considered 
adequate SMA mouse models. Although muscle as well as neuronal knock-out mice do 
develop the SMA phenotype it is not surprising because SMN is essential to cell 
survival, and these mice were engineered so that the protein was abolished rather than 
reduced as it is in the human disease; SMN levels that are too low such as in the cases 
here induce cell death by disrupting the constitutive cellular function of SMN. 
Additionally, the nerve-targeting experiments abolished SMN indiscriminately in all 
neurons. In summary, these mice do not appropriately mimic the human SMA pathology 
nor provide complete or precise knowledge into motor neuron vulnerability [19, 96].   
 A potentially better mouse model was engineered later on by Park and 
collaborators (2010) in which endogenous Smn was conditionally depleted in motor 
neuron progenitor cells by Cre-loxP targeting of the Smn exon 7 in the spinal cord; the 
Cre cassette was knocked into the locus of the motor neuronal progenitor expressing 
Olig2 gene. They used mice with the null Smn allele allowing them to produce 
heterozygotes with a floxed Smn allele on one chromosome and the null allele (SmnF7/−) 
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on its homolog. SMN was not completely ablated because the mutant model includes 
copies SMN2 (Olig2-Cre;SMN2;SmnF7/−). Their experiments did confirm that Olig2-
Cre-mediated recombination was specific to spinal motor and not sensory neurons. 
Through this approach about 70% of their mutant animals survived a year but were still 
clearly distinguishable from controls. By P2, these mice exhibited the SMA-like 
symptoms of reduced size and muscle mass, kyphosis of the spine, and significant 
weakness (determined by grip strength and the open field assay); however, some of these 
symptoms mitigated over time. By late-stage in the disease they observed a significant 
loss of cervical and lumbar spinal motor neurons. The authors concluded that SMA is 
likely a cell-autonomous consequence of reduced SMN in spinal motor neuron 
progenitors since depletion of SMN selectively in these cells was sufficient to cause 
SMA pathological hallmarks such as atrophic muscle fibers. The milder than expected 
phenotypes observed in these mice is probably due to the of the presence of SMN in 
tissues other than motor neurons thus lessening the phenotype directly or even indirectly 
by providing trophic support to the motor neurons slowing down disease progression 
[19]. 
1.7 RESTORATION HYPOTHESIS 
 Even though the role of SMN in assembly of the spliceosome has been 
extensively studied, the pathologically relevant cellular site of action is still unclear. A 
properly assembled spliceosome complex is vital for the normal functioning of all cells, 
thus it’s puzzling why the SMA pathology is expressed more significantly in motor 
neurons and the skeletal muscles they innervate when the disruption of a housekeeping 
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gene should affect the entire organism and not so selectively. Extensive research has 
been performed attempting to elucidate which tissues are more directly susceptible to 
reduced levels of SMN and how that leads to the primary symptoms of SMA. The 
existing mouse models for SMA have been engineered to express the phenotype 
observed in patients. Nonetheless, it has not yet been elucidated whether the problem in 
SMA is cell autonomous or not. The main dogma in SMA research is that motor neurons 
are the cells most affected by the paucity of SMN because: 
i) SMN might have a specific function in these cells that is not as essential in 
others. When said function is disrupted it could impair neuronal growth and 
differentiation [16]. 
ii) There is a very intrinsic property of motor neurons that makes them more 
susceptible.  
iii) They have a higher demand for small nuclear ribonucleoprotein assembly and 
messenger RNA processing [41]. 
iv) Inefficient small nuclear ribonucleoprotein assembly could cause inappropriate 
splicing of vital motor neuron-specific messages. 
v) Motor neurons lack a compensatory mechanism.  
 
 We have hypothesized that if motor neurons are indeed the key cells 
responsible for the SMA phenotype, then selective restoration specifically in these cells 
should have a critical impact on survival and ameliorate the characteristic symptoms.  
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1.8 JUSTIFICATION 
 It is widely known that different restoration efforts in mouse models have 
produced vast improvements in their SMA pathology and even increased lifespan 
significantly. For example, pan-neuronal expression of SMN in severe mutant mice 
(Smn-/-; SMN2+/+) increased the lifespan of mutant animals up to approximately 210 
days [110]; SMAΔ7 mice treated with CNS or peripherally-directed viral vectors 
expressing SMN also greatly increased the lifespan between 50 to 200 days [78, 111]; 
and both CNS and peripherally-delivered oligonucleotides correcting the exon skipping 
defects in SMN2 functioned to improve lifespan past 100 days [64, 72]. However, those 
approaches fail to elucidate precise cell specificity. 
 Patients have particularly low levels of spinal cord SMN [11] and motor neurons 
are the cells that exhibit vast pathology and appear most affected by the loss of this 
ubiquitous protein. Furthermore, muscle-specific SMN restoration does not improve 
lifespan [110] ruling it out as a primary target, and though the genetic reduction of SMN 
solely in motor neurons does not cause lethality it does yield the SMA pathology (such 
as NMJ structural and physiological abnormalities) [19, 55, 107]. Thus, motoneuronal-
specific SMN restoration is a logical approach to both understand the basic mechanisms 
underlying SMA and to develop therapeutic strategies for site-specific delivery of SMN 
in motor neurons of SMA patients. However, it is important to highlight that during the 
course of this research, two independent groups attempted a motoneuron-specific 
restoration of SMN in SMA mouse models. These two groups reported on improvements 
or complete rescue of several signs of SMA pathology but achieved only a modest 
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increase in lifespan. These results contribute to the growing body of evidence that SMA 
may not be a cell-autonomous disorder and that motor neuron rescue is critical though 
not sufficient for significant increases in lifespan [57, 107].  
 In our study we have aimed at determining whether or not SMA is a cell-
autonomous disease as well as to have a better understanding of the role that motor 
neurons have in the SMA pathology. We used two strategies, each with a different 
mouse model, to restore the SMN protein (exogenously or endogenously) selectively in 
α-motor neurons of the ventral horn of the spinal cord by means of the Hb9 promoter. 
First, we tested restoring human SMN expression driven by the motor neuron specific 
promoter Hb9 in transgenic animals generated in our lab. We determined whether 
crossing them to severe SMA mice, which die perinatally, would rescue survival. Our 
results indicate that in spite of detecting the presence of transgenic human SMN, 
inheritance of the transgene was insufficient to increase the survival of severe SMA mice 
(mean lifespan ~ 1 day). However, the transgene does allow for the expression of a 
stable SMN protein with a long turnover that was capable of significantly reducing 
neonatal mortalities in transgene-positive control mice and possibly improving motor 
function at an early time point. These experiments are described in Chapter II of this 
dissertation. 
 In the second approach we have attempted to restore endogenous motoneuronal-
SMN expression following prenatal Hb9-dependent Cre recombination of a conditional 
hybrid mutant allele (Smnres) in another severe SMA mouse model (SMAΔ7-like). Cre 
recombination irreversibly transforms the Smnres allele to WT. We confirmed that 
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recombination of the conditional allele occurs exclusively in the spinal cord. Yet, mean 
lifespan, weight loss, and motor behavior did not significantly differ between our rescue 
and mutant mice. Another group performed similar motoneuron-selective rescue 
experiments of SMAΔ7-like mice. Though increase in lifespan was modest, they found 
improvements in SMA neuromuscular junction (NMJ) phenotypes by using a choline 
acetyltransferase (ChAT)-Cre driver to rescue the inducible allele [57]. We found that 
our Hb9-Cre driven SMN expression is significantly lower than the ChAT-Cre driven 
SMN in their rescue model, likely explaining the difference in phenotype between our 
and their mouse lines. However, like in ChAT(Cre+)SMA mice, we detected rescue of 
NMJ size and innervation status in denervation-susceptible muscles. Our results indicate 
that our Hb9-Cre driven SMN expression is insufficient to improve survival but 
sufficient to rescue two NMJ structural parameters very sensitive to changes in 
motoneuronal SMN levels. These experiments have been published (Paez-Colasante et 
al. (2013) [56]) and are described, with additional supporting results, in Chapter III of 
this dissertation.  
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CHAPTER II 
RESCUE OF A SEVERE SMA MOUSE MODEL WITH TRANSGENIC HUMAN 
SMN RESTORATION DRIVEN BY THE MOTOR NEURON-SELECTIVE HB9 
PROMOTER 
 
2.1 SYNOPSIS 
 Spinal muscular atrophy (SMA) is a common neuromuscular disorder in humans 
characterized by the loss of -motor neurons and atrophy of their target muscles. SMA 
is caused by mutations in the SMN1 gene that reduces the SMN protein to subnormal 
levels. Restoring levels of SMN in SMA animal models is perceived to be a viable 
therapeutic option. Since motor neurons are the cells most affected, we report on an 
attempt to restore human SMN selectively in motor neurons by driving its expression 
with the motor neuron-selective Hb9 promoter. We have assessed whether their crossing 
into a severe SMA mouse model, which dies perinatally, could extend their survival and 
rescue their SMA-like phenotype. At the protein level, transgene expression was 
detected by immunostaining in embryos and until at least postnatal day (P) 6 in the 
ventral horn of the spinal cord. Expression of human SMN was specifically detected in 
spinal cord but not skeletal muscle by Western blot. Nonetheless, transgenic hSMN 
mRNA expression was undetected by late embryogenesis. Thus, slow protein turnover 
appeared to account for the detection of transgenic protein postnatally, despite the failure 
to detect transgenic mRNA prenatally. This result likely explains why hemizygous 
inheritance of the transgene was insufficient to increase the survival of severe SMA 
  48 
mice, as both transgene-positive and transgene-negative animals survived only to P1 on 
average.  
 
2.2 INTRODUCTION 
 SMA is a leading genetic cause of infant and early childhood mortality [2, 4, 5]. 
It is a recessive disorder resulting in degeneration of motor neurons and severe atrophy 
of their target muscle due to the paucity in SMN protein production [5, 28]. The protein 
SMN functions mainly in the assembly of the spliceosome in all cells [8, 103] and is 
encoded, in humans, by SMN1 and SMN2 [11]. These genes lie adjacent to each other 
and are almost identical except by one key nucleotide, a C-to-T transition in exon 7, 
which alters an exon splice modulator [1, 28, 33]. This single nucleotide causes the 
majority of the transcript from the SMN2 gene to lack exon 7 (SMN7), whereas SMN1 
produces full-length SMN transcripts [8, 28, 35]. Mutations in SMN1 cause SMA, while 
the SMN2 gene is retained [2, 8, 35, 37]. The protein SMN7 does not oligomerize 
efficiently and is rapidly degraded, thus causing a reduction in SMN levels, which are 
insufficient for the correct function and survival of motor neurons [8, 28]. The 
phenotypic severity of SMA is modulated by how many copies of SMN2 are present [14, 
40, 44].  
 The existing mouse models for SMA have been engineered to express the 
phenotype observed in patients. Nonetheless, it has not yet been elucidated whether the 
problem in SMA is motor neuron-cell autonomous or not. Extensive research has been 
performed attempting to elucidate which tissues are more directly susceptible to reduced 
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levels of SMN and how that leads to the primary symptoms of SMA. For many years in 
the SMA field, the dogma has been that motor neurons are the most susceptible cells to 
the SMA pathology and thus are the first ones in need of rescue to ultimately stop the 
overt pathology progression. Reduction of SMN selectively in motor neurons is enough 
to yield some features of the SMA phenotype in mice [19]. If the dogma is accurate, 
selective SMN restoration in motor neurons should greatly ameliorate the pathological 
hallmarks. To test this hypothesis, we have attempted to restore human SMN expression 
driven by the motor neuron specific promoter Hb9 in transgenic animals generated in our 
lab. We determined whether crossing them to severe SMA mice (Smn-/-; SMN2+/+), 
which die perinatally (described in Chapter I), would extend the survival of these short-
lived animals.  
 Hb9 is a homeodomain transcription factor in the central nervous system vastly 
motoneuron specific [112]; it is composed of 3 exons (6 kb) with an open reading frame 
of 1206 nucleotides coinciding with a diverged homeodomain [113]. We are using an 
Hb9 promoter because previous data has clearly demonstrated that Hb9 is mostly 
specific to motor neurons and widely conserved in vertebrates, making it a useful marker 
for motor neuron phenotype and a tool to assess the function of motor neurons in SMA. 
The Hb9 gene is properly activated in newly formed spinal motor neurons but not in 
adjacent cell populations in the developing spinal cord. Hb9 functions to sort the 
different classes of motor neurons along the spinal cord and for their axons to extend to 
their appropriate pathways [114]. This transcription factor is also found in V2 
interneurons though more modestly than in motor neurons. The progenitor cells of motor 
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neurons and V2 interneurons express a similar profile of genetic markers meaning that 
pathways in the specification of these neurons are closely related but Hb9 serves to 
separate the identities of these two during development; furthermore, Hb9 suppresses 
interneuron genetic programs and facilitates the development of normal patterns of 
motor neuron connectivity [114], thus it is useful to distinguish between motor neurons 
and interneurons [114, 115]. Mice and chick embryos with null mutants of Hb9 have 
deficiencies in motor neuron development and these motor neurons aberrantly express 
genes ordinarily restricted to V2 interneurons. Also, proper cell fate specification in the 
spinal cord is dependent on the exclusion of Hb9 from neighboring interneuron 
populations [114].  Boon et al. (2009) used zebrafish to test the role of motor neurons by 
restoring SMN specifically in these cells and determining if there was a rescue of 
phenotype in terms of synaptic vesicle protein, SV2, quantification. SMN was restored 
to motor neurons by expressing SMN through the Hb9 promoter. Their experiments 
demonstrated that their mutant zebrafish with decreased SV2 expression were rescued 
when normal SMN levels were restored. Boon and co-authors not only demonstrated that 
SMN is vital for the maintenance of SV2 in presynaptic terminals, but most importantly 
that restoration of human SMN with an Hb9 promoter is a viable strategy [7].  
 To exogenously restore SMN, transgenic mice were previously generated by our 
group to selectively express the human SMN (hSMN) protein in motor neurons by 
means of the motor neuron promoter Hb9. In the design, a murine Hb9 promoter was 
inserted upstream of an expression cassette containing human SMN1 cDNA, an internal 
ribosomal entry site (IRES), and enhanced green fluorescent protein (EGFP). The single 
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mRNA produced here yields hSMN and EGFP as separate proteins so the presence of 
EGFP indicates the existence of hSMN in tissues, i.e., GFP is a marker or proxy gene 
(Fig. 2.1). The green fluorescent protein (GFP), from the jellyfish Aequorea victoria, is 
an autofluorescent protein that is a widely used reporter in gene expression and protein 
localization studies. The emission of GFP does not require any cofactors or substrates.  
The fluorescence of GFPs is dependent on the key sequence Ser-Tyr-Gly. Enhanced 
GFP (EGFP) contains mutations of Ser to Thr at amino acid 65 and Phe to Leu at 
position 64 and is encoded by a gene with human optimized codons [116]. The plasmid 
pHISG with the transgenic construct, denominated herein as Hb9(hSMN/Gfp), was 
inserted into zygotes of an FVB background after three rounds of pronuclear injections 
yielding two transgenic lines, line 151 and line 4 (Rimer et al; unpublished).  
 
 
 
 
 
Fig. 2.1. Transgenic construct. Standard molecular cloning techniques were used to produce a transgenic 
construct with murine Hb9 promoter upstream of an hSMN1-IRES-EGFP expression cassette.  This 
construct was introduced into zygotes of FVB background through pronuclear injection (Rimer et al., 
unpublished). 
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 Previous experiments performed by the lab (M.J. Rimer, unpublished) 
determined that only line 151 mice strongly expressed the hSMN transgene during 
embryogenesis (embryonic (E) day 13.5) and after birth. Expression was detected by 
immunostaining in embryos and until at least postnatal day (P) 6 in the ventral horn of 
the spinal cord. It was concentrated in motor neurons, with weaker staining in medial 
ventral interneurons (Fig. 2.2). 
 
 
 
 
 
Fig. 2.2. GFP expression in the ventral horn of the spinal cord. Both transverse sections of whole 
E13.5 (A) embryos and spinal cords from P6 neonates (B,C) were fixed in PFA, blocked with goat serum 
and stained with a polyclonal antibody against GFP. A. GFP expression restricted to the ventral half of the 
cord. Short arrow points to staining in ventral roots. B. Staining was detected in large cells in the ventral 
horn (rectangle). Arrowheads point to two GFP+ interneurons C. Higher magnification of selected area 
(rectangle) in B (Rimer et al., unpublished). 
 
 
 
 To study the presence and localization of hSMN, a monoclonal antibody specific 
for hSMN (a kind gift from Drs. Adrian Krainer and Yimin Hua, Cold Spring Harbor 
laboratory, NY), along with anti-GFP, were used to label cross sections of P6 spinal 
cords of Hb9-SMN1 mice. hSMN/GFP co-localized to the nuclei of spinal cord extracts 
in aggregates that are presumably the “gem” nuclear structures described by Liu and 
Dreyfuss 1996 [26]; Coady and Lorson, 2011 [8] (Fig. 2.3).  
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Fig. 2.3. Co-localization of hSMN and GFP proxy marker in motor neurons. Cross sections of P6 
spinal cords were incubated ON in monoclonal Ab (1:50) anti-hSMN and in polyclonal Ab (1:500) anti-
GFP. The secondary antibodies used were rhodamine-goat anti-mouse  and fluorescein-donkey anti-goat 
to detect hSMN and GFP seen in the merge image as red and green, respectively.. GFP/hSMN co-
localized to nuclei of one motor neuron in the ventral horn. Structures resembling gems within the nucleus 
are hSMN+. (Rimer et al., unpublished). 
 
 
 
 The transgene was indeed found to be selective for motor neurons. Co-
localization of hSMN/GFP was found explicitly in the motor neurons of the ventral half 
of the spinal cord. SMN puncta, indicating gems, were also observed (Fig. 2.4). 
 
 
 
 
 
Fig. 2.4. hSMN and GFP expression in spinal cord from Hb9-SMN mice. Cross sections of E13 
embryos stained with anti-human SMN monoclonal Ab (1:10) and in anti-GFP polyclonal Ab (1:500). 
Strong transgene expression in cells in the ventral horn observed. Human SMN puncta staining restricted 
to GFP-expressing cells seen in the color merge from the rightmost panel. The image from the leftmost 
panel was taken with a 10X objective and the images of the rest of the panels were taken with a 40X 
objective (scale bar: 25m) (Rimer et al., unpublished). 
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 Western blots were also used to determine the tissue specificity of SMN detected 
with the hSMN antibody in early postnatal tissue. The transgene was expressed in spinal 
cord but not skeletal muscle (Fig. 2.5). 
 
 
 
 
 
Fig. 2.5. Expression of hSMN in P6 spinal cord (SpC) and skeletal muscle (SkM) extracts from 
Hb9(SMN/Gfp) mice. Western blot: Equal amounts (50µg total protein) of extracts were fractionated in a 
12.5% acrylamide gel, which was then transferred to a nylon membrane. *Left: Entire membrane blotted 
for hSMN shows essentially one band of the expected molecular weight (~37kDa) in spinal cord (SpC) but 
not in skeletal muscle (SkM) extracts.  Two, non-specific bands were detected in SkM. *Right: The same 
membrane was stripped and re-probed for mouse α-tubulin to check for loading. 
 
 
 
 After confirming the presence and tissue specificity of the transgene, 
Hb9(hSMN/Gfp) mice were crossed to another set of mice carrying a mutation in Smn 
yielding a null allele (Smn+/-). Homozygous inheritance of the null allele is embryonic 
lethal in mice [5, 40].  To prevent embryonic lethality, these mice harbor human SMN2, 
though the presence of SMN2 is not enough to prevent the appearance of the SMA 
pathology. Thus, this is the most severe SMA mouse model (genotype: Smn-/-;SMN2+/+), 
which dies perinatally due to the lack of functional full-length SMN (detailed in Chapter 
I) [44]. Mice from this cross that were heterozygous for both murine Smn and the hSMN 
transgene, (detected with a genomic PCR for Gfp), as well as homozygous for SMN2 
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(annotated as Gfp+/?; Smn+/-; SMN2+/+) were crossed to transgene-negative mice (Smn+/-; 
SMN2
+/+) to produce a fraction of progeny carrying the homozygous null Smn allele 
with our transgene (i.e., Gfp+/?; Smn-/-; SMN2+/+).These were the experimental mice, 
used alongside controls, in our procedures.  
 Here, we aimed to rescue perinatal mortality and increase the lifespan of severe 
SMA mice. We assessed the survival of our experimental mice and the effects of the 
transgene on control animals as well.  Our results indicate that hemizygous inheritance 
of the transgene was insufficient to increase the survival of severe SMA mice. We 
carried out these experiments because we detected transgenic protein at later times than 
P1, the mean survival time of the severe SMA mice used here (Figs. 2.2-2.5, above). 
However, on experiments conducted later on we were unable to detect transgenic mRNA 
at E18, just prior to birth. These results suggest that slow protein turnover may explain 
our transgene expression results.  
 
2.3 MATERIALS AND METHODS 
 2.3.1 Ethics Statement  
 Care and treatments of all animals followed the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals, and were approved by the 
Institutional Animal Care and Use Committee (IACUC) of Texas A&M University 
under animal use protocol 2010-0258.  
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 2.3.2 Transgenic Mice  
 First, a line of transgenic mice (005024) was purchased from Jackson Labs 
(http://jaxmice.jax.org/strain/005024.html). These mice were produced thus: the 
endogenous Smn gene was disrupted in a set of mice and were then crossed to mice 
carrying an SMN2 homozygous transgene, generated by Dr. Arthur Burghes, to prevent 
embryonic lethality. The final product was a mouse, of the genotype Smn+/-, SMN2+/+, 
that when intercrossed can yield a severe SMA mouse model Smn-/-, SMN2+/+. The 
Jackson 005024 mice were crossed to our mice expressing the hSmn/Gfp transgene. 
Several rounds of breeding were required to select for the Gfp+/?; Smn+/-; SMN2+/+ mice. 
These mice were then intercrossed to produce the experimental animals. The genotype of 
each mouse was determined by standard PCR assays.  
 2.3.3 Genotyping 
 Upon either death or weaning of the experimental progeny, tail biopsies were 
obtained. DNA was extracted and amplified by PCR using REDExtract-N-Amp Hot start 
according to manufacturer instructions (Sigma-Aldrich, St. Louis, MO). Primers: Smn 
mutant: Forward 5’-CTT GGG TGG AGA GGC TAT TC-3’, Reverse 5’-AGG TGA 
GAT GAC AGG AGA TC; Smn wild-type: Forward 5’-TTT TCT CCC TCT TCA GAG 
TGA T-3’, Reverse 5’-CTG TTT CAA GGG AGT TGT GGC-3’; and Gfp+: Forward 5’-
ATG GTG AGC AAG GGC GAG GAG CT, Reverse 5’-TCG TTG GGG TCT TTG 
CTC AGG GC-3’. SMN2 was detected with primers oIMR5065, oIMR5066, oIMR5067 
(Jackson labs, Bar Harbor ME). 
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 2.3.4 Western Blot 
 Western blots were performed on protein homogenates from P6 transgene-
positive spinal cords and skeletal muscles. Samples were run on a 12.5% acrylamide gel. 
A monoclonal primary antibody specific for hSMN (provided by Drs. Krainer and Hua) 
was used to detect the ~37kD protein, followed by a secondary anti-mouse HRP 
antibody. The blots were also probed with an antibody against tubulin as a protein 
loading control. 
 2.3.5 Quantitative-Real Time-Polymerase Chain Reaction (qRT-PCR)  
 Adult female and male mice of the genotypes Gfp+/?; Smn+/-;SMN2+/+ and Gfp-/-; 
Smn
+/-
;SMN2
+/+  were set up to breed overnight. The following day, females were 
evaluated for vaginal plugs and separated from their respective male partners. After 18 
days following the presence of a plug and confirmation of pregnancy, the females were 
euthanized and all embryos were extracted in utero. The entire spinal cord along with a 
section of back skeletal muscle was removed separately from each embryo and flash 
frozen in liquid nitrogen and stored at -80oC. Total RNA was extracted from E18 whole 
spinal cords and muscle samples using Trizol reagent according to manufacturer 
instructions (Life Technologies, Grand Island, NY) and stored at -80oC until use. 0.5 µg 
of RNA per sample were reverse transcribed to cDNA using the High Capacity cDNA 
reverse transcription kit according to manufacturer instructions (Life Technologies, 
Grand Island, NY). Quantitative-RT-PCR for hSMN transcripts encoded by the 
transgene was performed according to the general guidelines of Taqman® Gene 
Expression Assays (Life Technologies, Grand Island, NY). hSMN primers:  SMN1 and 
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SMN2-fl transcripts were amplified by using the same primer pair (SMN_abs-F: 5’-
TACATGAGTGGCTATCATACTGGCTA-3’ and SMN_abs-R: 5’-
AATGTGAGCACCTTCCTTCTTTTT-3’, located in exons 6 and 7, respectively), 
obtaining 72 bp PCR products (Integrated DNA Technologies, Coralville, IA). Full-
length transcripts of the two genes were differentiated by using two different Taqman 
MGB probes, labeled with different fluorochromes, on the basis of the C-T transition 
located in exon 7 (SMN1_abs: 5’-NEDTATGGGTTTCAGACAAA-NFQ-3’ and 
SMN2_abs: 5’-VIC-ATATGGGTTTTAGACAAAA-NFQ-3’) (Life Technologies, 
Grand Island, NY) [117]. These molecular probes are short oligonucleotides 
complimentary to the target sequence. A reporter fluorophore is attached to one end of 
the oligonucleotide and a non-fluorescent quencher moiety is attached to the other end of 
the oligonucleotide. In their stem-loop structure the fluorophore and quencher are in 
close proximity so that energy from the fluorophore can to be transferred directly to the 
quencher through contact quenching. Through binding with the target nucleic sequence, 
the probes undergo a conformational change that forces the stem-loop to dissociate and 
the fluorophore and the quencher are separated from each other, restoring fluorescence 
[118]. NED and VIC are Life Technologies’ proprietary flourophores with excitations of 
~550nm and ~540nm, respectively to be used with Taqman assays ([118] and personal 
communication Life Technologies). Non-fluorescent quenchers (NFQ) absorb excitation 
energy from the fluorophore and dissipate the energy. When the two are close together 
the fluorophore's emission is suppressed [118].  Murine gapdh served as a ubiquitous 
control to normalize the Cycle threshold (Ct) values (Taqman® Gene Expression Assays, 
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Life Technologies, Grand Island, NY). Primers for the amplification of mouse choline 
acetyltransferase (chat) were used as a control to ensure appropriate spinal cord 
dissection (Taqman® Gene Expression Assays, Life Technologies, Grand Island, NY). 
Samples were set up in triplicate using a Taqman® Master mix (Life Technologies, 
Grand Island, NY) and run for 52 cycles in an ABI Prism 7900HT Fast Real-Time PCR 
System (Life Technologies, Grand Island, NY). The ∆∆Ct method [119] was used to 
determine changes in mRNA transcript expression levels between groups. 
 2.3.6 HeLa Cell Culture 
 In order to obtain a positive control for the qRT-PCR assay, the immortal human 
cell line HeLa was cultured until confluence with Dulbecco modified Eagle medium 
(DMEM) + sodium pyruvate (Life Technologies, Grand Island, NY) and horse donor 
serum. RNA was extracted using an RNeasy mini kit (Qiagen, Hilden, Germany) 
according to manufacturer’s instructions and stored at -80oC after determining the 
concentration with a Nanodrop.  
 2.3.7 hSMN Transgene 
 For another positive control used in the qRT-PCR assay, two different plasmids 
carrying cDNA for human SMN1 were purified from DH5E. coli host stocks. The 
bacteria were first plated on petri dishes with LB media agar and ampicillin and left to 
form colonies ON at 37oC. The following day 3-4 colonies were picked and incubated 
ON in LB media with constant agitation. Subsequently, the plasmids were purified using 
Qiagen’s mini prep kit according to the manufacturer’s protocol (Qiagen, Hilden, 
Germany).  
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 2.3.8 Survival Studies 
 The offspring of the experimental cross was expected to fall under the following 
proportions of genetic inheritance:  ~20% Gfp+/?; Smn-/-; SMN2+/+ (Hb9(Gfp+)SMA i.e. 
experimental animals), ~6% Smn-/-; SMN2+/+ (Hb9(Gfp-)SMA i.e. diseased mutant 
animals/negative controls),  and ~56% Gfp+/?; Smn+/-; SMN2+/+ or Gfp+/?; Smn+/+; 
SMN2
+/+ (WT/Controls). Progeny of these crosses were monitored daily for mortalities. 
Deceased mice were collected, date of death was recorded and a tail necropsy was taken 
for DNA extraction. Subsequently, PCR assays were performed for the alleles Gfp, Smn 
mutant and WT, and hSMN2 as described in 2.3.2. Mice were grouped according to 
genotype and length of survival. Values were plotted on a Kaplan-Meier Survival Curve. 
 2.3.9 Motor Function Assays  
 Transgene positive and transgene negative, Smn+/- or Smn+/+, (control) mice were 
evaluated using the hindlimb suspension (Tube) test and the righting reflex test was 
performed every three days after birth. The test consisted of placing the pup in supine 
position on a flat surface and measuring the time it took to turn over onto an upright 
position, or to “right” itself, by having all four paws simultaneously on the flat surface. 
This measurement was taken in duplicate and averaged. All animals assayed were 
grouped according to genotype and mean time to “right” for each time point was scored 
according to the following scale, modeled after Monani and co-workers [19]: 0-4s=5, 5-
9s=4, 10-14s=3, 15-20s= 2, 21-49s=1, 50->60s=0. A score of 0 was considered a failed 
test. Scores were plotted using Prism5 (GraphPad Software, La Jolla, CA). A heat block 
was used while working with the pups to prevent hypothermia. The hindlimb suspension 
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(tube) test was performed according to El-Khodor and colleagues [120]. Each animal 
was suspended from an upright 50ml canonical tube by its hindlimbs. A cotton ball or 
tissue was placed inside the tube to prevent injury. The time it required for the mouse to 
fall into the tube (latency) was recorded from two consecutive trials. Values from the 
two trials were averaged. Only latency time to fall (up to 60s) was considered in the 
analysis. 
 2.3.10 Statistical Analysis 
 Quantitative data are expressed as mean  SEM. Values for number of animals 
are given in the figures and/or figure legends. Kaplan-Meier survival curves were 
generated and tested for statistical significance using the log-rank test with Prism5 
GraphPad Software®. Student’s t-test, computed either with Microsoft Excel (Microsoft 
Corporation, Seattle, WA) was used to determine statistical significance in the 
expression assays. Microsoft Excel (Microsoft Corporation, Seattle, WA) or Prism5 
GraphPad Software, along with Analysis of the Variance (ANOVA) through SAS 
software (SAS Institute, Cary, NC), was used to probe for statistical significance in 
motor function assays. Significance was set at p  0.05 for all tests. 
 
2.4 RESULTS 
 2.4.1 Survival of Hb9(Gfp+)SMA Mice 
 To assess whether insertion of the transgene improved the survival length of the 
severe SMA mouse model, the progeny of our experimental crosses was evaluated daily, 
all mortalities collected, genotyped, grouped accordingly, and plotted on a Kaplan-Meier 
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Survival Curve. The severe SMA mouse model used here is reported to survive 
perinatally [44]. In our hands, median survival for Hb9(Gfp-)SMA mice was 0.83±1.58 
days (n=30) and for Hb9(Gfp+)SMA was 0.71± 1.05 (p=0.92 log-rank test; Fig 2.6 and 
Table 2.1). The majority of control animals (n=139) survived well beyond weaning. 
Lifespan was not assessed after P21. The Gfp primer set used in our genotyping assay 
does not distinguish between homozygous and heterozygous inheritance of the 
transgene. To determine homozygosity, fourteen (14) Gfp+/? mice were crossed to 
transgene-negative C57/B6 mice. If homozygosity is plausible, then 1/4 of the breeders 
(~ 3-4 mice) would be expected to be homozygous, that when crossed to transgene 
negative mice would yield 100% Gfp+/- progeny. This was not the case for any of the 14 
crosses indicating that homozygous inheritance of the transgene is likely embryonic 
lethal. Hence, heterozygous inheritance of the Hb9(Gfp/hSMN) transgene is insufficient 
to rescue the survival of severe SMA mice. 
 
 
 
 
 
Fig. 2.6 Inheritance of the Hb9(Gfp/hSMN) transgene is insufficient to rescue severe SMA mice. 
Kaplan-Meier survival curves indicating the cumulative survival of the Hb9(Gfp+)SMA, Hb9(Gfp-)SMA, 
and control mice plotted with Prism 5 GraphPad software®. Transgene positive and transgene negative 
mice did not significantly differ in their lifespan (P = 0.92). Control animals were right censored in the 
analysis. No follow-up was performed after weaning (P21).  
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Table 2.1 Comparative survival between Hb9(Gfp+)SMA and Hb9(Gfp-)SMA mice. 
Genotype Mean lifespan (days) n 
p vs. control 
Hb9(Gfp
-
)SMA mice 
Log-rank test 
Hb9(Gfp
-
)SMA 0.83±1.58 30 - 
Hb9(Gfp
+
)SMA 0.71±1.05 28 0.92 
Controls ND 139 <0.0001 
 
 
 
 2.4.2 Effect of the Hb9(Gfp/hSMN) Transgene on FVB/N Background  
 Control Mice 
 To determine whether inheritance of the transgene had any beneficial or 
detrimental effects on the background of the experimental animals, a comparative 
survival analysis was performed on transgene-positive and transgene-negative control 
animals (Gfp+;Smn+/-;SMN2+/+ or Gfp+;Smn+/+;SMN2+/+ and Smn+/-;SMN2+/+ or 
Smn
+/+
;SMN2
+/+ , respectively).  Hb9(Gfp+)SMA mice had significantly less perinatal 
mortalities than Hb9(Gfp-)SMA (p= 0.0040, Fig. 2.7) though the majority of animals in 
both groups survived to adulthood. These results indicate that, at least in control animals, 
insertion of the transgene does not interfere with normal progression and it could be 
providing beneficial effects during the first postnatal week.  
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Fig. 2.7 The Hb9/hSMN transgene prevents early mortality in control mice. Kaplan-Meier curves 
demonstrate an overall increase in early survival (p = 0.0040, log-rank test). Mean lifespan is 
undetermined since subjects were not evaluated past weaning (P21) though the majority did survive to 
adulthood. Inheritance of the transgene may provide beneficial effects during the first days after birth 
reducing the chances of perinatal mortality. 
 
 
 
 Due to the tendency for improved survival rates during the first postnatal days in 
transgene-positive control mice, we proceeded to determine whether inheritance of the 
transgene had beneficial effects on motor behavior as well. Motor behavior was assessed 
using the righting reflex and the hindlimb suspension tests (Fig. 2.8). Both control 
groups displayed an age dependent improvement in motor behavior. Transgene-positive 
control mice [Hb9(Gfp+), Smn WT or heterozygous, n=46] displayed a tendency to 
perform better than transgene-negative mice [Hb9(Gfp-) Smn WT or heterozygous, 
n=25] on the righting reflex test during the first postnatal week (Fig 2.8.A), but this was 
only statistically significant at P3 (p=0.05). The overall performance until weaning did 
not differ significantly between the two groups. The opposite was found with the 
hindlimb suspension (Tube) test. In this case, the overall motor behavior did not differ 
significantly between Hb9(Gfp+) control and Hb9(Gfp-) control mice but we did find that 
Hb9(Gfp-) controls scored better on their first measurement (P3) (p=0.04), Fig 2.8.B). 
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However, the Hindlimb Suspension test might not be the most adequate test for motor 
behavior in SMA mouse models. In at least two other studies that assessed motor 
function using motor neuron-rescued SMA mice, the results indicated that rescued 
animals performed worse than the diseased SMA animals by this test. On the other hand, 
rescued animals scored better than the disease ones in the Righting Reflex, which was 
more consistent with the overall improvements in SMA phenotype seen in their studies 
[57, 107].  
 With these data we conclude that insertion of the transgene does not cause any 
detrimental effects in heterozygous or WT mice, which also suggests that our breeding 
strategy did not alter the basic phenotype of the model mice. On the contrary, it is 
possible that inheritance of the transgene is providing beneficial effects during the first 
postnatal days as determined by the survival studies and one motor function assay. 
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Fig. 2.8. Inheritance of the transgene does not improve the overall motor behavior. Comparative 
analysis of motor behavior between transgene-positive and transgene-negative control mice. Motor 
behavior was assessed by the righting reflex (A) and hindlimb (tube) suspension (B) tests. Only the 
latency to fall was recorded for the tube assays. Both controls groups improved their performance with 
age. There was no overall effect of genotype on motor function but in a point by point comparison we 
detected statistical difference between transgene-positive Hb9(Gfp+) and Hb9(Gfp-) control mice on both 
of these motor function assays at P3 only. 
 
 
 
 2.4.2 Expression of Hb9(Gfp/hSMN) 
 To restore SMN expression selectively in motor neurons, we have used an Hb9 
promoter to drive the exogenous expression of human SMN in a severe SMA mouse 
model. Homeobox gene Hb9 is selectively expressed in spinal cord somatic and visceral 
motor neurons and Vx interneurons starting at E 9.5 [56]. Under normal conditions, 
SMN is strongly expressed in neurons in both fetal and postnatal spinal cord [17], thus 
we expected that our restored SMN would follow a similar pattern.  
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 Given the transgene’s failure to improve survival of severe SMA model mice 
despite its detection at the protein level, we sought to determine if the transgene was 
truly being expressed at sufficient quantities. We should have seen an improvement in 
the phenotype of our mutant mice, even a modest one if we are indeed restoring 
sufficient levels of SMN in motor neurons. For this, we used qRT-PCR to measure the 
levels of the hSMN transgene in E18 spinal cords and muscle from Hb9(Gfp+)SMA and 
Hb9(Gfp-)SMA mice. We followed the same methodology described by Paez-Colasante 
et al. [56]. The primers and probes tested were designed to specifically recognize hSMN 
and have been used previously by Tiziano et al. [117]. Cycle threshold (Ct) values 
obtained for murine gapdh RNA were used to equalize differences in total RNA per 
sample. Transcript level fold change was determined by the ∆∆Ct method and values 
normalized to the Ct values obtained for Hb9(Gfp-)SMA spinal cord samples. For 
positive controls, cDNA from human HeLa cells and two plasmids containing the 
Hb9(Gfp/hSMN) transgene were used. Surprisingly, we were unable to detect hSMN 
expression by quantitative RT-PCR in any of our spinal cord or muscle Gfp+ or Gfp- 
animals (Table 2.2). The hSMN primers did detect HeLa cell cDNA confirming primer 
efficacy (Table 2.2). The integrity of both spinal cord and muscle cDNA was confirmed 
since both gapdh and SMN2 primers detected these samples and the Ct values obtained 
were consistent and within expected values (Table 2.2). The negative controls (no RT, 
no RNA, and water samples) were undetected by all three primer/probe sets used thus 
confirming the specificity of the assay. 
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Table 2.2. Quantitative RT-PCR data for expression of SMN1, SMN2, gapdh and chat 
mRNA transcripts in transgene-positive and negative spinal cord and skeletal muscle E18 
samples 
Mean ± SEM Cycle Threshold values 
 SMN1 SMN2 gapdh chat 
Hb9(Gfp-)SMA 
spinal cord 
UD 30.25 ± 0.32 20.51 ± 0.56 26.84 ± 1.02 
Hb9(Gfp+)SMA 
spinal cord 
UD 29.81 ± 0.35 20.99 ± 0.27 28.71 ± 0.06 
Hb9(Gfp-)SMA 
skeletal muscle 
UD 31.43 ± 0.33 20.33 ± 0.50 36.64 ± 0.52 
Hb9(Gfp+)SMA 
skeletal muscle 
UD 30.29 ± 0.66 21.8 ± 0.40 35.85 ± 1.49 
HeLa cells 24.71 ± 0.25 25.30 ± 0.02 UD UD 
UD: Undetected signal from transcript 
   
 
 
 As an additional control for the hSMN primer set, we assayed cDNA from the 
HeLa cell positive control, genomic DNA from two Gfp+ and two Gfp- mice (same mice 
included in qRT-PCR assay), and two samples of plasmid DNA containing the hSMN 
transgene. Sample DNA was amplified via a PCR reaction using the hSMN primers and 
then run on a 2% agarose gel. A ~72bp band indicated the presence of the transgene in 
the plasmid DNA, the genomic Gfp+, and HeLa cell cDNA samples but not the genomic 
Gfp
- samples or water (negative control) (Fig 2.9). Thus, the Hb9-hSMN1 mice we 
generated indeed carried the expected transgene in their genome. 
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Fig. 2.9. hSMN qRT-PCR primer set accurately amplify the ~72bp band for hSMN in transgene-
positive samples. 2% agarose gel. Lane description: (M) Marker of 100bp, (1) hSMN transgene-positive 
plasmid #1; (2) hSMN transgene-positive plasmid #2; (3) Gfp+ genomic DNA sample #1; (4) Gfp+ 
genomic DNA sample #2; (5) Gfp- genomic DNA sample #1; (6) Gfp- genomic DNA sample #2; (7) HeLa 
cell cDNA; (8) water, negative control. 
 
 
 
 To confirm tissue specificity and overall quality of the spinal cord extracts, the 
same samples (Gfp+ and Gfp- mutants) of both spinal cord and skeletal muscle used in 
the hSMN assay were tested by qRT-PCR for ChAT expression. This enzyme synthesizes 
the neurotransmitter acetylcholine and is found in high levels in the spinal cord but only 
modestly in muscle. We found that our E18 spinal cord samples express ~200-fold more 
ChAT than the E18 skeletal muscle samples (Fig. 2.10, Table 2.2.). This confirms that 
the samples used to test for hSMN expression are indeed extracts from spinal cord and 
RNA was efficiently extracted.  
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Fig. 2.10. Relative chat transcript expression in Hb9(Gfp+)SMA and Hb9(Gfp-)SMA E18 spinal 
cords. The ordinate, in log scale, shows chat expression in spinal cord normalized to levels in skeletal 
muscle samples of the same animals. Spinal cord samples displayed ~200-fold higher expression than 
Hb9(Gfp+)SMA and Hb9(Gfp-)SMA skeletal muscle samples. N= 4–5, per tissue group. 
 
 
 
2.5 DISCUSSION 
 The Hb9(Gfp/hSMN) transgene is expressed early on and is vastly motor neuron-
selective. Its expression was detected from embryogenesis through early postnatal days 
at the protein level in spinal cord and not in skeletal muscle thus confirming tissue 
specificity. However, transgene expression most likely drops to minimal levels during 
late embryogenesis and the first postnatal days when the presence of SMN is very 
critical to the survival of motor neurons. Therefore, hemizygous inheritance of the 
transgene was insufficient to extend survival of a severe SMA mouse model (Smn-/-, 
SMN2
+/+) past P1.  
 Three groups performed different SMN restoration experiments using SMA7 
mice and determined that there are specific temporal requirements dictating when SMN 
restoration is most efficient to achieve the maximum overt rescue of the SMA 
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phenotype. These studies concluded that there is a neonatal period of time when high 
SMN levels are required. Early induction is the most efficacious [2, 28, 111] and even 
though improvements are found by increasing SMN at later stages of pathology, there is 
a window of time within which the protein must be restored for optimal effect by 
therapeutic efforts [2, 28]. Timely restoration of SMN may be capable of pausing the 
progression of the SMA pathology and serve as an effective post-symptomatic treatment 
[2]. Our experimental design is in agreement with this principle. In the spinal cord of 
mammals, motor neuron-specific-Hb9 is expressed during early embryogenesis (E9) in 
newly formed embryonic motoneurons [121]. The important timing of expression and 
function of Hb9 is in postmitotic motor neurons [122]. Thus in our transgene, Hb9 drives 
the expression of hSMN very early on. This explains why the transgene was clearly 
detected by mid-embryogenesis (E13) in spinal cord cross sections with 
immunohistochemical staining. In theory if our experimental design is efficient then the 
transgene should be providing the developing motor neurons with the SMN protein that 
they are lacking. Nonetheless, this was not the case. It was very puzzling why expression 
was undetected at the mRNA level towards late embryogenesis. There is the possibility 
that the expression of Hb9 peaks by late embryogenesis and then begins to decrease thus 
halting the expression of hSMN in transgene-positive animals at the time period when it 
is most needed. Hence, the timing and efficacy of Hb9 as a driver for transgenic 
expression is not in line of what is expected from the endogenous Smn promoter likely 
explaining the lack of rescue in severe SMA mice. To circumvent this problem, motor 
neuron-restoration of SMN by Hb9 should be continuous and permanent to prevent time-
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related alterations in protein expression and meet the protein demands at the appropriate 
window. 
 There could also be a requirement for the transgene to be expressed from both 
alleles to produce enough SMN per cell to have a significant effect on the SMA 
phenotype. Nevertheless, since homozygous inheritance of the transgene seems to be 
embryonic lethal, perhaps due to its pattern of insertion in the genome, this was not be 
possible.  
 All the above could explain our lack of rescue except that the transgenic protein 
was detected up to several postnatal days. We have hypothesized that the extended half-
life of both the hSMN and GFP proteins explain why mRNA was undetected as early as 
E18 but the protein was present postnatally. Though present, the concentration of hSMN 
is likely not high enough to produce significant rescue of motor neurons necessary for 
phenotypical improvements.  
 The stability of the SMN protein is modulated by complex formation; i.e., 
recruitment of SMN into large macromolecular complexes as well as increased 
association with several Gemin proteins increases its stability. This process is regulated 
by the cyclic AMP (cAMP)-dependent kinase, protein kinase A (PKA). A study by 
Burnett and collaborators (2009) found that SMN exists in at least two populations: a 
low-molecular-weight population consisting of SMN monomers with a relatively short 
half-life of a few hours and a high-molecular-weight population that consists of SMN in 
complex that is resistant to degradation with a half-life of several days. The fraction of 
SMN associated with Gemin 3, Gemin 5, and Gemin 6 is dramatically more stable 
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compared to total cellular SMN. Additional evidence found by this group is that 
mutations that inhibited SMN oligomerization and complex formation reduced SMN 
half-life [35]. A study by Garbes et al. (2009) showed that SMN is post-translationally 
stabilized via reduced ubiquitinylation in human SMA fibroblasts and upon its 
incorporation into the SMN complex [123]. Another study using normal and SMA 
patient fibroblasts determined that the half-life of FL- SMN messenger RNAs is 
approximately only 5 to 6 hours for both cells from patients with SMA and in unaffected 
cells [124].  
 According to Wahlers (2001), a factor that may influence conclusions about the 
potency of a given gene transfer vector is the use of a sensitive reporter with a long 
protein half-life, such as GFP [125]. GFP has a compact structure increasing its stability 
under a variety of conditions [116]. Both GFP and EGFP are indeed very stable proteins 
and very resistant to proteolysis, with a half-life exceeding 24 h; this has been found 
consistently in several studies both in vivo and in vitro with cultured mouse LA-9 cells 
[116, 125, 126].  The high stability means that once made, GFP will persist in a cell even 
after the promoter that drives its expression is shut down [127]. The stability of GFP 
limits its application in some studies, including transcriptional induction studies [116]. 
Thus, vectors that express stable proteins are not necessarily promising to express a 
given therapeutic protein to adequate levels in the cell type of interest [125]. 
 The proteins produced from the Hb9(Gfp/hSMN)  transgenic construct are thus 
detected postnatally due to their extensive half-life, a property conferred by their 
stability, but not at functional concentrations to optimally produce beneficial changes in 
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motor neuron pathology in severe SMA mice. However, the presence of the long-lived 
SMN protein was sufficient at reducing neonatal mortalities in transgene-positive control 
animals (Fig. 2.7). Consistent with this, transgene-positive control animals performed 
better on the Righting Reflex test during the first measurement (P3) than transgene-
negative animals (p=0.05). If more time points would have been taken during the first 
week, we hypothesize that we would have observed a marked tendency for improved 
motor behavior during that period. The results obtained with the Hindlimb Suspension 
test were not in agreement with this. However, after performing this assay, we suggest 
that the Hindlimb Suspension test might not be the most accurate way to determine 
hindlimb strength or atrophy since we detected other influential factors. For example, we 
observed less willingness from the mice to cooperate on the Hindlimb Suspension test 
than with the Righting Reflex. From our observations, time of latency seemed to be 
affected by the animal’s weight and size, as well as stress and fear. Even thought this 
assay has been used in several other studies [56, 57, 61, 107, 120], some of the results 
from the Hindlimb Suspension test differ from the motor behavior reported with the 
Righting Reflex test. For instance, Gogliotti et al. (2012) found that in the Hindlimb 
Suspension test SMA mice performed better than motoneuron-rescued mice until P6 
when the former began to rapidly decline and the latter showed an age-dependent 
improvement. This datum differs from the results of the Righting Reflex test in which 
rescued animals performed much better than the mutant SMA animals [107]. A similar 
interpretation can be given to the motor behavior in another study that used a different 
inducible SMA line, ChATCre mice, to study motor neuronal-SMN rescue. With the 
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Hindlimb Suspension test, Martinez et al. (2012) observed that in the initial time points 
of the assay their rescue animals consistently outperformed the diseased ChATCre- mice 
but then at P8-10, the opposite occurred. Again, these results differed from the Righting 
Reflex test, in which ChATCre+ rescue animals presented an age-dependent continuous 
improvement over the SMA mutant mice [57]. The improvements seen in rescue animals 
from both studies on the Righting Reflex assay were also more in line with the overall 
improvement in SMA pathology that these researchers found in each of their studies. 
 Our control group survival and Righting Reflex results are consistent with our 
expression analysis at the protein level showing that the transgenic construct yields a 
long-lived functional protein. The increase in survival in transgene-positive, control 
mice occurred during the critical neonatal window determined in the SMN restoration 
studies mentioned above [2, 28, 111]. We only observed these improvements in 
transgene-positive control animals and not severe SMA mutants because the severity of 
the SMA mouse model, demonstrated by their perinatal symptom onset and rapid 
deterioration, causes their rescue to be very difficult with such small increases in FL-
SMN.   
 Amongst our possible explanations for the observed survival and motor function 
improvement in transgene-positive controls is the idea that the addition of small 
quantities of FL-SMN can compensate for the potentially detrimental effects of the 
additional SMN7 protein present with the insertion of copies of human SMN2 in this 
mouse model. Overexpression of SMA7 is apoptotic for neurons [6] and SMN-
deficient mice suffer from massive apoptosis during embryogenesis [128]. SMN and 
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SMN7 form heterotopic complexes, which stabilize SMN7, at least in transfected 
cultured cells. The presence of increased SMN7 results in more oligomeric SMN-
complex and a reduced phenotypic severity [6, 128]. The small increases in FL-SMN 
provided by the transgene along with the 10% of FL-SMN also produced by SMN2, may 
be able to overcome the pro-apoptotic toxic effects by SMN7 because of possible anti-
apoptotic properties of FL-SMN [6].   
 Since disease severity is inversely proportional to SMN2 copy number, one 
would expect that SMN7, the main product of SMN2, would have beneficial effects. 
Though it is possible that the protective effect of SMN2 may only be coming from the 
10% FL-SMN produced and not SMN7 [6]. We can also hypothesize that the 
additional quantities of FL-SMN that the Hb9(Gfp/hSMN) transgene is providing to 
control mice can influence the competition for Gemin binding between SMN and 
SMN7. When present, SMN7 may be temporarily binding to the SMN-complex 
components before it is degraded due to its stability, thus preventing proper SMN 
binding to the complex. Additional SMN may be displacing the inefficient SMN7 and 
restoring its proper place and function ultimately providing beneficial effects to 
transgene-positive control motor neurons. 
 Lastly, our group has not yet mapped the site of transgene insertion. This leaves 
open the possibility that the precise site may be located in such a way that it can 
influence a protective gene modifier of SMA. This could be something important to look 
into in future studies. One possibility is that our transgene has been inserted near 
Plastin3.  Plastin3 is a protective SMA modifier that is an isomer in the family of actin-
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binding proteins involved in the stability and organization of actin F-filaments. In 
zebrafish motor neurons, it has been found to increase the amount of F-actin thus 
improving axon outgrowth. Yanyan et al. found that higher expression of Plastin3 in 
patients with SMA may act as a compensatory mechanism [129]. However, several other 
studies have found that this SMA modifier might be sex-dependent with mild SMA 
female patients having higher levels of Plastin3 expression [130, 131]. We did not 
separate our experimental groups by sex so this cannot be easily demonstrated.  
 In conclusion, the Hb9(Gfp/hSMN) transgene from our experimental approach is 
being expressed in developing motor neurons during embryogenesis. The expression of 
the transgene is significantly reduced by late embryogenesis. Though, due to the stable 
properties, the early translated SMN protein appears to have a long enough half-life to 
functionally persist during the first postnatal days, when it is critically needed, and 
produce beneficial outcomes in transgene-positive control mice. Our experiments 
demonstrate that the transgene is indeed inherited and protein is both detectable and 
functional in motor neurons. Nonetheless, these increases in SMN are not sufficient to 
rescue the severe phenotype of our experimental mice, but they are indicators of the 
importance of motor neuronal-SMN restoration and that even small additions of the 
functional protein are enough to yield detectable improvements.  
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CHAPTER III 
 IMPROVEMENT OF NEUROMUSCULAR SYNAPTIC PHENOTYPES 
WITHOUT ENHANCED SURVIVAL OR MOTOR FUNCTION IN SEVERE 
SPINAL MUSCULAR ATROPHY MICE BY SELECTIVE  
SMN RESTORATION IN MOTOR NEURONS  
 
3.1 SYNOPSIS 
 In the inherited childhood neuromuscular disease SMA, lower motor neuron 
death and severe muscle weakness result from the reduction of the ubiquitously 
expressed SMN protein. Although SMA mice recapitulate many features of the human 
disease, it has remained unclear if their short lifespan and motor weakness are primarily 
due to cell-autonomous defects in motor neurons. Using Hb9Cre as a driver, we 
selectively raised SMN expression in motor neurons in conditional SMA∆7 mice. Unlike 
a previous study that used choline acetyltransferase (ChATCre+) as a driver on the same 
mice, and another report that used Hb9Cre as a driver on a different line of conditional 
SMA mice, we found no improvement in survival, weight, motor behavior, endplate 
morphology, and presynaptic neurofilament accumulation. However, like in ChATCre+ 
mice, we detected rescue of endplate size and mitigation of NMJ denervation status. The 
rescue of endplate size occurred in the absence of an increase in myofiber size, 
suggesting endplate size is determined by the motor neuron in these animals. Real time-
PCR showed that the expression of spinal cord SMN transcript was sharply reduced in 
Hb9
Cre+ SMA mice relative to ChATCre+ SMA mice. This suggests that our lack of 
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overall phenotypic improvement is most likely due to an unexpectedly poor 
recombination efficiency driven by Hb9Cre. Nonetheless, the low levels of SMN were 
sufficient to rescue two NMJ structural parameters indicating that these motor neuron 
cell autonomous phenotypes are very sensitive to changes in motoneuronal SMN levels. 
Our results directly suggest that even those therapeutic interventions with very modest 
effects in raising SMN in motor neurons may provide mitigation of neuromuscular 
phenotypes in SMA patients. Most of the results from this chapter have already been 
published [56]. 
 
3.2 INTRODUCTION 
 SMA is an often fatal, childhood inherited neuromuscular disease caused by low 
levels of a ubiquitous protein required for spliceosome assembly, SMN. Reduction of 
SMN leads to loss of lower motor neurons, muscle denervation and atrophy. Humans 
harbor two genes encoding SMN, SMN1 and SMN2. In SMA patients SMN production is 
drastically reduced by homozygous deletion/mutation of SMN1. In such patients SMN is 
solely derived from SMN2. SMN2 is essentially identical to SMN1 except for a CT 
nucleotide change that causes exon 7 skipping in the splicing of ~90% SMN2 RNA, 
leading to the synthesis of an unstable, minimally functional protein (SMN∆7). Only 
~10% of SMN2 transcripts code for a full-length SMN protein and this reduced level is 
insufficient for motor neuron survival. SMN2 can exist in multiple copies and SMA 
disease severity correlates inversely with SMN2 copy number. 
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 As detailed in Chapter I Introduction, mice only harbor one SMN gene, whose 
homozygous deletion (Smn-/-) is embryonic lethal. Smn-/- mice with two copies of SMN2 
(i.e. Smn-/-; SMN2+/+) die perinatally and show features resembling the most severe 
human disease [44]. Addition of a transgene encoding the cDNA for SMNΔ7 to these 
mice (i.e. Smn-/-; SMN2+/+; SMNΔ7) improves survival to 14 days on average (SMAΔ7 
mice), but they still display a severe SMA phenotype. Thus, among other features, they 
demonstrate impaired motor behavior, inability to thrive and gain weight, and structural 
and functional defects in their NMJs that include presynaptic accumulation of 
neurofilaments (NF), smaller and immature postsynaptic apparatus and diminished 
neurotransmission [6, 9, 30, 40, 61, 132]. A selective vulnerability to denervation of 
specific, clinically relevant muscles has also been reported for these animals [104].  
 Although SMA mice recapitulate many features of the human disease, it remains 
unclear if their short lifespan and SMA phenotype are primarily due to cell-autonomous 
defects in motor neurons. The general expectation in the field has been that selective 
SMN reduction in motor neurons should mimic the phenotype of the severe SMA model 
mice, and that conversely, selective restoration of SMN in motor neurons should 
dramatically rescue the phenotype of SMA model mice. These predictions have not been 
entirely borne out by the experiments.  Thus, Olig2-Cre-driven conditional reduction of 
SMN in motor neuron precursors yields central and NMJ phenotypes in these animals 
that are present in the SMA mice, but the former animals have very mild SMA with a 
surprisingly long lifespan [19]. To conditionally restore SMN expression in motor 
neurons and other cells, two independent groups generated mice with inducible mutant 
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Smn alleles that can be reverted to functional, wild-type-like alleles after Cre 
recombination. These are the hybrid rescue allele, SmnRes [2] (Fig. 3.2) and the Smn2B-neo 
allele [108]. Recently, choline acetyltransferase-(ChAT)-driven Cre was used to restore 
SMN expression in motor neurons of SmnRes/Res mice in the SMAΔ7 background [57], 
while Hb9-driven Cre was used to restore SMN expression in motor neurons of the 
Smn
2B-neo/2B-neo SMA mice [107]. Mice rescued by both approaches showed measurable 
improvements in weight, motor behavior, central and neuromuscular phenotypes relative 
to diseased controls, but displayed a very modest increase in survival (8 and 5 days over 
diseased controls, respectively). These latter results contrast with the dramatic 
improvements, particularly in lifespan, produced by pan-neuronal expression of SMN in 
Smn
-/-
; SMN2
+/+ mice (210 days) [110], or in SMAΔ7 mice treated with CNS or 
peripherally-directed viral vectors expressing SMN (50-200 days) [78, 111], or CNS and 
peripherally-delivered oligonucleotides that correct the exon skipping defects in SMN2 
(>100 days) [64, 72]. 
 To better understand whether the SMA phenotype is primarily due to cell-
autonomous defects in motor neurons and whether motor neuronal-selective SMN 
restoration is a viable strategy to rescue pathology we have used two approaches, each 
with a different severe SMA mouse model, to answer these questions. Chapter II of this 
dissertation details our initial efforts to rescue a very severe SMA mouse model by 
motor neuron-selective SMN restoration using Hb9 to drive the expression of a 
transgene harboring cDNA for human SMN. However, we found that expression of Hb9 
peaks by mid to late embryogenesis halting the production of functional SMN at the 
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perinatal stage when SMN is most needed for motor neuron survival. Additionally, the 
severity of the SMA mouse model used, demonstrated by their perinatal symptom onset 
and rapid deterioration, caused both their rescue and assessment to be a challenging task. 
To circumvent the limitations of the very severe mouse model and the timing of 
expression for Hb9, we used a second approach that addressed both of these 
confinements by using a less severe mouse model with an average survival of ~14 days 
and a strategy in which SMN was to be restored permanently at embryogenesis. Thus, 
here we report on our attempt to restore SMN selectively in motor neurons of SmnRes/Res 
SMAΔ7 mice with the same Hb9-Cre driver used to rescue Smn2B-neo/2B-neo SMA mice. 
We found no improvement in survival, motor behavior, presynaptic NF accumulation, 
endplate morphology, and a marginal weight increase in our Hb9(Cre+)SMA mice 
relative to Hb9(Cre-)SMA mice. However, we detected rescue of endplate size and 
significant mitigation of NMJ denervation status in Hb9Cre+ SMA mice. The rescue of 
endplate size was not a consequence of an increase in myofiber size. This pattern of 
mitigated peripheral structural phenotypes in Hb9Cre+ SMA mice is similar to that in 
Myf5
Cre+ SMA mice [57], although the latter had restored SMN both in skeletal muscle 
and spinal cord, thus suggesting that this rescue in the Myf5Cre+ SMA mice is due to 
neuronal and not muscle SMN restoration. Quantitative real time-polymerase chain 
reaction (qRT-PCR) showed that expression of the repaired SmnRes allele (SMN67m8h, 
Fig. 3.2) was vastly lower in spinal cord in our Hb9Cre+ SMA mice than in the spinal 
cord from ChATCre+ SMA mice and this proportion remained regardless of varying the 
concentration of cDNA used in the assay. This suggests that our lack of overall 
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phenotypic improvement is most likely due to an unexpectedly poor recombination 
efficiency driven by Hb9Cre. Nonetheless, our data show that specific structural NMJ 
phenotypes are very sensitive to small changes in SMN levels selectively in motor 
neurons and thus can be mitigated by very small increases in spinal cord SMN levels that 
fail at enhancing lifespan, weight and motor behavior. Although prior studies (e.g. [104, 
133, 134]) have suggested that therapeutic interventions with very modest effects in 
raising SMN could potentially mitigate motor neuron-autonomous phenotypes in SMA 
patients, our results are the first to reach that conclusion directly based on an approach to 
selectively raise SMN levels in motor neurons. Additionally, we suggest that our 
experiments establish a threshold of SMN expression that distinguishes an order of SMN 
sensitivity for different SMA phenotypes.  
 
3.3 MATERIALS AND METHODS 
 Note: a detailed description of the methods can be found in the Appendix A of 
this dissertation. 
 3.3.1 Ethics Statement  
 Care and treatments of all animals followed the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals, and were approved by the 
Institutional Animal Care and Use Committee (IACUC) of Texas A&M University 
under animal use protocol 2010-0258.  
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 3.3.2 Mice  
 Mice were housed in a vivarium at 25°C with a 12h light/dark cycle, fed ad 
libitum and monitored daily for health. Human alleles are referred in the text with the 
standard convention of capital letters in italics. SmnRes carriers (SmnRes/+; SMN∆7+/+; 
SMN2
+/+, JAX stock #007951) and Hb9Cre carriers (Hb9Cre+/-; Smn+/-; SMN∆7+/+; 
SMN2
+/+, JAX stock # 007022) were initially acquired from the Jackson Labs, Bar 
Harbor, ME. The Hb9Cre allele in 007022 came from JAX stock# 006600, the same Hb9-
Cre line used by DiDonato and colleagues to rescue Smn2B-Neo/2B-Neo mice [107], and 
which has also been used by other groups in many developmental studies of motor 
neurons (e.g. [135, 136]). These lines were bred in our facility to generate Hb9Cre+/-; 
Smn
Res/+; SMN∆7+/+; SMN2+/+ mice. For experiments, the latter were bred to SmnRes 
carriers. The genotype for the rescued animals, designated as Hb9(Cre+)SMA, was 
Hb9
Cre+/-; SmnRes/Res; SMN∆7+/+; SMN2+/+. The genotype for the disease animals, 
designated as Hb9(Cre-)SMA, was Hb9Cre-/-; SmnRes/Res; SMN∆7+/+; SMN2+/+. Controls 
were SmnRes/+ or Smn+/+ mice derived from the same crosses. 
 The initial design of the study assumed that precise measures of lifespan, from 
birth until death, were essential to determine the effects of the selective raising of SMN 
in motor neurons of SMA mice. Thus, the approved animal use protocol for this study 
allowed death without euthanasia as an endpoint for the survival analysis. This 
accommodation turned out to be critical as the results showed that our experimental 
manipulation had no effect on survival. Had the differences in lifespan been more clear 
between our rescued and diseased animals, it would have been possible for us to 
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establish a set of symptoms and criteria that would have allowed euthanasia before death 
without fear of changing or affecting the final results of the survival analysis. To 
minimize the number of SMA mice used in the study, animals that were followed for 
survival analysis were also used for longitudinal studies of weight progression and 
righting reflex. A separate set of control and SMA mice were used later to perform the 
hind-limb suspension test. This experiment was terminated at postnatal day (P) 12, 
before the SMA animals reached their mean lifespan of ~14 days. NMJ phenotypes were 
analyzed in P9-P11 animals.  
 3.3.3 Genotyping 
 Upon either death or weaning of the experimental progeny, tissue samples were 
obtained from tail, spinal cord, skeletal muscle, kidney, brain, heart and stomach. DNA 
was extracted and amplified by PCR using REDExtract-N-Amp Hot start according to 
manufacturer instructions (Sigma-Aldrich, St. Louis, MO). Primers: Cre was detected 
using the custom primers: Forward: 5’-CATTTGGGCCAGCTAAACAT-3’, Reverse: 
5’-CCCGGCAAAACAGGTAGTTA-3’. The product was 454 bp. Smn- was detected 
with the following custom primers: Forward: 5’-CTTGGGTGGAGAGGCTATTC-3’, 
Reverse: 5’-AGGTGAGATGACAGGAGATC-3’. Smn+ was detected with primers 
oIMR7033 and oIMR7034 (Jackson labs, Bar Harbor, ME). SMN2 was detected with 
primers oIMR5065, oIMR5066, oIMR5067 (Jackson labs, Bar Harbor ME). 
 3.3.4 Quantitative-Real Time-Polymerase Chain Reaction (qRT-PCR)  
 Total RNA was extracted from P4 whole spinal cords and hindlimb skeletal 
muscle using Trizol reagent according to manufacturer instructions (Life Technologies, 
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Grand Island, NY). 1µg of RNA per sample was reverse transcribed to cDNA using the 
High Capacity cDNA reverse transcription kit according to manufacturer instructions 
(Life Technologies, Grand Island, NY). Quantitative-RT-PCR for full length SMN 
transcripts encoded by the recombined SmnRes allele (SMN67m8h, Fig. 3.2) was 
performed as described previously by Paez-Colasante et al. (2013) [56]. The 18S rRNA 
and gapdh 20X primers and probe were Taqman® Gene Expression Assays (Life 
Technologies, Grand Island, NY). Samples were set up in triplicate using a Taqman® 
Master mix (Life Technologies, Grand Island, NY) and run for 48-50 cycles in an ABI 
Prism 7900HT Fast Real-Time PCR System (Life Technologies, Grand Island, NY). The 
∆∆Ct method [119] was used to determine changes in mRNA transcript expression 
levels between groups. 
 3.3.5 Western Blot  
 Whole spinal cords from three Hb9(Cre+)SMA, three Hb9(Cre-)SMA and three 
WT control animals were dissected and frozen instantly in liquid nitrogen. Spinal cords 
were each homogenized and tissue was lysed with radioimmunoprecipitation assay 
(RIPA) buffer in order to extract proteins. Tail samples from P4 mice were taken for 
DNA extraction and genotyped with PCR assays. Samples were run on a 12.5% 
acrylamide gel and the membrane was incubated overnight in an anti-mouse SMN 
(1:3000) antibody, followed by a secondary anti-mouse HRP antibody. Same samples 
were incubated separately in -Tubulin as a loading control. Levels of the ~37kD SMN 
protein were quantified against -Tubulin and normalized to the WT control group. 
Protein bands were compared through band intensity analysis.  
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 3.3.6 Survival Analysis  
 Our experimental litters were monitored twice daily for potential mortalities. As 
soon as death of an animal occurred, lifespan was recorded and samples of the above-
mentioned tissues were taken for genotyping. All animals assayed (n= 187) were 
grouped according to genotype and lifespan (days). Survival data was plotted on Kaplan-
Meier survival curves using Prism5 (GraphPad Software, La Jolla, CA).  
 3.3.7 Weight Progression  
 On P3, pups were tattooed with Indian black ink for identification purposes and 
henceforth weighed every three days to determine weight changes over the time course 
of 21 days (until weaning for controls and death for mutants). All animals assayed 
(n=150) were grouped according to genotype and mean weights for each time point were 
plotted using Prism5 (GraphPad Software, La Jolla, CA). 
 3.3.8 Motor Function  
 A righting reflex test was performed every three days on the same animals used 
for weight progression above. This measurement was taken in duplicate and averaged. 
All animals assayed (n=150) were grouped according to genotype and mean time to 
“right” for each time point was scored according to the following scale, modeled after 
Monani and co-workers [19]: 0-4s=5, 5-9s=4, 10-14s=3, 15-20s= 2, 21-49s=1, 50-
>60s=0. A score of 0 was considered a failed test. Scores were plotted using Prism5 
(GraphPad Software, La Jolla, CA). The hindlimb suspension (tube) test was performed 
as described by El-Khodor and colleagues [120] except only latency time to fall (up to 
60s) was used in the analysis (See Fig. 3.1, section and Appendix for details). 
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Fig. 3.1. Hindlimb suspension (tube) test. Mice are suspended from their hindlimbs onto a 50ml conical 
tube with a cotton ball or tissue at the bottom to prevent injury. Latency time is recorded up to 60s 
maximum.  
 
 
 
 3.3.9 Neurofilament (NF) Accumulation Assay  
 NMJ staining was performed on fixed whole mounts of P10-P11 tibialis anterior 
(TA) muscle. To label NF’s, samples were incubated overnight at room temperature on a 
rocker with 2H3 monoclonal antibody (1:100, Developmental Studies Hybridoma Bank, 
Iowa City, IA). The following day, muscles were washed in PBS-T and then incubated 
in rhodamine goat anti-mouse secondary antibody (1:200, Jackson Immunoresearch, 
West Grove, PA) and fluorescein-conjugated α-bungarotoxin (BTX) (1:1000, Life 
Technologies, Grand Island, NY) to label acetylcholine receptors (AChRs). After 
washing, muscle bundles were separated and mounted on microscope slides using 
VectaShield (Vector Laboratories, Burlingame, CA). Slides were observed under an 
epifluorescence microscope fitted with a Z-motorized stage (Nikon Eclipse E1000, 
Nikon, Tokyo, Japan) with a 100X, 1.3 NA oil objective. Images of NMJs were taken 
with a CoolSNAP fx CCD camera (Photometrics, Tucson, AZ) and captured with 
MetaMorph (Molecular Devices, Downingtown, PA). An observer, blind to genotype, 
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initially classified NMJs as either NF accumulation positive (diseased) or negative 
(normal). NMJs were later grouped according to genotype for quantitative analysis.   
 3.3.10 Innervation Status 
  P9 triceps muscles were dissected, fixed and cryoprotected. Muscles were sliced 
in a cryostat into 40µm longitudinal sections. Free-floating sections were blocked in 
PBS + 10% normal goat serum. Sections were later incubated overnight in either an 
antibody to synaptophysin (1:300, Life Technologies, Grand Island, NY) or in a 2H3 
monoclonal antibody (1:100, Developmental Studies Hybridoma Bank, Iowa City, IA). 
The following day all sections were washed and incubated either in rhodamine goat anti-
rabbit antibody (1:1000, Jackson Immunoresearch, West Grove, PA) or in rhodamine 
goat anti-mouse secondary antibody (1:200, Jackson Immunoresearch, West Grove, PA) 
respectively. Fluorescein-conjugated α-bungarotoxin (BTX) (1:1000, Life Technologies, 
Grand Island, NY) was added to label acetylcholine receptors (AChRs).  After washes in 
PBS-T, all free-floating sections were mounted on slides using VectaShield. A 40X, 1.3 
NA oil objective was used to acquire wide field images of NMJs with MetaMorph 
Software. Endplates stained with synaptophysin were assessed blind to genotype for 
their innervation status by qualitatively classifying each junction into either fully-
occupied (>75%), partially-occupied (25-75%) and unoccupied (<25%) depending on 
the relative proportion of synaptophysin staining versus the overall area of the AChR 
staining. NMJs stained for NF and BTX were assessed for status of innervation by 
categorizing them as innervated if there was any overlap between the two stains or 
denervated if NF was completely absent at the synaptic site. 
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  3.3.11 Endplate Size  
 AChR area was calculated from the images of P9 TA whole mounts and from P9 
triceps longitudinal sections using the MetaMorph software.  
 3.3.12 Endplate Morphology 
  AChR morphology was determined from the images of the same P9 triceps 
longitudinal sections described in 3.2.10 and 3.2.11 using the categories: 1) plaque, 2) 
perforated, 3) “C”-shape, and 4) complex. Plaque shape is the most immature stage of 
development and is characterized by an endplate without any perforations; perforated, as 
the name indicates, characterizes the receptors with one or more perforations; “C”-shape 
refers to an open and more mature configuration; and finally the complex shape is the 
most mature category and was assigned to highly branched receptors with numerous 
perforations and the typical “pretzel”-like shape. These categories were adapted from the 
ones previously described by Kummer et al. (2004) [137]. 
 3.3.13 Myofiber Area and Diameter 
 P9 TA muscles were dissected and flash frozen with OCT medium (tissue tek) in 
an isopentane/liquid N2 bath. 14μm-thick cross-sections were cut in a cryostat and 
mounted on a slide. Sections were fixed in 1% PFA then washed in PBS-T. The cross 
sections were blocked in PBS + 10% normal goat serum and then incubated overnight in 
a dystrophin antibody (1:300, Abcam, Cambridge, MA). The following day, muscle 
sections were incubated with a fluorescein-conjugated goat anti-rabbit secondary 
antibody (1:200). After washes, slides were mounted using VectaShield. A 20X, 0.5 NA 
oil objective (Nikon) was used to acquire wide field images of myofibers with 
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MetaMorph Software, taking as many images needed to encompass the entire area of a 
single whole muscle section avoiding overlapping myofibers. The dystrophin stained 
images were analyzed for myofiber area and diameter by first thresholding the calibrated 
image for dark objects and manually adjusting said threshold to fill the entire interior 
core surrounded by dystrophin staining of as many myofibers as possible per image. 
Next regions were drawn automatically around each individual fiber, and lastly the 
integrated morphometric analysis tool in MetaMorph was used to determine area and 
breath, which is the caliper width of the object perpendicular to the longest chord.  This 
approach allows simultaneous accurate determination of myofiber size parameters in a 
large number of fibers. It is quicker than the traditional approach of measuring these 
parameters in single fibers at a time. 
 3.3.14 Statistical Analysis 
  Quantitative data are expressed as mean  SEM. Values for number of animals 
and NMJs analyzed are given in the figure legends. Kaplan-Meier survival curves were 
generated and tested for statistical significance using the log-rank test with Prism5 
GraphPad Software. Analysis of the Variance (ANOVA) was used to check for 
significance in weight and motor function data using SAS software (SAS Institute, Cary, 
NC). Student’s t-test, computed either with Microsoft Excel (Microsoft Corporation, 
Seattle, WA) or Prism5 GraphPad Software, was used to probe for statistical 
significance in NF accumulation, innervation status and endplate size data.  Significance 
was set at p0.05. 
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3.4 RESULTS  
 3.4.1 Spinal Cord-Specific Recombination of the Smnres Allele 
 The hybrid SmnRes allele has an inverted (i.e. 3’5’), translationally silent mouse 
Smn exon 7 in the intron between human SMN2 exon 7 and 8 (Fig. 3.2). Mutant 
(lox71/lox66) loxP sites in opposite orientation were engineered upstream of SMN2 exon 
7 and downstream of the inverted Smn exon 7, respectively. In this form, this allele 
potentially codes for transcripts containing Smn exons 1-6 and SMN2 exons 7 and 8. 
However, it was found that in this configuration SmnRes fails to encode transcripts for 
full-length SMN and only produces transcripts lacking SMN2 exon 7 that code for 
SMN∆7 protein (Fig. 3.2). Hence SmnRes is functionally a null Smn allele [2]. Upon Cre 
recombination, Smn exon 7 5’3’ orientation is irreversibly restored so that transcripts 
containing Smn exons 1-7 and SMN2 exon 8 (SMN67m8h) are generated, which encode 
full length SMN (Fig. 3.2). SmnRes/Res mice are embryonic lethal, however, when SmnRes 
replaces the Smn null allele in an SMA∆7 background, the resulting SmnRes/Res mice 
display essentially the same SMA phenotype as standard SMA∆7 mice [2]. Thus, these 
mice are “conditional” SMA∆7 mice. Repairing the SmnRes allele using Cre-lines that 
express the recombinase ubiquitously from early development rescued the normal 
phenotype of the mice, validating the recombined, hybrid SmnRes allele as a WT-
surrogate Smn allele [2]. 
 To restore SMN expression selectively in motor neurons, we sought to drive the 
repair of the SmnRes allele with Hb9-Cre. The homeobox gene Hb9 is selectively 
expressed in spinal cord somatic and visceral motor neurons and Vx interneurons starting 
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at embryonic (E) day 9.5 [122, 138]. In the Hb9Cre allele an IRES-Cre cassette was 
knocked-in into the first exon of the Hb9 gene. Thus, Cre expression under Hb9 control 
follows the expression pattern of endogenous Hb9. Hb9Cre is homozygous lethal thus 
only heterozygous animals survive past birth. The experimental crosses consisted of 
Smn
Res
 carriers (SmnRes/+; SMN∆7+/+; SMN2+/+, JAX stock #007951) bred to Hb9Cre+/-; 
Smn
Res/+; SMN∆7+/+; SMN2+/+ mice. The genotype for the rescued animals, designated 
as Hb9(Cre+)SMA, was Hb9Cre+/-; SmnRes/Res; SMN∆7+/+; SMN2+/+. The genotype for the 
disease animals, designated as Hb9(Cre-)SMA, was Hb9Cre-/-; SmnRes/Res; SMN∆7+/+; 
SMN2
+/+. Controls were SmnRes/+ or Smn+/+ mice derived from the same crosses. Their 
precise genotypes were: Hb9Cre?/-; SmnRes/+; SMN∆7+/+; SMN2+/+ and Hb9Cre?/-; Smn+/+; 
SMN∆7+/+; SMN2+/+. 
 
 
 
 
 
Figure 3.2. Schematic representation of the Smn WT allele and the SmnRes conditional hybrid 
mutant allele before and after Hb9-Cre recombination. Blue boxes represent mouse Smn exons. Red 
boxes represent human SMN2 exons. Arrows within boxes display orientation relative to transcription 
start. Green stars show approximate location of loxP sites (lox71, lox 66) in SmnRes. Black lines connecting 
exons show splicing pattern for the predominant transcript encoded by each allele. Protein products are 
named to the right. SMN67m8h is the transcript encoded by the repaired SmnRes allele. Not drawn to scale. 
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 Genomic PCR confirmed spinal cord-selective, Hb9Cre driven recombination of 
Smn
Res in our Hb9(Cre+)SMA mice as the repaired allele was only detected in spinal 
cord, but not in skeletal muscle, kidney (Fig. 3.3A), brain, heart or stomach (data not 
shown). 
 
 3.4.2 Comparison Between Hb9Cre and ChATCre Driven Repair of the SmnRes 
 Allele 
 We used quantitative RT-PCR to measure the levels of the recombined, repaired 
transcript SMN67m8h, which encodes full-length SMN (Fig. 3.2), in P4 spinal cord and 
muscle. We chose this early time point because disease symptoms were not overt at this 
stage. We used as controls P4 spinal cord and muscle tissue from ChATCre+ and Myf5Cre+ 
conditional SMA∆7 mice [57]. Primers were designed to recognize the SMN67m8h 
transcript. The forward primer cut across Smn exons 6 and 7 exon/intron boundary and 
the reverse primer bound to SMN2 exon 8 ([57] Fig. 3.2). For endogenous controls, we 
used primers for 18S rRNA and gapdh. Cycle threshold (Ct) values obtained for either 
18S rRNA or gapdh were used to normalize the Ct values from the SMN67m8h 
transcript by equalizing differences in total cDNA per sample. The assays with each 
housekeeping gene were set up separately on different trials. Transcript level fold change 
was determined by the 2-DeltaDeltaCt method [119] and values were normalized to the Ct 
values obtained for ChATCre+; SmnRes/Res spinal cord samples in every case. In our hands, 
relative SMN67m8h expression levels for ChATCre+; SmnRes/Res and Myf5Cre+; SmnRes/Res 
samples were very similar to those reported before independently of the control primers 
used [57] (Fig. 3.3B). In fact, the Ct values obtained with these samples were almost 
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identical to the Ct values obtained previously with other samples with the same 
genotypes [57]. However, P4 Hb9Cre+; SmnRes/Res spinal cord had approximately 100-fold 
lower levels of SMN67m8h transcript than ChATCre+; SmnRes/Res spinal cord when using 
18S rRNA primers as an endogenous control to normalize (Fig. 3.3B).  
 
 
 
 
 
Fig. 3.3. A. Spinal cord-specific Cre recombination of the SmnRes in Hb9(Cre+)SMA mice. Genomic 
DNA was prepared from spinal cord (SpC), skeletal muscle (SkM), and kidney (K) from 2 Hb9Cre+ and 2 
Hb9Cre- SMA animals postmortem. All animals died within the first two postnatal weeks suggesting they 
were SmnRes/Res. Top panels: Genomic PCR specific for the inverted, recombined SmnRes allele 
demonstrated its presence only in the spinal cord samples and not in the skeletal muscle or kidney 
samples. All these samples were positive for SMN2, which showed DNA integrity. Sizes of the expected 
DNA bands are indicated to the left of each panel. M: 100 bp ladder. (+): positive controls. Spleen DNA 
from a germline inverted SmnRes/Res animal was used as positive control for the recombined allele PCR. B. 
Relative SMN67m8h expression in Hb9Cre, ChATCre and Myf5Cre SMA lines at P4. The ordinate, in log 
scale, shows SMN67m8h expression normalized to levels in ChATCre SMA spinal cord. Hb9Cre SMA 
spinal cord displayed ~100-fold lower expression than ChATCre SMA spinal cord. N= 2–4, per genotype.  
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 Subsequently, primers for gapdh were used to confirm the initial results 
normalized with 18S. On this other gene expression assay with the SMN678 transcripts 
equalized to gapdh transcripts we obtained a ~70-fold change between Hb9(Cre+) and 
ChAT(Cre+) spinal cord samples (Fig. 3.4). We performed an additional experiment to 
validate our results. We altered the methodology of the qRT-PCR set-up by using 4X the 
concentration of cDNA. In this assay the Ct values obtained were also normalized to 
gapdh transcripts. As expected, Ct values lowered ~2-3 cycles for all of the groups yet 
the relative SMN678 transcript expression levels remained very similar to initial results 
with a difference of ~70-fold between Hb9(Cre+)SMA and ChAT(Cre+)SMA spinal 
cords. The average Ct values were: Hb9(Cre+)SMA spinal cord: 1X cDNA = 38.92 ±  
0.41 vs. 4X 36.96 ± 0.33;  ChAT(Cre+) spinal cord: 1X cDNA = 34.56 ± 1.00 vs. 4X 
31.39 ± 0.77; Myf5(Cre+) spinal cord: 1X cDNA = 35.83 ± 0.32 vs. 4X 32.17 ± 0.26 and 
Myf5(Cre+)SMA muscle: 1X cDNA = 30.46 ± 0.23 vs. 4X cDNA 26.70 ± 0.05.  
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Fig. 3.4. Relative SMN67m8h expression in Hb9Cre, ChATCre and Myf5Cre SMA lines at P4 normalized 
to gapdh. The ordinate, in log scale, shows SMN67m8h expression compared to levels in ChATCre SMA 
spinal cord. Hb9Cre SMA spinal cord displayed ~70-fold lower expression than ChATCre SMA spinal cord 
when equalized to gapdh. Thus confirming the results with 18S rRNA primers which indicate that the 
SMN transcript generated from Hb9(Cre+)SMA spinal cords is vastly lower than that produced in the 
spinal cords of ChAT(Cre+)SMA mice. 
 
 
 
 Consistent with our prior results at the genomic level (Fig. 3.3A), SMN67m8h 
transcript was undetectable in muscle samples from either Hb9Cre+; SmnRes/Res or Hb9Cre-; 
Smn
Res/Res mice (data not shown). Nor was SMN67m8h detected in spinal cord from 
Hb9
Cre-
; Smn
Res/Res animals (data not shown). Thus, although these results confirm at the 
mRNA level the spinal cord specific recombination driven by Hb9Cre in conditional 
SMA∆7 mice, they unexpectedly show that full length SMN expression in these mice is 
remarkably much lower than in ChATCre+ conditional SMA∆7 mice. 
We failed to detect an increase in SMN protein levels by Western blot in spinal 
cord from Hb9Cre+; SmnRes/Res animals relative to spinal cord from Hb9Cre-; SmnRes/Res 
mice (Fig. 3.5) This is not surprising in light of the fact that this increase was not even 
observed when ChATCre drove the repair of SmnRes in conditional SMA∆7 mice [57], 
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which is probably due to the small proportion of motoneuron-derived material in lysates 
from whole spinal cord.  
 
 
 
 
Fig. 3.5. SMN protein expression between Hb9(Cre+)SMA and Hb9(Cre-)SMA mice. Western blot 
analysis of SMN protein levels: Whole spinal cord protein samples from three Hb9(Cre+)SMA, three 
Hb9(Cre-)SMA and three WT control animals were incubated overnight in an anti-mouse SMN (1:3000) 
antibody. Same samples were incubated separately in -Tubulin as a loading control. Levels of SMN were 
quantified against -Tubulin and normalized to the WT control group. We found no significant increase in 
SMN levels between our Cre+ and Cre- mice (P > 0.05).  
 
 
 
 3.4.3 Survival, Weight Progression and Motor Behavior in Hb9(Cre+)SMA 
 Mice 
 Having obtained evidence of spinal cord-selective recombination and expression, 
we next characterized the phenotype of Hb9(Cre+)SMA mice. Figure 3.6A and B 
exemplifies the vast qualitative differences between P9 Hb9(Cre+)SMA and WT control 
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littermate mice. These SMA mice are differentiated to controls by their visibly obvious 
small size and muscle atrophy that causes them to lose motor function.  
 
 
 
 
 
Fig 3.6. Images exemplifying phenotypical differences between P9 WT (*) and Hb9(Cre+)SMA (x) 
littermate mice. Images show both the size difference and the inability of mutant animals to stand up or  
“right” themselves. A. One WT mouse (*) is compared to two Hb9(Cre+)SMA mice (x, one very diseased 
brown mouse and one white mouse in the middle of the image), and one Hb9(Cre-)SMA mouse (x, brown 
mouse in the far upper left corner). B. Example of a very diseased mutant animal compared to a healthy 
control. The mutant animal was unable to stand on its own and had very limited limb movements, and was 
very lethargic with possible breathing difficulties. Images not to scale. 
 
 
 
 Median survival for Hb9(Cre-)SMA mice was 14.6 ± 2.64 days (n=20) (Fig. 
3.7A). This value agrees very well with the mean survival reported by others for these 
mice [2, 57] and for the original SMA∆7 animals [6], which suggests that our breeding 
strategy did not alter the basic phenotype of the mice. Hb9(Cre+)SMA mice displayed a 
statistically similar lifespan (Fig. 3.7A; 13.41 ± 3.73 days, n= 37, p = 0.6436, log-rank 
test). Both SMA lines were clearly unable to gain the weight that controls did (Fig. 3.7B 
and Fig. 3.6). Hb9Cre+ and Hb9Cre- conditional SMA∆7 mice gained some weight 
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between P3 and P9, but it declined steadily henceforth until time of death (Fig 3.7B). 
Hb9(Cre+)SMA mice tended to be a little heavier than Hb9(Cre-)SMA mice between P9 
and P15, but this difference was statistically significant by ANOVA only at P12 
(F=9.78; p=0.004).  
 Motor behavior was assessed using the righting reflex (Fig. 3.7C and Fig. 3.6B) 
and the hindlimb suspension tests (Fig. 3.7D). As expected heterozygous and WT 
controls performed much better than SMA mice in these tests. No statistical differences 
in motor function were apparent between Hb9(Cre+)SMA and Hb9(Cre-)SMA mice. 
Thus we failed to detect improvements in lifespan and motor behavior in 
Hb9(Cre+)SMA animals, even though there was a slight tendency for increased weight. 
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Figure 3.7. Hb9-Cre recombination fails to improve lifespan, weight gain and motor behavior in 
SMA7 mice. A.  Kaplan-Meier curves demonstrate no increase in survival, p = 0.6436, log-rank test. 
Mean life span: Hb9(Cre+)SMA: 13.41 ± 3.73 days, n=37. Hb9(Cre-)SMA mice: 14.6 ± 2.64 days; n=20. 
Controls: n=130. B. While controls (n=107) gained weight as expected, no statistical differences in weight 
were found during the lifespan of Hb9(Cre+)SMA and Hb9(Cre-)SMA mice except at P12 (*p=0.004, 
F=9.78, ANOVA). Hb9(Cre+)SMA: n=10-27 per time point. Hb9(Cre-)SMA: n=3-16 per time point. C 
and D. Motor behavior was assessed by the righting reflex (C) and hindlimb (tube) suspension (D) tests. 
Only the latency to fall was recorded for the tube assays. While controls improved their performance with 
age, SMA mice motor behavior deteriorated as they approached end stage. For the righting reflex assays: 
Controls: n=107 per time point. Hb9(Cre+)SMA: n=7-27 per time point. Hb9(Cre-)SMA: n=4-16 per time 
point. For the tube test: Controls: n=148 per time point. Hb9(Cre+)SMA: n=7-28 per time point. Hb9(Cre-
)SMA: n=5-17 per time point. 
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 3.4.4 Neuromuscular Phenotypes in Hb9(Cre+)SMA Mice 
 While Hb9-Cre-driven rescue of conditional SMA∆7 mice had no apparent effect 
at the whole animal level, it was still possible that their NMJ pathology could be rescued 
by this approach. Accumulations of neurofilament (NF) staining at the nerve terminal are 
a hallmark pathological feature in SMA mice [30, 40, 132, 139], and they were reduced 
to control levels in ChATCre+ conditional SMA7 mice [57]. We stained whole mount 
preparations from P10 tibialis anterior (TA) muscle for NF and AChRs to mark NMJs. 
While about 10% of endplates had pre-synaptic NF accumulations in controls, over 80% 
of NMJs displayed them in Hb9Cre+ or Hb9Cre- conditional SMA∆7 preparations (Fig. 
3.8). Thus, NF accumulations in nerve terminals persisted in Hb9(Cre+)SMA mice. 
 
 
 
  
 
Fig 3.8. Neurofilament (NF) accumulation at nerve terminals fails to be rescued in Hb9(Cre+) SMA 
mice. Whole mounts of P10 TA muscle stained for components of the NMJ. A. Representative images for 
each of the 3 genotypes assayed. Protuberances or “blebbing” of the nerve terminals (arrowheads) are 
distinct evidence of SMA pathology. Green: NF, Red: BTX. Scale bars: 20µm. B. Quantification of NF 
accumulation as seen in A. The ordinate plots the mean percentage of NMJs with NF accumulation per 
genotype. Most NMJs in Hb9(Cre+) and Hb9(Cre-) SMA mice had NF accumulations, while only a 
minority of endplates in controls showed so. Controls n=9 animals, 107 NMJs. Hb9(Cre+)SMA n=4 
animals, 52 NMJs. Hb9(Cre-)SMA n=3 animals, 95 NMJs. 
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 Endplate size in TA muscle, as measured by the area occupied by AChRs, was 
one of the synaptic phenotypes rescued in ChATCre+ conditional SMA∆7 mice [57]. We 
determined AChR area in whole mount TA preparations and in longitudinal sections of 
triceps muscles from P9 animals. To capture many NMJs per image and to ensure 
imagining of the entire junctional surface, wide field 3D images of the BTX-stained 
tissue were taken with an epifluorescence microscope fitted with a motorized Z-axis. 
Using Methamorph software, the Z-stacks were first flattened to the X/Y dimensions and 
endplate area was determined after thresholding of images. The average TA endplate 
areas for control (185.10  6.87 µm2) and Hb9(Cre-)SMA (115  0.94 µm2) genotypes 
were  very similar to those reported previously for P9 TAs in control and SMA∆7 mice, 
respectively, which were imaged by confocal microscopy [132]. In Hb9(Cre+)SMA mice 
average TA endplate area was 170.11  7.08 µm2.  Figure 3.9 A,B shows that endplate 
area for both TA and triceps NMJs was restored to control values in Hb9(Cre+)SMA 
mice. Thus, appendicular muscles innervated by pools of motor neurons in opposite ends 
of the spinal cord, cervical (triceps), lumbar/sacral (TA), had their average endplate area 
rescued in Hb9(Cre+)SMA mice.  
 In normal animals endplate size correlates with myofiber size [140]. Following 
labeling of transverse sections for dystrophin to mark cell surface, we determined mean 
myofiber area and diameter in TA muscles from P9 controls, Hb9(Cre+) and Hb9(Cre-
)SMA mice. We focused on this muscle because it was used previously by Martinez et 
al. (2012) [57] in their analysis of these parameters in ChATCre-, Myf5Cre- and MyoDiCre- 
SMA∆7 mice. Dystrophin staining was normal and qualitatively similar between 
  
 
104 
genotypes (Fig. 3.9C) despite the pronounced muscular atrophy in mutant animals. Thus, 
dystrophin is not altered in SMN-deficient spinal cords but is in SMN-deficient muscles 
as was observed by Cifuentes-Diaz et al. (2001) [54]. As expected, mean myofiber area 
and diameter were larger in controls than in SMA mice and were within the range 
reported previously [57, 132]. However, there were no differences in these parameters 
between Hb9(Cre+) and Hb9(Cre-)SMA mice (Fig. 3.9 D,E) (Control, area=449.4±44.94 
µm2; diameter=22.07±1.08 µm. Hb9(Cre+)SMA, area=297.06±11.10 µm2; 
diameter=17.53±0.37 µm. Hb9(Cre-)SMA, area=268.05±32.49 µm2; 
diameter=16.96±0.86 µm). Thus, the increase in endplate size in the TA muscle from 
Hb9(Cre+)SMA mice was observed in the absence of a corresponding increase in 
myofiber area and diameter. 
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 Fig. 3.9. Endplate size is rescued in Hb9(Cre+) SMA mice without change in myofiber size. 
A. and B. Quantification of endplate size in P9 TA and triceps muscles, respectively.  TA endplate size 
was determined in whole-mount preparations. Triceps endplate area was determined in longitudinal 
sections from images such as that displayed in Fig. 3.11A. Endplate area was rescued in both muscles in 
Hb9(Cre+)SMA mice. TA: Controls: n=5 animals, 512 NMJs. Hb9(Cre+)SMA n=3 animals, 465 NMJs. 
Hb9(Cre-)SMA n=3 animals, 303 NMJs. Triceps: Controls n=5 animals, 505 endplates. Hb9(Cre+)SMA 
n= 3 animals, 524 endplates. Hb9(Cre-)SMA n= 3 animals, 316 endplates. **p=0.002. *p=0.008 (t-test). 
C. Representative images of dystrophin stain for 14-µm-thick transverse sections of control and SMA P9 
TA muscles. Dystrophin staining is qualitatively similar between genotypes but differences in fiber caliber 
between control and SMA muscles are evident. Scale bars: 50 µm. D. and E. Quantification of mean 
myofiber area and diameter of P9 TA muscles, respectively. Controls: n=2 animals, 3116 fibers. 
Hb9(Cre+)SMA n=3 animals, 5729 fibers. Hb9(Cre-)SMA n=3 animals, 4511 fibers. 
 
 
 
 We also assessed NMJ receptor morphology, similarly to what was done in Lee 
et al. (2011) [40] and Kummer et al. (2004) [137], to determine if we were able to rescue 
Hb9(Cre+)SMA mice from an impairment of postsynaptic maturation. In developing and 
early postnatal mice, AChRs have an immature morphology appearing as even simple 
plaques. As the mouse matures, so does the endplate with its morphology evolving to 
more complex forms with perforations and branches, eventually resembling a “pretzel”. 
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In SMA-like mutant mice the progression from a simple plaque to a complex form is 
severely delayed with the persistence of an immature plaque-like morphology in the 
majority of NMJs [40].  Sections of P9 triceps from Hb9(Cre+)SMA, Hb9(Cre-)SMA, 
and controls were observed and the postsynaptic AChR aggregates were classified into 
one of four different categories (plaque, perforated, C-shape or complex) . At P9, the 
triceps of Hb9(Cre+)SMA mice had 80.51 ± 2.36 % of the endplates evaluated (n= 3 
animals/ 190 endplates per animal) in the immature plaque-like stage. This was almost 
identical to what was observed for the Hb9(Cre-)SMA in which 81.23 ± 3.56% of the 
endplates assessed (n= 3 animals/ 185.3 endplates/animal) were plaques as well (Fig. 
3.10). However, this was not surprising in light that the control group also had the 
majority of its NMJs assessed in the immature plaque-like stage, likely due to the very 
young age (P9) at which the animals were evaluated (80.34 ± 2.61%, n= 4 animals/110.5 
endplates per animal). The remaining percentages of receptors were classified between 
the categories perforated [Hb9(Cre+)SMA = 9.37 ± 4.26%; Hb9(Cre-)SMA = 12.10 ± 
2.35%; Controls = 11.72 ± 2.24%], C-shape [Hb9(Cre+)SMA = 4.67 ± 3.83%; Hb9(Cre-
)SMA = 5.85 ± 1.22%; Controls = 4.89 ± 1.65%], or complex [Hb9(Cre+)SMA = 3.22 ± 
1.61%; Hb9(Cre-)SMA = 2.84 ± 0.47%; Controls = 3.00 ± 1.20%] (Fig. 3.10). We found 
no statistical difference between Hb9(Cre+)SMA and Hb9(Cre-)SMA mice (p≥0.60). 
Also, there was also no difference between either of these two and the control group for 
any of the categories (p≥0.62). Lee et al. observed open, more mature, configurations of 
control sternomastoid muscles starting at P12 but in the soleus and EDL muscles, most 
of the receptors were yet immature at this stage. This is consistent with the known rostral 
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to caudal pattern of maturation of the NMJ. In our case, we expected that a proximal 
muscle such as the triceps would present WT endplates at more mature stages. We 
suggest that this is due to the early stage at which the endplates were evaluated and thus, 
future studies should be conducted on older end-stage animals. 
 
 
Fig. 3.10. AChR aggregate morphology. In P9 Hb9(Cre+)SMA, Hb9(Cre-)SMA and control triceps most 
of the AChR aggregates still remained in the plaque stage, while the few remaining receptors were 
distributed evently amongst the three groups into more mature stages of perforated, C-shape and complex 
morphological stages. We found no effect of genotype on receptor morphology and no significant 
difference between our P9 animal groups in any of the categories included in the assay at P9. 
 
 
 
 Ko and colleagues demonstrated a selective vulnerability to denervation of 
specific, clinically relevant muscles in SMA∆7 mice [104]. Denervation of vulnerable 
muscles was restored to control values in ChATCre+ conditional SMA∆7 mice [57]. We 
determined the innervation status of NMJs in the triceps, one of the reported vulnerable 
appendicular muscles [104], by first co-staining longitudinal sections for AChRs and 
synaptophysin, a synaptic vesicle marker. While lack of synaptophysin staining may not 
  
 
108 
be indicative of structural denervation (i.e. absence of an axon terminal), increased 
synaptophysin coverage of an endplate is necessarily associated with axon terminal 
presence. Images were taken and processed as above. Endplates were classified as fully-
occupied if at least ~75% of the AChR area was covered by synaptophysin staining. On 
the other hand, they were deemed as unoccupied if less than ~25% of the AChR area 
showed synaptophysin staining. Endplates with synaptophysin staining in between were 
categorized as partially occupied. We found a statistically significant improvement in the 
synaptophysin coverage of the P9 triceps endplates in Hb9(Cre+)SMA mice (Fig. 
3.11B). Thus, the fraction of fully-occupied synapses increased in Hb9Cre+ SMA∆7 mice 
over that in SMA mice [Hb9(Cre+)SMA=57.47 ± 5.58%; Hb9(Cre-)SMA= 23.00 ± 
1.65%], while the fraction of unoccupied endplates decreased in the rescued animals 
relative to SMA mice [Hb9(Cre+)SMA=25.97 ± 6.2%; Hb9(Cre-)SMA=48.93 ± 3.37%]. 
Partially-occupied synapses also were reduced in numbers in Hb9(Cre+)SMA mice 
[15.29 ± 0.86% vs. 29.46 ± 2.11% in Hb9(Cre-)SMA animals]. However, the 
improvement in synaptophysin occupancy in the Hb9Cre+ SMA∆7 mice did not quite 
reach the levels observed in the control animals (Fig. 3.11B). To directly assess 
structural innervation, we co-stained serial triceps longitudinal sections for AChRs and 
neurofilament, a structural axonal marker. Synaptic sites labeled with BTX were 
considered innervated if there was overlap, however small, between NF and AChR 
staining, while complete lack of NF at synaptic sites categorized them as denervated 
(Fig. 3.11C). Innervation was also improved clearly in Hb9(Cre+)SMA triceps using 
overlap between NF and BTX as scoring criterion (Fig. 3.11D). Thus, Hb9(Cre-)SMA 
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triceps had 56.29±1.11% of innervated endplates, whereas Hb9(Cre+)SMA triceps 
displayed 86.36±2.6 % innervated synapses, a percentage  similar to controls. 
 
 
 
 
 
 Fig. 3.11. Innervation status is improved in Hb9(Cre+) SMA mice. A.  A longitudinal section (40 µm-
thick) from triceps muscle, from a P9 Hb9(Cre+)SMA animal, co-stained for synaptophysin (SYN) and 
BTX, to label nerve terminals and AChRs, respectively. A flattened 2D image derived from a wide field 
3D stack for the fluorescein (AChR) and rhodamine (SYN) channels and their merge is shown. Two NMJs 
in the upper left have complete coverage of SYN staining over AChR staining, and are examples of fully-
occupied (FO) NMJs. Two endplates in the bottom right (arrow), one sideways, one en face, lack 
detectable SYN staining, and are examples of unoccupied (U) endplates. The one endplate in the middle is 
partly covered by SYN staining and is an example of a partially-occupied (PO) NMJ. Scale bar: 20µm.   
B. Quantification of synaptophysin occupancy of triceps endplates. The percentage of fully-occupied 
NMJs was increased, and the percentage of partially- and unoccupied endplates were reduced in 
Hb9(Cre+)SMA mice relative to Hb9(Cre-)SMA animals (*p < 0.008, t-test). Controls: n=5 animals, 403 
endplates. Hb9(Cre+)SMA: 3 animals, 394 endplates. Hb9(Cre-)SMA: 3 animals, 439 endplates C. Top 
panels: Representative merged images of P9 triceps longitudinal sections stained for NF (red) and BTX 
(green). Bottom panels: NF channel in black & white. In the top left panel (control) axons can be seen 
overlapping part of the BTX stain or barely entering the synaptic site (endplate on the lower right corner).  
Arrowheads in the middle panels indicate NF accumulations at synaptic sites on Hb9(Cre+) SMA tissue. 
All the synapses in the middle panels were considered as innervated, three of them are indicated as (I). The 
right top panel (Hb9 (Cre-) SMA) shows two examples of endplates completely lacking NF/BTX overlap 
and thus considered denervated (D). These two endplates have been outlined in green in the bottom right 
panel, to further clarify their lack of overlapping NF staining. Scale bars: 50 µm. D. Quantification of 
triceps innervation using NF/BTX overlap as criterion. The percentage of innervated endplates was 
increased and the percentage of denervated NMJs were reduced to control levels in Hb9(Cre+)SMA mice 
relative to Hb9(Cre-)SMA animals (*p = 0.0004, t-test). Controls: n=3 animals, 533 endplates. 
Hb9(Cre+)SMA: 3 animals, 478 endplates. Hb9(Cre-)SMA: 3 animals, 559 endplates. 
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 Thus, of the three NMJ structural phenotypes that were different between WT 
and SMA mice, endplate area and innervation status, but not presynaptic NF 
accumulation showed significant improvements in Hb9(Cre+)SMA mice relative to 
diseased animals. Interestingly the increase in endplate size appeared to occur in the 
absence of an increase in myofiber size. 
 
3.5 DISCUSSION 
 Compared to previous studies [57, 107, 141], ours seems to be the one in which 
restored spinal cord SMN levels are the lowest. Yet we were able to document full 
rescue of endplate size regardless of the susceptibility of a muscle to denervation and 
substantial recovery of innervation on a denervation vulnerable muscle. The increase in 
endplate size was not the result of an increase in muscle fiber size. The implication for 
therapeutics evaluation of this observation is that rescue of endplate size could be 
interpreted as a direct benefit on motor neurons rather than an indirect result of an 
increase in muscle fiber girth. Hence, our experiments uniquely highlight the exquisite 
sensitivity of these NMJ phenotypes to very small changes in SMN in spinal cords. 
These two phenotypes can be rescued by SMN levels that fail at reducing presynaptic 
NF accumulation, maturation of the endplate morphology, increasing animal weight and 
lifespan or improving overall motor performance. All of the above phenotypes were 
rescued or improved in ChATCre+ conditional SMA∆7 mice [57] , which our data imply 
display substantially more efficient Cre-mediated recombination in spinal cord than 
Hb9
Cre+
 conditional SMA∆7 mice. Thus, we suggest that our experiments establish a 
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threshold of SMN expression in motor neurons that distinguishes an order of SMN 
sensitivity for different SMA phenotypes.  
 Despite the inefficient restoration of motoneuronal SMN in Hb9Cre+ conditional 
SMA∆7 mice, the subclinical neuromuscular innervation improvements that can be 
measured in them raise the possibility that similar benefits could be seen in SMA 
patients even when the latter are under therapeutic interventions with known modest 
effects in raising SMN levels.  
 The pattern of structural neuromuscular phenotypes rescued in Hb9Cre+ 
conditional SMA∆7 mice was very similar to that in Myf5Cre+ conditional SMA∆7 mice 
[57]. Thus, TA endplate size and innervation status of a vulnerable muscle (the splenius 
capitis), but not levels of NF accumulation, were rescued in Myf5Cre+ conditional 
SMA∆7 mice. Myf5Cre+ is strongly expressed in skeletal muscle but also weakly in 
spinal cord, including motor neurons (Fig. 3.3B [57]). Although whole spinal cord 
samples from Myf5Cre+ and ChATCre+ conditional SMA∆7 mice seemed to have similar 
SMN67m8h levels (Fig 3.3B, [57]), it is important to point out that only a fraction of the 
full-length SMN expression in Myf5Cre+ conditional SMA∆7 mice may come from motor 
neurons themselves as Myf5Cre+ was found strongly expressed in ChAT-negative ventral 
horn neurons and in dorsal root ganglia [57]. Thus, it is possible that expression of 
Myf5
Cre+ and Hb9Cre+ in motor neurons may be more similar than suggested by our qRT-
PCR in whole spinal cord samples. Our results with Hb9Cre+ SMA mice strongly suggest 
that the rescue of endplate size and innervation status in Myf5Cre+ SMA mice is 
explained by its expression in motor neurons and not in muscle. This is consistent with 
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the observation that these phenotypes were not rescued in MyoDiCre+-expressing animals, 
which only had Cre expression in muscle but not spinal cord [57]. In normal animals, 
there is a direct correlation between muscle fiber girth and endplate size [140]. However, 
TA fiber diameter increased in MyoDiCre+-expressing animals without a corresponding 
increase in endplate size [57] and the increase in P9 TA endplate size observed here 
occurred without a change in average muscle fiber size (Fig. 3.9 C-E). Thus, together 
these data suggest that endplate size, at least in SMA severe mice, is largely a motor 
neuron cell autonomous phenotype. While structural NMJ phenotypes, excluding NF 
accumulation, were improved in Hb9Cre+- and Myf5Cre+-conditional SMA∆7 mice (this 
work and [57]), central structural phenotypes (i.e. loss of motor neuron numbers and of 
glutamatergic synapses onto their somas), which we did not analyze here, were not 
rescued in Myf5Cre+-expressing animals [57]. They were mitigated in the higher SMN 
expressing ChATCre+ conditional SMA∆7 mice [57]. Together the above results suggest 
that peripheral structural phenotypes may be more sensitive to levels of SMN than 
central structural phenotypes.  
 The expression patterns for ChAT and Hb9 largely overlap in that they both are 
present in motor neurons. Hb9 may come up earlier during development than ChAT, but 
it is not surprising that the latter drives higher levels of transcription than the former, as 
transcription factor genes are generally expressed at lower level than other genes. Sets of 
non-overlapping interneurons in the spinal cord also express Hb9 and ChAT. The former 
is expressed in glutamatergic Vx interneurons, while the latter is expressed in cholinergic 
V0c interneurons [138]. V0c interneurons are marked by expression of the Pitx2 
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transcription factor and interestingly modulate motor output amplitude [142]. It is a 
remote, though testable, possibility that restoration of SMN expression in V0c 
interneurons in ChATCre+ conditional SMA∆7 mice contributes to the difference between 
our results and those of Martinez and colleagues [57]. Much more likely is the 
possibility that recombination of the SmnRes allele is more efficiently driven by ChATCre 
than by Hb9Cre simply because higher levels of the recombinase result from the former 
than the latter. Thus, one possibility is that recombination fails in many more motor 
neurons in Hb9(Cre+)SMA than in ChAT(Cre+) SMA mice. This may be critical to 
mitigate whole animal phenotypes such as survival, weight and motor function but not 
NMJ phenotypes such as endplate size and innervation status as long as the endplates 
where these phenotypes are examined are innervated by motor neurons where Cre 
recombination occurred. Another possibility is that both SmnRes alleles are repaired in 
more ChATCre-expressing than Hb9Cre-expressing motor neurons. This would translate 
into higher levels of SMN protein per motor neuron in ChATCre animals. Thus, a 
combination of these non-exclusive alternatives may account for the higher SMN67m8h 
transcript levels in spinal cord from ChAT(Cre+)SMA mice, which lead to a more 
extensive rescue. 
 While our finding that spinal cord from Hb9Cre+ conditional SMA∆7 mice had 
remarkably much lower levels of full-length SMN transcript than spinal cord from 
ChAT
Cre+ conditional SMA∆7 mice explains our results vis-à-vis those of Martinez and 
colleagues [57], it is more difficult to account for the results of Gogliotti and colleagues 
[107], who used the same Hb9Cre line we used here, albeit to rescue a different 
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conditional Smn allele (Smn2B-Neo). To generate Smn2B-Neo, three nucleotide substitutions 
(GGATTT) were engineered in the exon splice enhancer within Smn exon 7 and a 
pgk-neo cassette, flanked by WT loxP sites, was inserted downstream in the intron 
between Smn exons 7 and 8 [108].  Upon Cre recombination, the pgk-neo cassette is 
excised, and the allele becomes Smn2B [106, 108]. Smn2B/2B mice show no signs of SMA 
phenotype and have a normal lifespan, despite ~66% decrease in SMN protein in spinal 
cord [106]. Contrary to SmnRes [2], the Smn2B-Neo allele yields transcripts encoding full-
length SMN prior to Cre recombination (~7.5% WT allele levels [108]), although like 
SMN2, the majority of its transcripts encode SMN∆7 [108]. Smn2B-Neo/2B-Neo mice are 
embryonic lethal that die between E9.5-E12.5, later than Smn-/- embryos, which die at 
E7.5 [108]. Full length SMN protein could be detected in Smn2B-Neo/2B-Neo embryos at 1-
3% WT levels, somehow lower than predicted by the levels of transcript [108]. This 
embryonic lethality can be rescued in Smn2B-Neo/2B-Neo; SMN2+/- mice, which die 
perinatally around P7 [107]. Like us, Gogliotti et al. used Hb9Cre to selectively restore 
SMN in motor neurons of Smn2B-Neo/2B-Neo; SMN2+/- mice [107]. However, unlike results 
reported here with conditional SMA∆7 mice, they found improvements in lifespan (to 
just P12 on average), weight, and motor behavior assayed by the righting reflex and 
hindlimb suspension tests, the same tests used here. NMJ pathology also improved in 
Hb9
Cre+/-
; Smn2B-Neo/2B-Neo; SMN2+/- mice. We propose that their more extensive rescue 
was due to the endogenous low levels of full length SMN protein afforded by the Smn2B-
Neo allele, that together with those provided by the Smn2B allele (i.e. after recombination) 
yielded higher overall levels of SMN in motor neurons. This interpretation assumes that 
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the recombination efficiency of SmnRes and Smn2B-Neo was the same in the two 
experiments as both used the same Hb9Cre line. However, the recombination efficiency 
may not only depend on the levels of Cre but also on the nature of the two conditional 
alleles. Hence, to be repaired Smn2B-Neo requires the excision of the pgk-neo cassette, 
while SmnRes requires the inversion of the 3’5’ Smn exon 7 (Fig. 3.2). The pgk-neo 
cassette in Smn2B-Neo is flanked by WT loxP sites, while the inversion cassette in SmnRes 
is flanked by mutant lox66/lox71 sites, which ensures the irreversibility of the inversion 
reaction [143]. To reach comparable levels of recombination efficiency in vitro, Cre-
mediated inversion of lox66/lox71-flanked DNA regions requires 2-3 fold more Cre than 
Cre-mediated excision of WT loxP-flanked DNA regions [143]. In vivo, the same study 
showed that lox66/lox71 inversion was slightly less efficient than WT loxP excision 
[143]. Thus, it is possible that the Hb9Cre-driven recombination efficiency of Smn2B-Neo is 
higher than that for SmnRes. This, together with the likely higher basal levels of full-
length SMN in Smn2B-Neo/2B-Neo; SMN2+/- mice relative to conditional SMA∆7 mice, may 
account for the amelioration of less SMN-sensitive phenotypes observed by Gogliotti et 
al. [107], which we failed to observe in our experiments. Recent experiments by others 
indicate that pathology in cells other than motor neurons critically underlie the short 
lifespan of severe SMA mice (for review see [144]). As the two lines carrying the 
inducible conditional Smn alleles, SmnRes and Smn2B-Neo, continue to be used to determine 
the contribution of other cell types to the SMA phenotype and lifespan, it will be 
important that the research community be aware of the differences between these two 
conditional lines regarding their endogenous SMN levels and their differential demand 
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for Cre drivers. While used successfully by many for excision of floxed alleles (e.g. 
references in http://jaxmice.jax.org/strain/006600.html), our results raise the possibility 
that Hb9Cre might not be a robust Cre driver for inversion of floxed alleles in general. 
 Notwithstanding the involvement of other cell types suggested by animal models, 
survival and other defects in motor neurons are still expected to be hallmark features of 
the human disease. Having biomarkers that directly reflect changes in motor neuron 
phenotypes following a therapeutic approach is still very important. The apparent higher 
SMN sensitivity and the easier experimental accessibility of the NMJ better position 
peripheral structural phenotypes to serve as biomarkers for testing therapeutic 
interventions than central structural phenotypes. Indeed, Ko and colleagues already 
demonstrated that denervation of vulnerable muscles can serve as a very sensitive 
biomarker to evaluate pharmacological interventions in SMA∆7 mice [104]. Results of 
the present study further support this conclusion. Our analysis of endplate area in one 
denervation-vulnerable (triceps) and one denervation-resistant (TA) muscle, innervated 
by motor neuron pools located in opposite ends of the spinal cord, indicates that this 
phenotype could also be used as a sensitive motoneuron-autonomous marker to evaluate 
drug therapies in SMA∆7 mice. Although both parameters appear equally sensitive to 
small increases in SMN levels, endplate size has the potential advantage of applying to 
all muscles, regardless of their vulnerability to denervation. An additional important 
conclusion derived from our study is that both endplate area and denervation status can 
be mitigated without impact on motor behavior. This suggests that in order to properly 
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evaluate drug efficacy the improvement of these sensitive parameters has to be 
considered in the context of parallel changes in motor function. 
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CHAPTER IV 
DISCUSSION AND CONCLUSIONS 
 
 Autosomal recessive SMA is characterized by the paucity in production of the 
SMN protein, which leads to loss of motor neurons causing muscle atrophy, paresis, and 
in the most severe cases infantile death (Type I and II SMA) [5, 36, 56].  A minimal 
level of SMN protein is essential for cell survival, regardless of cell type, and this is 
consistent with its essential housekeeping functions in spliceosome assembly. 
Nevertheless, motor neurons are the cells most severely and consistently affected by the 
reduction of SMN [41]. The pathology seen after SMN reduction could be due to altered 
splicing of a select group of genes important in motor neuron circuitry by the disruption 
of snRNP formation, alterations to the axonal functions for SMN, or both [5]. A recent 
transcriptome study by Zhang et al. (2013) has demonstrated that a significant 
contributor to the SMA pathology is the dysregulation of key mRNAs in motor neuron 
synaptogenesis that lead to motor neuronal impairments. This was found in motor 
neurons and surround glial cells in the spinal cords of SMA7 mice by P1, before any 
overt pathology is observed. Amongst the mRNA found to be altered were agrin’s Z 
exons that are critical for NMJ maintenance, a synapse pruning-promoting complement 
factor (C1q), and a transcription factor required for establishing sensory-motor circuitry 
(Etv1/ER81) [145]. These results directly link SMN’s general function in RNA 
metabolism with SMA pathogenesis in motor neurons. Extensive research has been 
performed attempting to elucidate whether SMA is a cell-autonomous disease, with 
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motor neurons as the primary target, or a non-cell-autonomous disease in which other 
cells are just as susceptible to low levels of SMN needing be rescued in conjunction.  
 Patients have particularly low levels of spinal cord SMN [11] and a direct 
implication of the phenotype is that correcting motor neuron insults should be the natural 
target of treatment development [36].  Additionally, neurons have a remarkable 
resilience towards some genetic insults that allows for their rescue making them a viable 
target [2]. Although the genetic reduction of SMN solely in motor neurons does not 
cause lethality it is enough to yield some features of the SMA phenotype in mice (such 
as NMJ structural, and electrophysiological abnormalities) [19, 55, 107]. SMN-deficient 
motor neurons and/or muscle fibers lead to SMA. Thus, it would be expected that 
restoration specifically in these tissues would bring forth conspicuously positive results. 
Yet, this has not been the case [56, 57, 107, 110].  Many questions remain unanswered 
regarding disease pathology and the causative pathways. Resolution of such enigmas is 
key for the development and optimization of therapeutic strategies [96]. In an attempt to 
address these key questions we focused on selectively raising SMN expression in motor 
neurons using two approaches with two different severe SMA models. First, we 
exogenously restored human SMN, driving its expression selectively in motor neurons 
with an Hb9 promoter, in severe SMA mice that die perinatally, to assess whether their 
survival could be extended. We determined that hemizygous inheritance of the transgene 
was insufficient to increase survival of SMA animals. At the protein level, transgene 
expression was detected by immunostaining in embryos and until the first postnatal 
week in the ventral horn of the spinal cord. Expression of human SMN was solely 
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detected in spinal cord. Nonetheless, transgenic hSMN mRNA expression was undetected 
by late embryogenesis likely due to the timing of expression of the Hb9 promoter, which 
decreases by this developmental stage. A slow hSMN and GFP turnover may explain the 
detection of transgenic protein postnatally. Transgene-positive control mice were found 
to have improvements in motor behavior, when determined by the Righting Reflex test, 
as well as significantly fewer neonatal mortalities than transgene-negative control mice. 
These benefits granted by the motor neuronal-restoration of low levels of SMN through 
the Hb9(Gfp/SMN) transgene are consistent with the idea that motor neurons are a 
necessary target in SMA rescue efforts.  
 In our second approach, we restored endogenous motor neuronal-SMN 
expression following prenatal Hb9-dependent Cre recombination of a conditional hybrid 
mutant allele (Smnres) in another severe SMA mouse model (SMA7-like). Cre 
recombination irreversibly transforms the Smnres allele to WT. Unlike a previous study 
that used choline acetyltransferase (ChATCre+) as a driver on the same mice, we found no 
improvement in survival, weight, motor behavior, endplate morphology, and presynaptic 
neurofilament accumulation. All of the above were improved or mitigated in ChATCre+ 
SMA mice. We did, nonetheless, rescue endplate size and mitigate NMJ denervation 
status. The rescue of endplate size occurred in the absence of an increase in myofiber 
size, suggesting endplate size is determined by the motor neuron in SMA7-like mice. 
Real time-PCR showed that the expression of spinal cord SMN transcript was sharply 
reduced in Hb9Cre+ SMA mice relative to ChATCre+ SMA mice. This suggests that our 
lack of overall phenotypic improvement is most likely due to an unexpectedly poor 
  
 
121 
recombination efficiency driven by Hb9Cre. However, from our results we can infer that 
endplate area and status of innervation may be NMJ parameters highly sensitive to low 
increases in SMN that can serve as biomarkers in SMA research. Furthermore, 
therapeutic interventions with very modest effects in raising SMN in motor neurons may 
still provide mitigation of neuromuscular phenotypes in SMA patients. Also, using a 
combination of dystrophin staining with imaging processing with the Metamorph 
sorftware, we devised a new method to measure myofiber size that is very fast, practical 
and allows for a large number of fibers to be measured simultaneously. 
 Though the results were not what we had hoped to find, we were able, through 
both approaches, to provide data that supports the notions that motor neurons are key in 
pathology and a necessary target (among others) for future therapy development. This is 
in line with past studies, which demonstrated that some motor neuron-SMN restoration 
is necessary to improve the phenotype though not sufficient to achieve a complete 
correction and suggest that increased levels of SMN are also required in other tissues 
including those in the autonomic nervous system [36].   
 It is unclear if there is a differential necessity for SMN expression levels in 
different cell types. A critical threshold for SMN that dictates the onset of SMA 
pathology has been derived from studies in the Smn2B mouse model. The presence of one 
or two Smn2B alleles is enough to reduce protein expression but these mice have a 
normal lifespan and physiology. When SMN levels are further reduced in Smn2B- mice 
(10% and 15% less than WT in spinal cord and brain respectively) the phenotype begins 
to resemble that of SMA [106]. Bowermann et al. (2012) suggest that the severity of 
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SMA is more dependent on a narrow threshold for SMN levels of expression rather than 
a linear function of pathology [106]. This is most likely because different cell 
populations have different needs of SMN levels, and as more cells reach their limit of 
functionality with low SMN, the overt pathology appears. Equally, small increases of 
SMN past the required threshold will be enough to improve the phenotype. Additionally, 
mice with 4 ≥ copies of SMN2 show complete rescue and a normal lifespan. This means 
that modestly enhanced ubiquitous expression of FL-SMN from the SMN2 gene can 
prevent SMA [96]..  
 Muscles may require a very high amount of SMN increase to rescue muscle-
related symptoms. Martinez et al. (2012) selectively restored SMN expression solely in 
skeletal muscle, using a MyoD promoter to drive Cre recombination of the same Smnres 
allele used by us. They found that a vast increase of almost 500% in FL-SMN protein 
was enough to restore myofiber size but only modestly improve lifespan (5-6 days) with 
no improvements in any of the NMJ phenotypes assayed [57]. This may suggest that 
muscle fibers are less sensitive to SMN levels and would require additional protein 
restoration.  
  It is also unclear whether there is a differential necessity for SMN expression 
during all stages of development. Early postnatal induction of SMN has been determined 
as the most efficacious [2, 28, 111] and if SMN is indeed restored in a timely manner, 
the progression of the pathology could be halted. Even though improvements are found 
by increasing SMN at later stages of pathology, it is becoming quite clear that, at least in 
SMA model mice, there is a window of time within which the protein must be restored 
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for optimal effect by therapeutic efforts [2, 28, 68]. The experimental approach of our 
first aim, described in Chapter II, has managed this. We found that Hb9 did drive the 
expression of exogenous human SMN from very early on as it was detected by E13 in 
immunohistochemical assays. Yet, the transcriptional activity of Hb9 is reduced by late 
embryogenesis since we were unable to detect the mRNA expression from the 
Hb9(Gfp/hSMN) transgene at E18 in transgene-positive spinal cords by qRT-PCR. This 
most likely accounts for the failure to increase lifespan in the severe SMA mouse model 
used. Nonetheless, this early restoration of SMN in motor neurons proves efficacious to 
improve neonatal survival and motor behavior in transgene-positive Smn heterozygous 
or WT littermates. Thus, our results further support the notion that early restoration 
proves beneficial. However, if the early restoration is not maintained to at least the 
perinatal stage there will not be a clear rescue.   
 To bypass the issues of SMN-restoration timing from our first approach, we 
moved forward with the second approach (described in Chapter III and Paez-Colasante 
et al. (2013) [56]). In this second study, SMN was restored by Hb9Cre-mediated 
recombination of the conditional Smnres allele in a permanent manner during early 
embryogenesis using the mouse’s own Smn promoter as opposed to the first approach in 
which an exogenous Hb9 promoter drove human SMN expression. If the Hb9Cre driven 
recombination were efficiently producing high enough levels of endogenous SMN, 
significant positive results over the phenotype were to be expected since this approach of 
protein restoration would be the most similar to the naturally occurring process in WT 
mice.  
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 Another question that remains is whether SMN is required in adult motor 
neurons to survive. We have not addressed this but it would be important because if 
SMN is indeed a survival factor for motor neurons during adulthood, it could be used as 
a therapeutic option for Amyotrophic lateral sclerosis (ALS) patients as well [96]. ALS 
is the most common adult-onset fatal neurodegenerative disease in which upper and 
lower motor neurons are lost. There is a lot of crossover between ALS and SMA 
pathologies [146], for example, gem depletion and similar patterns of neuroinflammation 
have been observed in both diseases [147, 148]. Copy number abnormalities of SMN 
have been reported in sporadic ALS. Expression of SMN in spinal anterior horn cells is 
significantly associated with cell size and may be reduced when these cells are atrophic. 
However, unlike in SMA, decrease of SMN in spinal anterior horn cells in ALS patients 
may be a secondary phenomenon in this disease [149]. Therefore, ALS patients could 
benefit from SMA-directed therapeutics currently in the pipeline. 
 Furthermore, an additional question that remains to be addressed is whether 
different severities of SMA will require differential levels of SMN, especially because 
the time frame when motor neurons are lost in milder types is not well known. It is 
proven that increases of SMN early on in life are needed to rescue severe SMA mice, but 
what if SMN is increased later on in life for type II or III patients in the more 
symptomatic stages? It might be possible that this would allow the remaining motor 
neurons to perform better according to Arnold et al. (2013) [68]. A future step will be to 
address this through clinical trials with patients of various types of SMA.  
 Despite the standing motor neuron dogma, research is now deviating towards 
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considering SMA as a non-cell autonomous disease with other important targets as key 
in pathology and therapy. Motor neuron cell loss has not been detected before postnatal 
P4 in SMA7 mice and is not significant towards the end-stage of survival [6], while 
muscle weakness is evident as early as P2 [30]. Thus, the first behavioral abnormalities 
are due to impairments in motor neuron function [6]. If motor neurons are lost, it can be 
in a similar amount between mice of ranging severity and produce very different 
outcomes. For example, even a 50% loss of motor neurons can still result in viable year-
old Smn heterozygous mouse as long as the remaining motor neurons are healthy [150], 
while just ~30% cell loss at the end-stage of severe SMA mice is lethal [30], indicating 
that the number of motor neurons lost is not as determinant of pathology but rather the 
time when these cells are lost and the state of the remaining motor neurons that can 
compensate may be the determinant [37]. We did not study motoneuron loss in our 
experiments with either of our two models.  
 If SMA, at least in SMA7 mice, is in fact a disease of motor neurons, it can act 
in a manner that does not result in their death or disconnection [40]. Motor neurons seem 
to be well connected to their targets except for the denervation-vulnerable muscles [104]. 
A group led by Dr. Ko has determined which muscles are most likely to suffer from 
denervation. The triceps was one of the appendicular muscles determined as 
denervation-vulnerable in SMA7 mice [104], therefore it was the muscle we assayed 
for status of innervation (Chapter II and Paez-Colasante et al. (2013) and found a 
significant improvement in Hb9(Cre+)SMA mice. Nonetheless, even with this parameter 
rescued and the fact that several important hindlimb muscles are not typically 
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denervated, the reduction of SMN still alters many aspects of neuromuscular 
development [40] and produces a reduction of synaptic vesicle release (~50% in quantal 
content) [132]. Consequently, it is unlikely that these abnormalities can account for the 
impairments of motor behavior, thus muscle weakness and motor dysfunction might be 
the result of alterations in spinal circuit function [55]. 
  It is possible that other neurons besides motor neurons are contributing to the 
motor impairments seen in SMA. Several studies have described pronounced early 
deficits of spinal reflexes and reduced numbers of proprioceptive synaptic inputs onto 
motoneurons of SMA7 mice. Ling et al. (2010) studied the spinal and neuromuscular 
circuitry of motor behavior in SMA7 mice. In the spinal circuitry they determined an 
approximate 30% loss of synapses onto lumbar motor neurons and a significant 
reduction in proprioceptive sensory neurons [51]. Proprioceptive neurons provide 
essential inputs to motor circuits and can serve as potential targets [50]. This group has 
inferred that synaptic defects may occur at multiple levels of the spinal and 
neuromuscular circuitry [51]. Another group’s findings indicate that profound spinal 
circuit dysfunction occurs very early on generating impairments in motor function. They 
have demonstrated, in the SMA7 mouse as well, that the strength of the monosynaptic 
connection between primary proprioceptive afferents and motor neurons is reduced and 
this occurs before detectable motor neuron cell loss [55]. Similar results are found in 
smn null Drosophila [50] though the differences between Drosophila and mammalian 
motor circuits limit the extrapolation of those results towards what may occur in SMA 
patients. Imalach et al. (2012) found that motor neuron-SMN restoration did not produce 
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great positive results but rather SMN is required in both proprioceptive and central 
cholinergic neurons to rescue defect in motor neurons and muscles, at least in the fruit 
fly smn mutants [50].  Though proprioceptive and central cholinergic neurons need to be 
rescued, they will most likely not be the only cell populations that require SMN 
restoration. Martinez et al. (2012) and Gogliotti et al. (2012) did rescue the loss of 
proprioceptive innervation to motor neurons in their experiments of motor neuron-
selective SMN restoration. Yet, they only achieved a modest increase in survival via 
their approaches. Other cell types in the spotlight for SMA research are glial cells. 
Reactive astrocytosis or gliosis are hallmarks of neurodegenerative diseases such as 
SMA or ALS. Gliosis in the spinal cord is associated with a severe reduction of motor 
neuron number and oxidative stress-related products that are deposited into the 
remaining atrophic motor neurons [148]. Increases in glial cell-derived neurotrophic 
factor levels have been detected in the cerebrospinal fluid of SMA patients. Glial cell-
derived neurotrophic factor is one of the most powerful survival factors for motor 
neurons [151].  
 Under healthy conditions, astrocytes are critical for maintenance of the blood 
brain barrier, nourishment, regulation of synapse formation and function, ion uptake, 
clearing of excess glutamate from the synaptic clefts, and growth factor secretion, 
among others [152, 153]. One very recent study has demonstrated that there are 
morphological, cellular, and activation state changes in astrocytes in SMA7 murine 
spinal cords seen prior to overt motor neuron loss [152]. McGivern et al. (2013) also 
observed increases in basal intracellular calcium levels and a reduced calcium response 
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to ATP in iPSC-derived astrocytes from two SMA patients [152]. Astrocytes should be 
considered as an additional target for therapeutic efforts. Low levels of SMN have been 
detected in Schwann cells and this has been linked to the induction of primary intrinsic 
changes. In Schwann cells, the SMN protein is required either to regulate translational 
control of key myelin proteins and/or to modulate protein turnover [154]. Schwann cells 
from SMA mouse models fail to respond normally to myelination cues in culture, 
therefore they are unable to myelinate healthy motor neurons efficiently and thus are 
detrimental to their stability. Cellular and molecular aspects of myelination are affected 
in peripheral nerves with a delay in maturation of axo–glial interactions at paranodes; for 
example, myelination in intercostal nerves was perturbed at early- and late-symptomatic 
stages of disease in two SMA mouse models. Also, apoptotic pathways are initiated in 
Schwann cells when they are directed towards a myelinating phenotype [154].  In a 
study by Hunter et al. (2013) myelin protein expression was restored in SMA Schwann 
cells following transfection with an SMN construct. By performing this experiment, the 
group demonstrated that the defects observed in Schwann cells/neuron co-cultures were 
due to deficiencies of Schwann cells themselves and that this process was SMN-
dependent and reversible [154].  
 Pan-neuronal SMN restoration seems to be the most promising strategy.  Further 
evidence that other neuronal cell populations besides motor neurons are important in 
SMA and that pan-neuronal expression of SMN is efficient at increasing lifespan is a 
study by Gavrilina et al. (2008). Here, SMN expression was mediated by the prion 
promoter PrP92 which accomplished to increase the lifespan of SMA model mice 
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significantly (~200 days) and rescued several aspects of pathology such as the number of 
motor neurons [110]. The prion protein promoter is expressed abundantly throughout the 
nervous system but also at very low levels in muscles [110], therefore it cannot be easily 
concluded that muscles are not important in restoration efforts in these experiments 
Another group determined that expression of transgenic SMN in the CNS by viral 
vectors is also able to rescue the survival and motor behavior of SMA7 mice [78, 110].  
 Increasing awareness of how low levels of SMN affect a wide range of cells has 
broadened the understanding of the contribution that non-neuronal cells have in the 
pathogenesis of SMA. Because of the observed abnormalities in non-motor neurons in 
severe SMA models, such as reduction of synaptic bouton area, sensory projection 
dysfunctions, central synaptic defects, affected neurogenesis and neuritogenesis, general 
pathological changes in brain including weight and size, one can conclude that other 
cells are affected by the reduction of SMN as well but with differential sensitivity to 
lesser SMN. There seems to be a gradient of susceptibility to SMN reduction in the 
nervous system in which motor neurons might be at one extreme of the spectrum having 
the highest susceptibility [96].  
 In conclusion, though we were unable to achieve vast improvements in lifespan 
and pathology of SMA model mice using two approaches to selectively restore SMN in 
motor neurons, we did find improvements or complete rescue of certain parameters such 
as NMJ endplate size and status of denervation in the second approach and prevention of 
neonatal mortalities and improved motor behavior in transgene-positive control animals 
in the initial study. These improvements by early induction of low increases of SMN 
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solely in motor neurons indicate that the importance of motor neurons in the causative 
pathways of SMA and as targets for therapy. Therefore, motor neurons cannot be ruled 
out as key players even though it is very likely that SMA is not a motor neuron-cell-
autonomous disease since genetic restoration of SMN in these cells alone has proven 
inefficient to rescue mutant lethality [56, 57, 107]. Evidence from our study and the 
current literature suggests a possible relative, rather than absolute, selective vulnerability 
of motor neurons to the loss of normal SMN levels [96] indicating that multiple SMN-
decreased cell populations are responsible for the progression of pathology. Most likely, 
therapies aimed at elevating SMN levels will need to be delivered systemically.  
 
4.1 FUTURE STUDIES 
 The results presented in Chapter II, indicate that hemizygous inheritance of the 
Hb9(Gfp/SMN) transgene, while insufficient to extend the lifespan of a severe SMA 
mouse model, was capable of clearly reducing perinatal mortality in transgene-positive 
control mice. The complete extent of this benefit was not assayed in these mice. Other 
motor function tests could be performed, such as the grip-assay or rotorod test on adult 
control mice, to determine if the improvements we observed with the Righting Reflex 
might be observed using other tests. These control animals could also be evaluated for 
differences in NMJ maturation in comparison to transgene-negative mice. If endplate 
size and status of innervation are very sensitive to small changes in SMN expression and 
can serve as biomarkers, then we can expect to see improvements in transgene-positive 
control animals as well at this level. This analysis should be done in those muscles 
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already known to be the most sensitive to diminished SMN such as levator auris longus, 
abductor auris longus, and auricularis superior [155]  
 We did not determine if there was any differential motor neuron loss between 
Hb9(Cre+) and Hb9(Cre-)SMA mice. This would be another interesting aspect to 
evaluate since low levels of SMN might be neuroprotective aiding motor neurons to 
survive longer towards the end-stage of SMA7-like mice even though the rescue does 
not translate into an increase of overall lifespan. Also interesting to look into would be to 
determine the exact levels of SMN per motor neuron restored by Hb9Cre-mediated 
recombination or the number of motor neurons in which recombination is occurring. 
This would allow setting a threshold of minimum levels of SMN expression needed to 
rescue NMJ parameters. Accurately setting this threshold in the context of an animal 
with a null Smn allele, like the one carried by the human patients, would be more 
relevant for therapy than the threshold that was derived from the Smn2B allele (see above, 
[106]), which is not a null allele nor is found in human patients. Furthermore, apart from 
the muscles (TA and triceps) used in our study to determine NMJ characteristics rescued 
by SMN restoration, a future approach would be to assess other denervation-vulnerable 
muscles such as the masseter, SPI, and longissimus capitis, which are axial muscles with 
a very high susceptibility for denervation, as well as the FBD-2, FDB-3, and biceps 
brachii, which are appendicular muscles [104].  
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APPENDIX A 
PROTOCOLS 
 
Note: these detailed protocols complement the Materials and Methods section in 
Chapters II and III 
 
DNA extraction from tissues (Sigma)* 
1. Take tail-tip or ear-punch (≤5mm) from mouse and place in 0.5mL tube 
2. Pipet 100µL of Extraction Solution into the tube and make sure the tissue is fully 
submerged 
3. Add 25µL of Tissue Preparation Solution and mix thoroughly 
4. Incubate at room temperature for 10 min 
5. Incubate at 95C for 3 min, vortex briefly (1-2 pulses), then transfer immediately 
to ice 
Note – Make sure heat block has water in it to ensure proper heat conductivity 
6. Add 100µL of Neutralization Solution B and mix well by vortexing for 30 sec 
7. Pulse-centrifuge to pull down liquid from the cap 
8. Transfer extract to a clean 0.5mL tube and store at -20C 
Note – Tail/tissue will appear undigested, but extract will contain sufficient DNA for 
genotyping.  Leftover tissue can be stored at -20C after extract has been 
removed 
 
Genotyping Mice – Sigma PCR Protocol* 
1. Thaw on ice: Red ReadyMix (Sigma) and respective forward and reverse 
primer mix. 
Note – Primer aliquots are a mixture of both F and R primers at 20M each. If a new 
aliquot is needed, make a 1:5 dilution with the original stocks (100M) 
2. DNA samples from 4C refrigerator should remain on ice until needed; pull 
positive control sample along with samples to be screened 
3. Label PCR tubes for each sample  
4. Make a master mix: 5L H2O, 10L Red ReadyMix and 1L F+R primer mix 
Note – This is the equivalent of what should be in each sample; to accommodate pipette 
error, make slightly more than needed to ensure adequate quantity 
5. Aliquot 4L of appropriate DNA to each of the PCR tubes; for the (-) control use 
4L H2O 
6. Distribute 16L of master mix into the appropriate tubes and mix gently. Close 
caps securely 
7. Place samples in PTC-100 PCR machine (or available lab thermo cycler), close 
lid, and tighten wheel securely 
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8. Run program depending on allele to be assayed. All cycles will start with a Taq 
polymerase activation phase of 95C for 15 min. The other phases will depend on 
the nature of the primers and they all conclude with a 4C hold final step that can 
go on indefinitely until the program is stopped.  
9. Store samples in 4C refrigerator until ready to run on an agarose (1.5 or 2%) gel 
 
 
Whole mount muscle preparations 
1. Euthanize animal with proper CO2 protocol 
2. Dissect muscles of interest 
3. Fix muscles in 4% PFA for 1h at RT  
4. Wash 3X with PBS for 15min 
5. Carefully “cut” muscles using a forceps, separating fiber bundles to expose the 
insides of the muscle for better antibody penetration 
6. Permeabilize with a bath of pre-chilled methanol for 5min at 4C 
7. Rinse with PBS 
8. Block muscles with a 0.3% Triton X-100- 0.2% BSA solution for 30min at RT 
Note: all of this is done on agar petri dish 
9. Take muscles and place carefully in 1.5ml eppendorf tube and incubate with 
required antibody in the same blocking buffer and incubate ON at RT (For this 
study, 1:100 2H3 was used for NF accumulation assay) 
10. The following day, wash muscles in PBS-T 3X for 15min each. 
11. Incubate in required secondary antibodies for 2h (for NF staining used 1:200 
rhodamine goat anti-mouse antibody (RGAM) and 1:1000 fluorescein 
bungarotoxin) 
12. Wash 3X in PBS-T for 10min each 
13. Mount on slides by carefully separating small bundles at a time and then adding 
one drop of vectashield (containing DAPI) 
14. Place coverslip carefully avoiding bubbles and aggregation of the bundles 
15. Straighten cover slip and seal edges with a light coating of clear nail polish 
16. Move slides promptly into a darkened slide holder to protect the fluorescent tags 
and store at 4C until ready to view 
 
Tissue Sectioning* 
1. The night before sectioning, transfer mold with Tissue Tek-embedded sample 
into the -20C to allow ~12 hours to equilibrate to that temperature 
2. Transfer mold with Tissue Tek-embedded sample to the cryostat and allow it to 
equilibrate there for ~1 hour 
3. Lay out 10 slides and label each 
4. Under Cryostat menu, turn on light and set Peltier station to ‘cool’; place one 
mounting block in the Peltier station to cool as well 
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5. Remove Tissue Tek block out of the mold and carefully cut out a rectangle 
around the tissue (be sure to leave at least about a 1mm buffer of Tissue Tek on 
all sides of the tissue to help keep it protected and supported 
6. Add Tissue Tek compound onto mounting block and immediately place tissue 
block in compound as it hardens quickly 
7. Once the Tissue Tek has solidified, place the mounting block into slicing 
apparatus and tighten to hold in place. Adjust angle of the block towards the 
back of the machine at an approximate 45 angle so the slices taken will be flat 
cross sections through the muscle 
8. Use the arrow buttons to move the apparatus holding the sample close to the 
knife; remove the protective covering over the knife to expose the blad 
9. Return to menu and remove the brake on the rotating wheel that controls the 
slicer; set the cuts to ‘trim’ to take 50m-thick pieces until the muscle has been 
cut down to a flat true cross section 
10. Set the cuts to ‘fine’ and start with taking a 12m slice; if a flat, clean slice does 
not come off, brush tissue away and make another cut until you get a good one 
11. Carefully lift the cover (do not let tissue stick to cover) and gently touch face-
down slide (slide number 1) to tissue section  
12. Check tissue section using brightfield microscopy: turn on power to Nikon, 
switch knob from ‘Off’ to ‘DIA’, use motor or manually change objectives (start 
with 4x), and visualize cells (filter #8). If a lot of air holes are present, cut sections 
thicker 
13. Brush away residue, lower cover, cut another slice, and put this section on slide 
number 2 in the same position as the piece from slide 1 
14. Repeat this process for all 10 slides, resulting in a series of 10 tissue sections 
15. Cut 5 extra sections and brush these away to get to a new part of the muscle 
16. Begin a second series of sections as described above (place these sections just 
below the first one on each slide 
17. Repeat this process of taking serial sections until the slides are full of serial 
sections or you run out of tissue 
18. Allow slides to dry for a minimum of 1 hour (more if sections are >20m thick), 
then place into a slide box and freeze at -80C until needed 
 
Free-floating sections 
1. Remove slides from box in freezer 
2. Carefully add PBS to slide to loosen tissue 
3. Once tissue is loose (careful not to lose is), use a thin paintbrush and remove 
individual sections 
4. Place in cell culture plate with small sized wells previously filled with PBS-T 
5. Wash to once remove excess tissue tek surrounding sections 
6. Wash 2-3X in PBS 
7. To remove buffer at every wash use a 1ml pipette and carefully suction buffer, 
discard, and replace with fresh buffer.  
8. Use enough for sections to “swim” freely in well 
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9. Remove PBS and add appropriate blocking buffer 
10. Incubate for 30-60min 
11. Use a paintbrush again to carefully pick up sections and place on a slide 
previously delineated with the Pap Pen. 
12. Add appropriate antibody/blocking buffer mix 
13. Proceed with standard immunostaining protocol. Instead of performing the 
washes on a slide, use cell culture dish wells. Overall protocol follows standard 
immunostaining steps below. 
  
 
Immuno Staining for sectioned tissue on slides (or free-floating sections)* 
1. Fix the slides in a Coplin Jar containing 1% paraformaldehyde (PFA) made in 
PBS for 5 min at room temperature, shaking gently 
Note – PFA stock is 4% use 15mL of this mixed with 45mL PBS as 60mL fills the jar 
well 
2. Pour solution in PFA waste container, then fill the jar with PBS-T (cover the 
slides) and shake gently for 5 min. Repeat this wash 2X  
3. Remove jar from shaker but do not pour out PBS-T (slides must stay moist) 
4. Remove a single slide from the jar with forceps, then carefully wipe the bottom 
and top with a kimwipe 
5. Using a PAP Pen (RPIcorp catalog number 195505), draw a boarder around the 
tissue samples to make a hydrophobic ‘well’ to hold liquid 
6. Gently add 200L of blocking solution onto the samples, filling the ‘well’ 
completely, then place the slide into the humid chamber 
7. Incubate at room temperature for 20-30 min 
8. Add 200L of primary antibody to the slides immediately after removing 
blocking solution (do not let slides dry out!) and put slides back into the humid 
chamber 
Note – See individual experiment notes for what kind of antibody and dilution 
9. Incubate either 2 hours at room temperature or overnight at 4C (make sure 
chamber is closed tight to prevent slides from drying!) 
10. Flick off the primary antibody solution and place slides back into Coplin Jar; fill 
with PBS-T until slides are covered and gently shake at room temperature for 15 
minutes; repeat this wash 2 more times 
11. Carefully flick the slides to remove excess PBS-T and wipe away excess fluid 
outside the hydrophobic well 
12. Add 200L of secondary antibody (with fluorescent tag) to the slides 
immediately after removing blocking solution (do not let slides dry out!) and put 
slides back into the humid chamber (make sure to cover chamber with foil to 
protect it from the light) 
Note – See individual experiment notes for what kind of antibody and dilution 
13. Flick off the secondary antibody solution and place slides back into Coplin Jar; 
fill with PBS-T until slides are covered and gently shake at room temperature for 
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15 minutes (cover jar with foil to protect from light); repeat this wash 2 more 
times 
14. Wash slides one final time in PBS as above 
15. Carefully flick the slides to remove excess PBS and wipe away excess fluid 
outside the hydrophobic well, then wick away excess PBS inside the well with a 
kimwipe 
16. Carefully but firmly wipe the PAP residue flat with a kimwipe tissue paper (do 
not touch tissue!) 
17. Place one drop of Vectashield Mounting medium (Vector Labs catalog number 
H-1000) in the center of the slide and use a set of forceps to carefully lower a 
coverslip onto the mounting medium  
18. Straighten cover slip and seal edges with a light coating of clear nail polish 
19. Move slides promptly into a darkened slide holder to protect the fluorescent tags 
and store at 4C until ready to view 
 
 
Fluorescent Microscopy* 
1. Turn on microscope power and wait to hear 2 beeps 
2. Turn on camera power and wait to hear 2 beeps 
3. Open Metamorph software 
Note – These machines must be turned on in this order; software will not recognize 
microscope otherwise 
4. Turn off overhead light for better visualization and preservation of fluorescent 
tags 
5. Use Brightfield microscopy to locate and focus image (filter #8) 
6. Switch to filter #2 to visualize fluoroscein tags (light will be blue as the green tag 
excites on the blue wavelength) or #3 to visualize rhodamine tags (light will be 
green as the red tag excites on the green wavelength) 
7. Find desired fields of view on 20x magnification, then add a drop of oil and 
switch to 40x oil lens for imaging 
8. Pull out rod in microscope to switch image to camera; on computer, click “Show 
live” to open up a black and white live image; adjust focus and exposure (in ms) 
as needed 
9. Once live display is satisfactory, capture image with “Acquire” 
10. Without moving the field of view or changing focus, switch filters and adjust 
exposure to capture same image in different wavelength  
Note – When not actively finding and taking an image, close the shutter to prevent rapid 
degradation of fluorescent tags from prolonged exposure to light 
11. Stack rhodamine and fluoroscein images to visualize overlap using “Color 
Align” and assigning the image taken with filter #3 image to “Red” and the one 
taken with filter #2 to “Green” and pressing “Apply” 
12. Save images in appropriate folder, and name according to fluorescent tag used 
(be sure to note the antibody concentration and magnification in “Annotate 
Image”) 
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13. If a close-up is necessary, shift to the 100x oil lens and repeat steps 9-13 
14. When finished, store slides at 4C in dark slide holder 
15. Close shutter (if not already shut), clean oil lenses with lens paper, and switch 
back to 10x objective for storage 
16. Exit Metamorph software then turn off camera, microscope, and mercury lamp  
 
Protein Extraction from Muscle – Liquid Nitrogen + Homogenizer* 
1. 1 hour in advance, wrap ceramic mortar and pestle in aluminum foil and freeze in 
-80C (use this approach for pulverizing samples if using adult muscles, skip for 
other tissues such as spinal cords, these can be added directly to the homogenizer 
+ buffer) 
2. Label 2 sets of 1.7mL eppendorf tubes for each sample being extracted 
3. Aliquot extraction buffer sufficient for 0.5mL/sample 
Note – See individual experiment for buffer used 
4. Add necessary inhibitors to the aliquoted buffer 
Note – See individual experiment for inhibitors used 
5. Fill a thermos of liquid nitrogen  
6. Remove mortar and pestle from -80C, unwrap, and place in an ice bucket 
Note – Bury mortar as much as possible without allowing ice to spill inside 
7. Place homogenizer in ice 
8. Transfer frozen tissue into cold mortar and promptly add liquid nitrogen 
9. Use the pestle to carefully grind the tissue into powder, adding new liquid 
nitrogen as soon as it evaporates out of the mortar 
Note – To avoid losing tissue pieces, start by pressing the pestle onto the tissue chunk 
and turning in place while applying pressure; once pieces are smaller, move on to a 
gentle stirring grind around the mortar interior 
10. Add more liquid nitrogen and start to scrape any caked tissue-powder off the 
mortar and pestle; as soon as the last of the liquid nitrogen evaporates, pull 
mortar out of the ice and scrape powder into the cold homogenizer 
11. Promptly add 0.5mL of buffer with inhibitors and use firm, careful strokes to 
completely grind the powdered tissue into solution with the glass pestle  
Note – This should not take long if tissue was properly ground already 
12. Allow to sit (on ice!) for 30-60 seconds to give bubbles a chance to dissipate, 
then pipet solution into one of the eppendorf tubes, close, and place on ice until 
all samples are finished 
13. Clean the homogenizer between samples by adding 2mL of buffer (no inhibitors) 
and agitating with pestle, then dumping buffer and flicking excess liquid out 
14. Repeat wash 2X 
15. Clean ceramic mortar between samples by rinsing with liquid nitrogen to remove 
all of the residue 
16. Retrieve the next sample in the same manner as the first, and continue process 
until all samples have been homogenized 
17. Centrifuge samples at 14,000xg for 15 min at 4C 
18. Transfer supernatant to clean, labeled tubes and store at -80C 
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Bradford Microassay (Protein Concentration)* 
1. Dilute a small sample 1:10 in H2O in an eppendorf tube (recommended – 2L 
sample in 18L H2O) 
2. Make a 1:100 dilution of the previous dilution in an eppendorf tube (recommended 
– 160L is needed for assay, so use 1.6L of sample dilution in 158.4L H2O) 
3. Have a “blank” sample at hand – 160L of H2O 
4. Add 40L of Protein Assay Dye Reagent Concentrate (Bio-Rad catalog number 
500-0006) to each tube and mix well by vortexing 
Note – Color should develop, anything between red and dark blue 
5. Incubate 5 min at RT 
6. Turn on Eppendorf BioPhotometer and attached printer; select assay #1 – Bradford 
and press that button until it loads the protocol with built-in calibration 
7. Open an eppendorf UVette cuvette (Eppendorf catalog number 952010051) and 
pipette in 100L of the H2O “blank” 
8. Insert cuvette into the reading compartment 
Note – Be sure the frosted sides are to the right and left, while the clear side faces 
the operator; in the right orientation the well inside the cuvette makes the 
clear side look like it has an arrow pointing downwards 
9. Press the “Blank” button to obtain measurement (should be all 0’s; if not, 
troubleshoot issue) 
Note – Printer will print automatically as long as it is on 
10. Leave the cuvette in place and carefully pipette out all of the H2O 
11. Pipette in 100L of the first sample and press the “Sample” button to obtain 
measurement 
12. Leave the cuvette in place and carefully pipette out all of the sample 
13. Repeat until all samples have been measured  
Note – Results are given in g/mL.  However, because of the initial 1:10 and subsequent 
1:100 dilution at the start of the assay, the sample being read is actually diluted a 
total of 1:1000, making the true concentration of the printed numbers g/L. 
 
Western Blot Analysis SDS-PAGE* 
14. Clean glass plates thoroughly and assemble them with 1.5mm spacers 
Note – Optional step is to fill plates with water to see if they leak, then pour out water 
and blot dry with a Kimwipe tissue paper 
15. Mix the separating gel (see recipe next page) in a 15mL falcon tube and pipette 
7.5mL promptly into the space between the plates  
Note – See individual experiments for what % separating gel to use 
16. GENTLY layer ddH2O on top of liquid gel to protect it during polymerization and 
allow it to sit at room temperature undisturbed for 20-30 min 
Note – The remaining gel in the tube can be used to monitor polymerization progress of 
the gel  
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17. When the gel has polymerized, carefully pour off the water layer and blot dry with a 
Kimwipe 
18. Mix the stacking gel (see recipe next page) in a 15mL falcon tube and pipette it on 
top of the separating gel until it nears the top of the plates (leave a little space) 
Note – See individual experiments for what % stacking gel to use 
19. Carefully add a comb with the desired number of wells and make sure no bubbles of 
air are trapped in the liquid gel 
20. Allow the stack to polymerize undisturbed for 10-15 min 
Note – The remaining gel in the tube can be used to monitor polymerization progress of 
the gel  
21. Carefully remove the plates and gel (do not allow them to separate) and assemble 
the electrophoresis apparatus 
22. Fill the apparatus with 1x Running Buffer (see recipe below) until the top of the gel 
is submerged 
23. Carefully remove the comb, allowing the buffer to fill the wells and sluice out any 
un-polymerized gel mix 
24. Load 8-10L of a protein ladder (Bio-Rad catalog number 161-0324) into one well 
and put samples in all the others (see individual experiments for how much sample 
to load) 
Note – If not all of the wells are needed for samples, load unused wells with plain 
sample buffer equal in volume to the loaded samples to prevent the protein from 
migrating horizontally through the gel 
25. Run the gel at 100V until the samples have cleared the stack, then turn voltage up to 
120V (should take 1.5-2 hours) 
26. Gel is finished when sample buffer front reaches the bottom of the gel  
Note – Watch the lower ladder marker to make sure you don’t lose the small proteins 
 
1L Running Buffer (10x) 
144.1g Glycine 
30g Tris 
10g SDS 
Fill to volume with ddH2O 
Dilute to 1x with ddH2O for electrophoresis 
 
Transfer – SemiDry 
1. Cut 2 pieces of blotting paper and one piece of PVDF membrane to the size of a 
smaller glass plate with a razor 
Note – Prepare membrane, paper, and buffers before the gel finishes running 
2. Fill four clean containers, one with Methanol, one with ddH2O, and two with 
Blotting Buffer 
Note – If blotting something phosphorylated, be sure to include phosphotase inhibitors 
in the Blotting Buffer (NaF is a MUST, Na3VO4 recommended but not required)  
3. Disassemble the electrophoresis apparatus and gently remove the small glass plate 
from the face of the gel 
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4. Carefully scrape away the stack and lift the gel from the lower plate, then place it 
into one of the Blotting Buffer containers 
5. Activate PVDF membrane by soaking it 15 seconds in Methanol, then 2 minutes in 
ddH2O, then move the membrane to the other Blotting buffer container 
6. Soak blotting paper in ddH2O until saturated 
7. Set up the ‘blotting sandwich’ by laying one of the water-soaked blotting papers on 
the drying surface of a SemiDry Transfer Cell, then laying out the activated PVDF 
membrane on top of that, then place the gel on top of the membrane, then place the 
other water-soaked blot paper on top of the gel and firmly close the lid over it all  
 
8. Connect the SemiDry Transfer Cell to a low-volt high-amp power supply and run for 
1 hour at 18V 
9. Remove the lid and discard the blotting paper, then carefully cut the membrane 
to the size of the gel, peel off and discard the gel, and quickly mark the protein ladder 
marks with a black ball-point pen 
1L Blotting Buffer (1x) 
5.8g Tris (final concentration 47.9mM) 
2.92g Glycine (final concentration 38.9mM) 
3.8mL 10% SDS (final concentration 0.038%) 
200mL Methanol (final concentration 20%) 
Fill to volume with ddH2O 
 
Probing 
1. Transfer marked membrane to a 50ml Falcon tube and fill with with blocking 
solution 
Note – See individual experiments for what kind of blocking solution was used 
2. Gently shake/rotate at room temperature for 1 hour 
3. Pour off blocking solution and add primary antibody solution 
Note – See individual experiments for what kind of primary antibody solution was used 
4. Gently shake/rotate at room temperature for 1 hour or overnight at 4C 
5. Pour off primary antibody (save and reuse unless solution is cloudy) 
6. Wash the blot by adding 1x TBS-T (see recipe below) and shaking vigorously for 
15 min  
7. Pour off wash solution and repeat two more times 
8. Pour off wash solution and add secondary antibody solution 
Note – See individual experiments for what kind of secondary antibody solution was 
used 
9. Gently shake/rotate at room temperature for 1 hour 
10. Pour off and discard secondary antibody 
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11. Repeat the above 1x TBS-T washes three more times 
12. After the last wash, dump the buffer and add just enough fresh buffer to cover the 
membrane to keep it wet until the last possible moment 
13. Prepare the Western Lighting-ECL Enhanced Chemiluminescence Substrate by 
mixing 2mL each of the Oxidizing Reagent and the Enhanced Luminol Reagent in a 
falcon tube 
Note – Work quickly as this chemical is light sensitive and will break down quickly 
14. Lift the membrane from the wash buffer and remove excess liquid by tapping the 
edges on a Kimwipe to wick away fluid, then place face-up in a clean tip box lid 
15. Pour the Substrate mix onto the membrane (the damp will create a surface-tension 
barrier that will hold the liquid on the membrane) and incubate for 1 minute at room 
temperature 
16. Lift the membrane out of the Substrate mix and remove excess liquid by tapping the 
edges on a Kimwipe to wick away fluid, then place face-down on a clean piece of 
plastic wrap 
17. Gently wrap the membrane (be sure the face surface only has the single layer of 
plastic over it) 
18. Place into Alphaimager system and use the FluorChemQ software to expose 
membrane  
Note – See individual experiments for exposure lengths 
 
Quantification Analysis – Alpha Imager* 
1. Open the gel image to be analyzed with the FluorChemQ program and zoom in 
4x 
2. Select the “Analysis Tools” tab and click “Band Analysis” to open a sub-menu 
3. Under the “Region” tab, select the Single Region Tools square option, then use 
the cursor to draw a box around the first band of interest 
Note – A chart will appear at the bottom, labeling that box as “1n” 
4. In the chart, select the “1n” frame, then go up the menu and click “Multi Region 
Copy” and duplicate the box over the band of interest in each of the lanes 
5. Once all the desired bands have a box, deselect “Multi Region Copy” 
6. Move and resize the individual boxes as necessary until they encompass the 
chosen bands and some of the background 
7. Next, select the tab “Background” and click to select “Local Background” to 
subtract out the background from the quantities in the chart 
8. Once this is done, select “Output” and choose to export to the clipboard 
9. Open an excel file and paste in the analysis results, then label the bands as 
needed since they will be called “1n”, “2n”, etc 
10. Repeat this process for as many sets of bands as necessary, then save the file 
 
1L TBS-T (10x) 
200mL 1M Tris-HCl pH 7.4 (final concentration 200mM) 
87.66g NaCl (final concentration 1.5M) 
10mL Tween (final concentration 1%) 
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Fill to volume with ddH2O 
Dilute to 1x with ddH2O for washing 
Membrane Stripping 
1. Pre-heat stripping solution (see recipe below) to 50C for 30 minutes 
Note – Keep membrane wet while waiting by soaking in 1x TBS-T 
2. Place membrane into a clean tip box lid and pour stripping solution over blot 
until it is completely submerged 
3. Incubate at 50C for 30 min 
4. Pour off stripping solution (this can be saved and re-used as long as it smells 
strongly of –mercaptoethanol, just store at 4C) 
5. Wash the blot by adding 1x TBS-T (see recipe below) and shaking vigorously for 
15 min. Pour off wash solution and repeat wash once more 
6. Store the blot for short term at 4C in standing 1x TBS-T (wrap container in 
plastic to avoid evaporation and drying of blot) or long term at -20C by 
sandwiching blot between two pieces of blotting paper soaked with 1x TBS-T 
and wrapping this in plastic wrap prior to freezing 
50mL Stripping Solution 
6.2mL 0.5M Tris-HCl pH 6.8 (final concentration 62mM) 
10mL 10% SDS (final concentration 2%) 
350L 14.3M –mercaptoethanol (final concentration 100mM) 
Fill to volume with ddH2O 
Store at 4C 
 
RNA extraction from Tissues: Trizol method  
1. Remove tissue of interest from freezer only if all of the materials and reagents 
required have been prepared and are available for immediate use. Weight the 
tissue in its same tube. 
2. Add 1000ml of Trizol for every 50-100mg of wet tissue. Transfer to 50ml 
conical tube. Use polytron at level speed 5-6. Homogenize tissue for ~1min. 
Observe sample. If tissue particles are visible, keep homogenizing until the 
solution looks even. Certain tissues may require longer times.  
3. Transfer liquid to a new eppendorf tube. Incubate samples at RT for 5 min. 
4. In the mean time, clean Polytron extensively at least 3X with water and a final 
time with 100% ethanol. Allow drying. Use clean paper towel if needed. 
5. Add 0.2ml chloroform/ 1 ml of Trizol used initially. Vortex samples vigorously 
until samples are opaque. 
6. Incubate at RT for 2 minutes. 
7. Centrifuge samples at <12000g for 10 mins at 4C 
8. Transfer aqueous phase to new eppendorf tube. Aqueous phase volume will vary. 
Make sure to not transfer any of the whitish middle layer or the pink Trizol layer 
remaining below. 
9. Add 0.5ml isopropyl alcohol (2-propanol) /1ml Trizol used initially. 
10. Incubate at RT for 10 min.  
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11. Centrifuge at <12000g for 10 mins at 4C.  
Note: RNA may form pellet at this time. If you do not see a pellet, it is ok. May form 
after next step. 
12. Remove supernatant (pour off carefully so the pellet is not disturbed) and wash 
pellet with 1ml 70% ETOH/ 1ml of trizol used initially. 
13. Vortex and centrifuge at <7500g for 5 mins at 4C. 
14. Pour off supernatant and allow pellet to air dry (10-15mins).  
Note: If you do not see a pellet it is ok. Small amounts of RNA will not have a visible pellet. 
15. Resuspend pellet in 100µl DNAse free, RNAse free H2O. 
16. Test concentration of RNA:  Optimal 260:280 ratio is 2.0 for RNA. 
17. For all of this procedure use only RNAse free water. This can be done in lab by 
incubating water with 0.01% of DEPC overnight and then autoclaving the next 
day. 
 
High capacity cDNA reverse transcription 
1. Remove the following reagents from the High Capacity cDNA Reverse 
Transcription Kit and thaw on ice: 10x RT buffer, dNTPs, and 10x random 
primers.  
Note: leave the Multiscribe Reverse Transcriptase enzyme and the RNAse inhibitor 
in the freezer. 
2. Calculate how much volume is needed from each RNA sample according to the 
results from the Nanodrop to use 1g of RNA per reaction. 
Note: this kit allows the reverse transcription of 0.2-2g of RNA. 
3. The total volume for the RNA sample needs to be 10l. Depending on the 
volume needed per RNA sample, complete to 10l with RNAse free water in 
single PCR tubes.  
4. To prepare the Master Mix (total volume: 10l) add the following per reaction: 
3.2l water, 2l 10X RT Buffer, 2l random primers and 0.8l dNTP.  
5. Once the Master Mix is made, add to each 10l RNA sample for a total volume 
of 20l/reaction. 
6.  Place all the PCR tubes in the thermocycler and run the program: 
 10min-25°C 
 120min-37°C 
 5min-85°C 
 ∞-4°C 
 
Set up qRT-PCR plate 
Note: Load plates using metal cooling block stored at -20°C and in the order – A1; 
A2; B1; B2....etc. Tip: print out a map of the 384-well plate and write on each well 
(cell in the table) the sample name of what sample is going in each well and what 
primer/probe set will be added to each set  
1. First dilute the cDNA. In a small rounded PCR tube add 1µl of cDNA per each 
well to be filled on plate and add 8 µl of nuclease-free water. Each sample is run 
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in triplicate for each primer/probe set to be assayed; therefore, make a diluted 
mix of cDNA/water with enough starting material for the number of wells 
needed plus 1 extra sample per every 10 wells. Place samples on ice. 
2.  Make the Master Mix by adding 1µl of primer/probe mix 20X gene expression 
assay (Life technologies) and 10µl of Taqman 2X reagent per well to be detected 
by that particular primer/probe set. Make extra reactions, 1 extra for every 10 
wells.    
3. Place on ice until distribution 
4. Load 9µl of the cDNA/water dilution to each well 
5. Distribute 11µl Master Mix accordingly to each well  
Note: Each well will contain 20 µl of solution (9µl of cDNA diluted in nuclease-free 
water; 11µl Master Mix & Primer solution). 
6. Cover the top of the plate using optical adhesive film (Life Technologies). 
7. Spin plate in large centrifuge up to 1000 rpm  
8. Place plate in PCR machine  
9. Open the SDS 2.4 software, select standard curve, add detectors to list, select 
wells with samples, select cycle program and run.  
Note: never leave plate in machine after run is over 
 
Hindlimb Suspension (Tube) Test 
1. Perform assessment every 3 days 
2. Set up a 50ml conical tube on a stable surface 
3. Place a cotton ball at the bottom of tube 
4. Take pups one by one and suspend by their hindlimbs from the rim of the tube 
5. Record the time of latency (time to fall inside tube) 
6. Remove pup from tube carefully and place on a warm surface such as an electric 
blanket to rest between repeats 
7. Repeat procedure and record time of latency again 
8. If mouse is capable of changing position and hold itself from the opposite rim with 
front limbs or crawl on the surface of the tube, do not count as an appropriate run. 
Remove animal from study or try the 2 runs of the assay after a period of rest 
9. Assay is stopped at 60s, remove pup from tube if it does not fall after this time 
 
* Adapted from Rimer Lab protocol files, courtesy of Bonnie Seaberg 
